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Abstract 
The use of chemical analysis of fingerprints as an alternative approach for drug testing has 
become subject of recent publications. However, the significance of the detection of drugs 
in fingerprints compared to a background population of non-drug users has not yet been 
explored. In this research, the main area of research was to determine the forensic potential 
of detecting cocaine and heroin use through the analysis of fingerprints. Fingerprint samples 
deposited on paper were extracted using an extraction solution (10% dichloromethane in 
methanol) and analysed using liquid chromatography – mass spectrometry (LC-MS). This 
research showed that cocaine and benzoylecgonine were detected in 100 and 94% of natural 
fingerprint samples (n= 65) collected from drug users, and similarly, heroin and 6-
acetylmorphine were detected in 98 and 100% of samples (n = 60). Cocaine and 
benzoylecgonine were also detected in 13 and 5% of natural fingerprints (n = 98) from a 
background population of non-drug users. In contrast, heroin and 6-acetylmorphine were 
detected in 0 and 1% of fingerprints from the background population. For cocaine, a 
threshold level was required to differentiate fingerprints from drug users and environmental 
exposure in non-drug users (at a ratio analyte (A) to internal standard (IS) 0.015). The 
analytes of interest could still be detected in fingerprint samples from drug users after a hand 
cleaning procedure, however this resulted in a lower detection rate compared to natural 
fingerprints. In contrast, the analytes were not present in fingerprints collected from non-
drug users after handwashing (1% false positive rate for cocaine). Furthermore, cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine can also be detected in fingerprint samples 
from dermal contact with the parent drug even after the use of hand cleaning procedures. 
The detection of illicit drugs in fingerprints is therefore not solely indicative of 
administration of a drug but does indicate that these analytes are not prevalent in a 
background population of non-drug users. Additionally, the detection of isoniazid and 
acetylisoniazid in fingerprint samples from tuberculosis medication showed the potential 
application of fingerprint testing to monitor adherence to drug treatments. The detection 
window of isoniazid and acetylisoniazid (<2 days) suggests that a fingerprint may confirm 
when a patient stops complying to their treatment. This demonstrates that a fingerprint test 
could confirm non-adherence to treatment, which can be used to help improve treatment 
plans for patients and improve success rates. Furthermore, the presence of cocaine and 
benzoylecgonine in urine and saliva collected from drug users was determined using 
 iii 
 
portable mass spectrometry to show the potential for on-site sample analysis for drug testing. 
Previous work has shown that illicit drugs can be detected in fingerprints, however the 
suitability of fingerprints for drug testing (namely cocaine and heroin use) has not yet been 
explored. This research provides information on the influence of the fingerprint sampling 
strategy, presence of contact residue and transfer of drugs between individuals. These 
aspects are important to consider in relation to the stages of fingerprint testing and highlight 
its strengths and weaknesses for further applications (e.g. workplace drug testing, 
rehabilitation centres and hospitals). To improve fingerprint testing, further work is required 
on the standardisation of a fingerprint collection procedure, including validation procedures. 
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Chapter 1 Introduction 
1.0 Introduction 
The possible use of fingerprints for drug testing purposes has been explored in recent 
research articles, due to the ease and non-invasive nature of sample collection. A fingerprint 
sample offers traceability as the identity of the donor is embedded in the fingerprint ridge 
pattern, making it difficult to falsify. There have been several approaches to the detection of 
drugs in fingerprints. However, only a few studies have investigated the detection of drugs 
from individuals who have administered a substance (Costa et al., 2017; Zhang et al., 2015; 
Jacob et al., 2008). This is of course different from the multitude of studies that have 
explored the detection of drugs in fingerprints from external contact with a substance 
(Groeneveld et al., 2015; Ng et al., 2009; West & Went, 2009; Ifa et al., 2008; Day et al., 
2004). No research has investigated the suitability of fingerprints for drug testing and the 
challenges associated with the use of a fingerprint as a sampling matrix. This research 
investigates the suitability of fingerprints for the detection of drugs by evaluating the 
influence of the sampling strategy as well as contamination from dermal contact and 
secondary transfer of drugs. The significance of the detection of drugs in fingerprints is 
assessed by exploring the prevalence of the specific analytes of interest in a background 
population of non-drug users (as a negative control group). The use of fingerprint testing in 
a clinical setting is also investigated to potentially monitor compliance with tuberculosis 
medication. Additionally, the use of a portable mass spectrometer for drug testing is assessed 
using more conventional matrices such as urine and oral fluid (saliva).  
1.1 Introduction to Fingerprints 
The palmar surface of the hands and fingers and the plantar surface of the feet and toes 
consists of friction ridges. Upon contact with a surface, perspiration excreted via the pores 
in the fingertips is transferred onto the surface, thereby leaving an imprint of the friction 
ridge pattern which is called a fingerprint (Lee & Gaensslen, 2001). The term fingerprint is 
used for impressions which are collected under controlled conditions (Forensic Science 
Regulator, 2013). Fingerprints have a key role in forensic investigation (as a form of 
biometrics) for the purpose of positively identifying an individual due to the accessibility 
and ease of classification (Lee & Gaensslen, 2001). No two fingerprints have been shown to 
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be identical and as such it is assumed that fingerprints are a unique characteristic to every 
individual (Nayak et al., 2010).  
1.1.1 Fingerprint composition 
Fingerprints may consist of naturally secreted material, such as sweat, sebum or lipids and 
foreign materials picked up on the hands (e.g. cosmetics, perfumes and food residues). The 
exact composition of a fingerprint deposit is always unknown (Lee & Gaensslen, 2001). The 
composition of sweat can be influenced by various factors, including diet and genetics (Cadd 
et al., 2015). Sweat is excreted via three secretory glands in the skin, including eccrine, 
apocrine and sebaceous glands (Lee & Gaensslen, 2001). Eccrine glands are located all over 
the body, but a greater density is found on the soles of the feet and palms of the hands 
(Holder et al., 2011). The composition of a fingerprint is therefore dominated by secreted 
material from eccrine sweat glands. Eccrine sweat glands contribute to temperature 
regulation by secreting sweat and metabolic waste products (e.g. urea) (Holder et al., 2011). 
Eccrine sweat is composed of approximately 98% water as well as organic and inorganic 
constituents (Cadd et al., 2015; Lee & Gaensslen, 2001). These constituents include 
potassium, sodium, calcium, chloride, urea, creatinine, amino acids, proteins, lipids and 
lactate (Cadd et al., 2015; Holder et al., 2011; Lee & Gaensslen, 2001).  
Sebaceous glands are located throughout the body, except for the palms of the hands and 
soles of the feet (Lee & Gaensslen, 2001). These glands are most abundant on the face, scalp, 
anus, nose, mouth and external portions of the ear (Holder et al., 2011). Sebaceous glands 
secrete sebum, which is primarily composed of lipids, including glyceride, fatty acids, wax 
esters, squalene and cholesterol (Cadd et al., 2015; Holder et al., 2011; Lee & Gaensslen, 
2001). Although these glands are not present on the fingertips, sebum can be found in these 
places as a result of transfer from other parts of the body (e.g. touching the face). Apocrine 
sweat glands are primarily found in the axillary and pubic area (Holder et al., 2011). Very 
few studies have been able to analyse secretions from the apocrine glands due to 
contamination from the eccrine and sebaceous glands (Lee & Gaensslen, 2001). Constituents 
of the apocrine glands include proteins, cholesterol, carbohydrates and iron (Holder et al., 
2011; Lee & Gaensslen, 2001). 
In addition to compounds secreted from the secretory glands, fingerprints can also contain 
many semi-exogenous and exogenous materials, such as cosmetic products, illicit 
substances, explosives and food residue (Girod et al., 2012). Constituents of cosmetic 
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products, such as skin lotion, hair products and perfumes have previously been identified in 
fingerprints (Weyermann et al., 2011; Croxton et al., 2010; Mong et al., 1999). It was found 
that fingerprints from female participants contained a significant amount of constituents 
likely to originate from cosmetic products, such as hydrocarbons (tetracosane to triacontane) 
from petroleum jelly (Mong et al., 1999). Additionally, octyl methoxycinnamate, which is 
a common constituent in cosmetic products has also been detected in fingerprints from a 
female participant (Weyermann et al., 2011). Although fatty acids and wax esters have been 
detected in fingerprints, these are also naturally present from endogenous compounds in 
fingerprints. Therefore the source of these constituents (exogenous versus endogenous) is 
difficult to differentiate (Girod et al., 2012). 
In addition to the detection of cosmetics, other semi-exogenous compounds, such as nicotine 
(from smoking cigarettes), has also been identified in fingerprints (Benton et al., 2010). It 
was shown that nicotine was detected in fingerprints from smokers but could also be detected 
in non-smokers through contact with smokers or contaminated surfaces. However, a 
significant difference in the levels of nicotine was observed between smokers and non-
smokers. 
Fingerprints have also been investigated for compounds related to gunshot residues after 
carrying out a controlled firing experiment (Gilchrist et al., 2012). Fingerprint samples 
showed increased levels of nitrate and nitrite compared to control fingerprints. However, 
levels of other gunshot residue constituents (cyanate) were not significantly increased. It is 
therefore possible that the observed increased level of nitrate and nitrite originated from 
induced endogenous sweat secretion rather than gunshot residue during the firing 
experiment. However, exogenous explosives have been detected and quantified in 
fingerprints (Gilchrist et al., 2015; Love et al., 2013).  
Finally, traces of drugs have also been detected in fingerprints, including methadone, 
lorazepam, caffeine, cold medicine and cocaine (Costa, 2017; Bailey et al., 2015; 
Kuwayama et al., 2014; Kuwayama et al., 2013; Goucher et al., 2009; Jacob et al., 2008). 
These studies have shown that fingerprints can contain traces of drugs due to the 
consumption of these substances and thereby integrated into the metabolic pathway. Further 
discussion on the detection of drugs in fingerprints is detailed in section 1.2.6. 
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1.2 Introduction to Drugs 
1.2.1 Drug misuse and treatment 
Drug misuse continues to negatively affect the health, wellbeing and quality of life of 
individuals. Between 2016 and 2017, around 1 in 12 (8.5%) adults aged 16 – 59 years old 
in England and Wales had taken a drug in the last year, which equates to an approximate 2.8 
million people (Home Office, 2017). However, this percentage is more than doubled 
(19.2%) for young adults (aged 16 – 24 years old), and equates to 1.2 million people (Home 
Office, 2017). The economic and social cost of drug supply in England and Wales is an 
estimated £10.7 billion a year, and just over half of this is attributed to drug related crime, 
such as burglary, robbery and shoplifting (HM Government, 2017).  
The second most commonly used drug in the last year (after cannabis) among adults aged 
16 – 59 years old was powder cocaine (Home Office, 2017). Approximately 2.3% of adults 
(760,000 people) and 4.8% of young adults (297,000) have taken cocaine, based on a 
2016/17 survey carried out by the Home Office. Although cocaine is one of the most 
commonly used drugs, the trend in cocaine use has remained relatively flat since 2009-10 
(Home Office, 2017). 
In 2016-17, 279,793 individuals received treatment for drug misuse through drug and 
alcohol services (HM Government, 2017). Most individuals were treated for opiate use. In 
addition, the lowest rate of successful completion (26%) was observed for opiate users 
compared to non-opiate and alcohol, and alcohol only use (Knight et al., 2017). The 
remaining individuals were discharged without completing treatment. This highlights the 
importance of the treatment programmes and quality of support in services for these 
individuals to improve the outcomes observed. Over the last few years, less individuals are 
entering treatment aged under 25 (Knight et al., 2017). However, there is an increase in the 
amount of young adults under 25 entering treatment for cocaine use (Knight et al., 2017). 
Drug misuse is commonly observed among individuals with mental health problems (HM 
Government, 2017). It has been shown that up to 70% of individuals in substance misuse 
treatment also experience mental illness (e.g. schizophrenia) (HM Government, 2017). In 
addition, the availability of treatment for these individuals is usually limited. As a result, 
33% of individuals in mental health treatment who committed suicide had a history of drug 
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use, but only 7% were in contact with drug and alcohol treatment services (HM Government, 
2017). 
The number of deaths (3,744) related to drugs in England and Wales is the highest number 
it has been since comparable records began in 1993 (Office for National Statistics, 2017). 
This includes deaths due to accidents and suicide involving drug poisoning, as well as drug 
abuse and drug dependency (Office for National Statistics, 2017). The majority of drug 
related deaths 2,593 (69%) were due to drug misuse, which equates to 0.5% of all deaths 
(Office for National Statistics, 2017). Most of the drug related deaths were for people aged 
30 – 49 years old. Comparison between genders showed that 73% of drug related deaths 
were for males (Office for National Statistics, 2017). Over half of the deaths related to drugs 
involved an opiate, mainly heroin/morphine. Additionally, the number of deaths related to 
cocaine use has increased 16% (to 371 deaths) since 2015 (Office for National Statistics, 
2017). 
1.2.2 Classification of illegal drugs 
In the UK, the Misuse of Drugs Act 1971 is the main regulation to control and classify drugs 
(Leg Gov, 1971). The term ‘controlled drugs’ was introduced and refers to substances that 
are dangerous or otherwise harmful when misused. The main purpose of the Act is to prevent 
the misuse of controlled drugs, and thus it is not lawful to import, export, supply, possess 
and produce controlled drugs (Leg Gov, 1971). The Act classifies controlled drugs into 3 
categories, namely class A, B and C, based on the harmfulness of the substance, with class 
A considered to be the most harmful. The penalties for the possession, supply and production 
of controlled substances depends on the class of the drug, with the highest penalties 
associated with class A drugs (Table 1.1) (Leg Gov, 1971). The lawful possession and 
supply of controlled drugs for legitimate purposes are regulated under the Misuse of Drugs 
Regulations 2001 (Leg Gov, 2001). 
The rise of new psychoactive substances causes great concern as the long-term effects are 
unknown. These substances are produced by modification of the chemical structure of other 
psychoactive substances (e.g. ecstasy or cocaine).  Due to the difference in chemical 
structure, these substances are not regulated under the Misuse of Drugs Act 1971. However, 
a new regulation has been introduced called the Psychoactive Substances Act 2016 (Leg 
Gov, 2016). This Act was initiated so that the production, import, export, supply and 
Chapter 1: Introduction 
5 
 
possession of any substance intended for human consumption that can produce psychoactive 
effect is not lawful (Leg Gov, 2016).  
Table 1.1: Penalties associated with the possession, supply and production of controlled 
drugs in the United Kingdom (Leg Gov, 1971). 
Class Drug Possession Supply and production 
A 
Crack cocaine, cocaine, 
ecstasy (MDMA), heroin, 
LSD, magic mushrooms, 
methadone, 
methamphetamine (crystal 
meth) 
Up to 7 years in 
prison, an unlimited 
fine or both 
Up to life in prison, 
an unlimited fine or 
both 
B 
Amphetamines, 
barbiturates, cannabis, 
codeine, ketamine, 
methylphenidate (Ritalin), 
synthetic cannabinoids, 
synthetic cathinones (e.g. 
mephedrone, 
methoxetamine) 
Up to 5 years in 
prison, an unlimited 
fine or both 
Up to 14 years in 
prison, an unlimited 
fine or both 
C 
Anabolic steroids, 
benzodiazepines 
(diazepam), gamma 
hydroxybutyrate (GHB), 
gamma-butyrolactone 
(GBL), piperazines (BZP), 
khat 
Up to 2 years in 
prison, an unlimited 
fine or both (except 
anabolic steroids – 
it’s not an offence to 
possess them for 
personal use) 
Up to 14 years in 
prison, an unlimited 
fine or both 
Temporary class drugs* 
Some methylphenidate 
substances (ethylphenidate, 
3,4-
dichloromethylphenidate 
(3,4-DCMP), 
methylnaphthidate 
(HDMP-28), 
isopropylphenidate (IPP or 
IPPD), 4-
methylmethylphenidate, 
ethylnaphthidate, 
propylphenidate) and their 
simple derivatives 
None, but police can 
take away suspected 
temporary class drug 
Up to 14 years in 
prison, an unlimited 
fine or both 
*New drugs placed under a temporary banning order, while the Advisory Council on the Misuse of 
Drugs (ACMD) decides on the classification of these substances. 
Additionally, since November 2011, a temporary class drug order has been initiated in the 
United Kingdom for new psychoactive substances (Leg Gov, 1971). The use of the 
‘temporary class drug order’ enables the government to prohibit these harmful substances 
for 12 months whilst the Advisory Council on the Misuse of Drugs (ACMD) determines 
how to permanently classify these (Leg Gov, 1971).  
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1.2.3 Cocaine and chemistry 
Cocaine is extracted from the leaves of the coca plant (Erythroxylum coca), which primarily 
grows in South American countries, such as Peru, Bolivia and Colombia (Negrusz & 
Cooper, 2013). It is a central nervous system stimulant that is used for its short-term 
neurological effects, including euphoria, pleasure, feeling of power, increased energy and 
awareness (Negrusz & Cooper, 2013). However, cocaine abuse is followed by many 
consequences once the effect of the drug gradually disappears, such as anxiety, fatigue and 
depression (Wild, 2013). 
According to the Misuse of Drugs Act 171, cocaine is classified as a class A controlled drug 
(Leg Gov, 1971). The molecular structure of cocaine is illustrated in Figure 1.1. It is a weak 
base as the nitrogen atom only has three bonds and has a molecular weight of 303.36 g/mol 
(Karch, 2016). 
 
Figure 1.1: Molecular structure of cocaine. 
1.2.3.1 Production of cocaine 
Cocaine is a widely abused drug that is available in two forms, a hydrochloride (HCl) salt 
(powder cocaine) and a free base form (crack cocaine) (Negrusz & Cooper, 2013). The 
production of illicit natural cocaine primarily involves three steps, including (i) extraction 
of crude coca paste from the coca leaf, (ii) purification of crude coca paste to cocaine base 
and (iii) conversion of cocaine base to the hydrochloride salt (Negrusz & Cooper, 2013). 
Cocaine hydrochloride is prepared by dissolving the alkaloid (naturally occurring chemical 
compound containing carbon, hydrogen, nitrogen and oxygen) in hydrochloric acid. When 
the free base form reacts with the hydrochloric acid, the nitrogen atom accepts a hydrogen 
atom (H+) and forms the hydrochloride salt of cocaine (Figure 1.2). Cocaine hydrochloride 
is a water-soluble, white crystalline powder that decomposes when heated (McQueen et al., 
2010).  Cocaine hydrochloride is converted to crack cocaine by adding baking soda (sodium 
bicarbonate) to aqueous cocaine hydrochloride and heating until the free base (deprotonated 
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amine form of the compound) starts to precipitate into small pellets (Negrusz & Cooper, 
2013; McQueen et al., 2010; Conaboy, 1997). The removal of the hydrochloride allows the 
drug to be administered via smoking due to the lower melting point (Hope et al., 2005). In 
contrast, cocaine hydrochloride is typically administered via nasal insufflation. Both cocaine 
hydrochloride and crack cocaine are harmful, however the route of administration of crack 
cocaine delivers a more intense effect compared to nasal insufflation (Wild, 2013).  
Cocaine is commonly cut using adulterants such as caffeine, levamisole and lidocaine to 
enhance weight and volume (Karch, 2016; Negrusz & Cooper, 2013). Additionally, cocaine 
contains numerous impurities from the co-extraction of coca alkaloids, solvent and 
processing chemicals used in the production process. These can include breakdown products 
(metabolites) of cocaine, such as benzoylecgonine, ecgonine methyl ester, norcocaine, 
norecgonine (Bogusz, 2008; Casale & Klein, 1993). 
 
Figure 1.2: Molecular structures of cocaine hydrochloride (powder cocaine) and crack 
cocaine (Negrusz & Cooper, 2013). 
1.2.3.2 Metabolism of cocaine 
Metabolism is the process of conversion of one chemical species to another (Jambhekar & 
Breen, 2009). Drug metabolism primarily occurs in the liver, because it contains a high 
concentration of metabolic enzymes (Poole Arcangelo & Peterson, 2006). However, kidneys 
also contribute to the metabolism of drugs, mostly for the parent drug (Jambhekar & Breen, 
2009; Poole Arcangelo & Peterson, 2006). Most drugs are metabolised from an active form 
to a less active or inactive form, although exceptions occur (e.g. cannabis and codeine) 
(Negrusz & Cooper, 2013; Poole Arcangelo & Peterson, 2006). The products of drug 
metabolism are more polar, which enhances the water solubility and excretion of the drugs 
(Gibson & Skett, 2001). 
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Following administration, cocaine is primarily converted to major metabolites 
benzoylecgonine and ecgonine methyl ester and then finally to ecgonine as shown in Figure 
1.3 (Karch, 2016; Khojasteh et al., 2011; Kolbrich et al., 2006; Platt, 2000; Gorelick, 1997).  
Cocaine is metabolised by both enzymatic and non-enzymatic (influenced by temperature 
and physiological alkaline pH) pathways (Karch, 2016; Baselt, 1983). Benzoylecgonine is 
the primary metabolite of cocaine in urine and plasma following nasal insufflation, 
intravenous, oral and smoked administration routes (Bogusz, 2008). It is formed through 
hydrolysis at the methyl ester bond of cocaine through both enzymatic and non-enzymatic 
pathways (Platt, 2000). Another major metabolite is ecgonine methyl ester, which is formed 
through enzymatic hydrolysis at the benzoyl ester bond of cocaine (Bogusz, 2008). Further 
hydrolysis of benzoylecgonine and ecgonine methyl ester produces ecgonine. Additionally, 
the co-administration of cocaine and alcohol can lead to the formation of cocaethylene. 
 
Figure 1.3: Metabolic pathway of cocaine to major metabolites benzoylecgonine and 
ecgonine methyl ester (Bogusz, 2008). 
In addition to the presence of cocaine, benzoylecgonine is predominantly used to indicate 
cocaine use in drug testing as the concentrations present in urine and plasma are considerably 
higher (by a factor of 10 or 11) than those of ecgonine methyl ester or any other metabolite 
(Karch, 2016; Kolbrich et al., 2006). 
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1.2.3.3 Detection window of cocaine in biological matrices 
Benzoylecgonine, one of the main metabolites of cocaine, has been detected in urine for 1 – 
2 days after a single intravenous dose (at 20 mg) (Cone et al., 1989). Peak concentrations of 
benzoylecgonine ranged from 4000 – 9000 ng/ml and occurred within the first 12 hours after 
administration. Another study reported that cocaine administrated via the intranasal route 
(single dose at 1.5 mg/kg) could be detected in urine for approximately 8 h (based on n = 6 
participants) (Hamilton et al., 1977). In contrast, benzoylecgonine was detected for up to 2 
– 3 days. Peak concentrations for cocaine and benzoylecgonine were 24 and 75 µl/ml, 
respectively. Similar results were obtained by another study, which reported that after a 
single dose administration of cocaine, benzoylecgonine has been detected in urine (for n = 
6 participants) up to 2 days (max 2.5 days) after intravenous (dose 25 mg), intranasal (dose 
42 mg) or smoked administration routes (dose 42 mg) (Cone et al., 2003). Peak 
concentrations observed were highly variable but were highest for benzoylecgonine, 
followed by ecgonine methyl ester and cocaine, respectively. In chronic users, 
benzoylecgonine was detected for 10 to 22 days in urine after last administration (Weiss & 
Gawin, 1988).  
Cocaine is the main analyte detected in oral fluid (saliva) and appears almost immediately 
after intravenous, intranasal or smoked administration (Cone et al., 1997). The major 
metabolites, benzoylecgonine and ecgonine methyl ester appear within 15 min of cocaine 
use (Negrusz & Cooper, 2013). In oral fluid, cocaine has been detected up to 3.9 h after 
intravenous administration (dose 25 mg) with peak concentrations ranging from 285 – 1303 
ng/ml, 5.7 h after intranasal administration (dose 32 mg) with peak concentrations ranging 
from 75 – 59600 ng/ml and 3.7 h after smoking (dose 42 mg) with peak concentrations 
ranging from 94 – 12582 ng/ml using a single dose (Cone et al., 1997). Peak concentrations 
for benzoylecgonine ranged from 14 – 43 ng/ml after intravenous administration, 28 – 1931 
ng/ml after intranasal administration and 17 – 49 ng/ml after smoking (Cone et al., 1997). 
Another study reported that the mean detection time (n = 7) of cocaine in oral fluid after 
intravenous injection (dose 44.8 mg) and smoking (dose 40 mg) was up to 7.5 h and 8.5 h 
(maximum up to 12 h), respectively (Jenkins et al., 1995). Saliva concentrations rapidly 
declined after intravenous administration and ranged from 428 – 1927 ng/ml (Jenkins et al., 
1995). In contrast, afters smoking the peak concentrations for benzoylecgonine ranged from 
15852 – 504880 ng/ml. In chronic users, the detection time of cocaine in oral fluid can be 
up to 10 days during abstinence (Cone & Weddington, 1989). Benzoylecgonine 
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concentrations ranged from 510 – 204500 ng/ml (n = 6) during this period. Another study 
measured the levels of cocaine, benzoylecgonine and ecgonine methyl ester in oral fluid for 
12 h (monitoring period) in participants who frequently used cocaine (Moolchan et al., 
2000). The concentration of benzoylecgonine and ecgonine methyl ester in later samples 
were higher than those observed for cocaine, which is consistent with the longer half-lives 
(7.9 h for cocaine, 9.2 h for benzoylecgonine and 10.0 h for ecgonine methyl ester) 
(Moolchan et al., 2000). Mean concentrations for cocaine and benzoylecgonine in oral fluid 
were 22.5 ± 49.5 ng/ml and 371.8 ± 484.7 ng/ml, respectively. 
In blood plasma, cocaine can be detected up to 11.5 h (max 24.1 h) after a subcutaneous low 
dose (75 mg/70 kg) and 9.5 h (max 47.6 h) after a high dose (150 mg/70kg) (Scheidweiler 
et al., 2010). Maximum cocaine concentrations after the low dose ranged from 108.6 – 434.1 
µg/ml (n = 19) and 253.5 – 1153.9 µg/ml (n = 14) after the high dose. Additionally, 
maximum benzoylecgonine concentrations ranged from 190.1 – 411.2 µg/ml after a low 
dose and 336.3 – 832.0 µg/ml after a high dose (Scheidweiler et al., 2010). The main 
metabolites benzoylecgonine and ecgonine methyl ester were detected up to 48 h (max 48 
h) and 24 h (max 48 h), respectively following low and high doses. In serum, the maximum 
elimination time of benzoylecgonine from chronic drug users (n = 6) was 5.1 h (maximum 
7.2 h) (Reiter et al., 2001). The concentration of benzoylecgonine present in serum ranged 
from 27.0 – 207.0 ng/ml. The elimination time of cocaine in serum was not determined due 
to the short half-life of cocaine in blood (ca. 6 h). 
1.2.4 Heroin and chemistry 
Heroin (also referred to as diacetylmorphine or diamorphine) is derived from the plant 
Papaver somniferum L. (Negrusz & Cooper, 2013). It is one of the synthetic derivatives of 
the opium poppy, which are classified as opioids. The most commonly abused opioid 
derivative is heroin. It is administered through intravenous or subcutaneous injection, 
inhalation of vaporised heroin or nasal insufflation (snorting) (Wild, 2013; Negrusz & 
Cooper, 2013). Heroin acts as a depressant of the central nervous system and includes effects 
such as euphoria, analgesia, constipation, reduction in anxiety, respiratory depression and 
pinpoint pupils (Negrusz & Cooper, 2013). Regular heroin use leads to tolerance and 
physical dependence, thus higher doses are required to produce the same effect (Wild, 2013). 
Heroin is classified as class A controlled drug (Leg Gov, 1971). The molecular structure of 
heroin is illustrated in Figure 1.4.  
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Figure 1.4: Molecular structure of heroin. 
1.2.4.1 Production of heroin 
Heroin is synthesised from morphine which is contained in the seed of the opium poppy 
(Karch, 1998). The production of heroin from the opium poppy includes four steps, namely 
(i) the cultivation of opium poppy, (ii) collection of raw opium from the opium seed, (iii) 
isolation of morphine from raw opium and (iv) the acetylation of morphine to heroin (Karch, 
1998). The seed heads of the plant are cut to release the liquid that contains morphine. The 
liquid dries on the seed head which is then collected as raw opium (Negrusz & Cooper, 
2013). Morphine is extracted from the raw opium and acetylated using acetic anhydride to 
produce heroin (Negrusz & Cooper, 2013; Karch, 1998). Heroin can contain opium alkaloids 
including papaverine, noscapine and 6-acetymorphine (metabolite of heroin) as impurities 
from the production process (Karch, 1998). Cutting agents for heroin can include sugars, 
paracetamol and caffeine (Negrusz & Cooper, 2013). 
1.2.4.2 Metabolism of heroin 
Heroin is rapidly metabolised through enzymatic hydrolysis of the esters bond to form 6-
acetylmorphine and subsequently morphine (Negrusz & Cooper, 2013; Karch, 1998; 
Kamendulis et al., 1996). The metabolic pathway for the major metabolites of heroin are 
shown in Figure 1.5. The free phenolic hydroxyl groups of morphine undergo further 
metabolism to produce water-soluble metabolites by conjugation with glucuronic acid to 
form morphine-3-glucuronide and morphine-6-glucuronide (Karch, 1998). Metabolism 
primarily occurs in the liver and the majority (90%) is excreted in the urine and the 
remaining 10% in faeces (Karch, 1998).  
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Figure 1.5: Metabolic pathway of heroin to major metabolites 6-acetylmorphine and 
morphine (Negrusz & Cooper, 2013). 
1.2.4.3 Detection window of heroin in biological matrices 
6-Acetylmorphine has been detected in urine up to 2.3 h (max 5.1 h) after a low dose (3 – 7 
mg) and up to 4.5 h (max 11.2 h) after a high dose (10.5 – 13.9 mg) of heroin administered 
intravenously or smoked (Smith et al., 2001). Morphine was detectable up to 4.3 h (max 
10.1 h) after a low dose (3 – 7 mg) and 34.4 h (max 53.5 h) after a high dose (10.5 – 13.9 
mg). Peak concentrations for morphine and 6-acetylmorphine in urine ranged from 1392 – 
9250 ng/ml and 6.1 – 568 ng/ml, respectively. According to the study, the results obtained 
were not significantly dependent on the route of administration. Additionally, for chronic 
users the detection time for 6-acetylmorphine in urine was on average 5 h (max 34.5 h) with 
maximum concentrations ranging from 35 – 3699 ng/ml (Reiter et al., 2001). In contrast, 
the average detection time for morphine was 118.8 h (max 270.3 h) after the last 
administration to the body with maximum concentrations ranging from  280 – 2105929 
ng/ml (Reiter et al., 2001).  
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6-Acetylmorphine has been detected in oral fluid for 1 – 2 h after smoked administration 
(dose 10.5 mg) and 1 – 4 h after intravenous administration (dose 12 – 20 mg) (Jenkins et 
al., 1995). Peak concentrations in oral fluid after smoking ranged from 3534 (2.6 mg) to 
20580 ng/ml (5.2 mg). After intravenous administration, concentrations ranged from 6 (10 
mg heroin HCl) to 30 ng/ml (12 mg heroin HCl). In chronic users, morphine and 6-
acetylmorphine have been detected in oral fluid up to 3 and 8 days, respectively after last 
administration (Vindenes et al., 2014). 
The detection time of heroin in whole blood was reported to be longer after intravenous 
injection compared to smoked administration (Jenkins et al., 1994). After smoking 10.5 mg 
of heroin, morphine was detected in whole blood up to 22 min – 2 h (Jenkins et al., 1994). 
In contrast, the active metabolite 6-acetylmorphine was detected up to 30 – 60 min. After 
intravenous administration of 12 or 20 mg of heroin, the detection time in whole blood was 
extended to 30 min – 2 h for 6-acetylmorphine and up to 8 h for morphine (Jenkins et al., 
1994). In addition, 6-acetylmorphine and morphine have been detected in blood plasma up 
to 45 min and 12 h, respectively after 9 mg of intranasal administration (Goldberger et al., 
1993). In chronic users (n = 51), morphine has been detected up to 5 days after the last 
administration to the body, with peak concentrations ranging from 29 – 1264 ng/ml  (Reiter 
et al., 2001). 
1.2.5 Biological matrices 
There are numerous biological matrices that can be used for the detection of drugs of abuse, 
including blood (plasma, serum and whole blood), urine, hair and oral fluid. The matrix 
selected for drug testing purposes is influenced by a variety of factors, including ease of 
collection, analytical and testing considerations and the interpretation of results (Caplan & 
Goldberger, 2001). A summary of liquid chromatographic – mass spectrometry (LC-MS) 
approaches for the analysis of cocaine and heroin use across various matrices including 
performance characteristics is detailed in Table 1.2. Various sample preparation methods 
are used for the extraction of drugs from biological matrices, including liquid extraction, 
solid phase extraction (SPE) and protein precipitation. Overall, the sensitivity of the methods 
across the matrices is in the ng/ml range. The relative detection window of drugs in various 
biological matrices is shown in Figure 1.6 (Caplan & Goldberger, 2001). The elimination 
time depends on the dose of drug taken, method of administration, single or chronic drug 
use, number of drugs taken simultaneously, health and genetics of the user. The ability to 
Chapter 1: Introduction 
14 
 
detect drugs also depends on the method of analysis, which affects the sensitivity (limit of 
detection and cut-off levels).  
 
Figure 1.6: Relative detection window of drugs in various biological matrices (Caplan & 
Goldberger, 2001). 
At NHS Drug and Alcohol Services, urine is the primary matrix used to determine drug use 
for individuals in treatment for drug dependency. Urine is preferred due to the ease of 
collection and longer detection window in comparison to blood. Additionally, a large 
volume can be obtained for analysis. Therefore, urine has been widely used in doping 
control, workplace drug testing, criminal justice and drug abuse treatment programmes 
(Allen, 2011; Bosker & Huestis, 2009; Chawarski et al., 2007). However, urine testing is 
also notorious for the potential for adulteration or substitution (Negrusz & Cooper, 2013). 
Blood (mainly plasma or serum) can also be used for drug testing purposes. A principal 
advantage of a blood sample is that it is very difficult to adulterate and relates to the level of 
impairment, thus indicating recent drug use (Negrusz & Cooper, 2013; Dasgupta, 2010). 
This is because it is collected by venepuncture and needs to be collected by trained personnel 
(Negrusz & Cooper, 2013).  In contrast, oral fluid is an alternative matrix that is more 
commonly used for drug testing (Bosker & Huestis, 2009). The main attribute of oral fluid 
samples is the ease and non-invasive sample collection. It is of particular interest in 
workplace drug testing and roadside drug testing (Negrusz & Cooper, 2013). Oral fluid is 
able to indicate recent drug use due to the rapid absorption from the blood into the salivary 
glands (Allen, 2011). However, the detection window for oral fluid is short and limited 
sample volume (1 – 5 ml) is collected (Negrusz & Cooper, 2013; Allen, 2011). Interestingly, 
it is difficult to differentiate heroin use from morphine or codeine administration using urine 
testing. However, 6-acetylmorphine is solely indicative of heroin use and is readily detected 
in oral fluid samples (Bosker & Huestis, 2009). 
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Table 1.2: LC-MS procedures and performance characteristics for the analysis of cocaine and heroin use in biological matrices. 
Analytes Sample type 
Extraction 
method Column type Mobile phase Instrumentation 
Type of 
measurement 
Limit of 
detection Ref. 
 COC, BZE, 
MOR, 6-AM 
including 
other analytes 
Urine SPE 
BEH C18 column 
(50 x 2.1 mm, 1.7 
µm) 
BEG* = Ethylene 
bridged hybrid 
Solvent A: 5 mM 
ammonium 
bicarbonate buffer 
(pH 10) 
Solvent B: MeOH 
Acquity UPLC coupled 
to a Waters Quattro 
premiere Xe mass 
spectrometer 
Quantitative 
0.001 - 0.02 
µg/ml 
LOQ: 0.003 - 
0.06 µg/ml 
(Berg et al., 
2009) 
COC, BZE, 
EME, AME, 
CE, NCOC, 
MOR, HER, 
6-AM 
Hair SPE 
Atlantis® T3 C18 
column (150 x 2.1 
mm, 3 µm) 
Solvent A: 2mM 
ammonium formate 
(pH 3) 
Solvent B: 90:10 
(v/v) Aceonitrile/A 
Perkin-Elmer Series 
200 HPLC coupled to 
an AB Sciex API 2000 
trile quadrupole mass 
spectrometer 
Quantitative 
0.005 and 
0.030 ng/mg 
LOQ: 0.050 
ng/mg 
(Imbert et al., 
2014) 
COC, BZE, 
MOR, 6-AM 
including 
other analytes 
Hair and 
oral fluid 
Protein 
precipitation  
Alltima C18 
column (250 x 4.6 
mm, 5 µm) 
Solvent A: 
Acetonitrile + 5 
mM formic acid 
Solvent B: Water + 
5 mM formic acid 
Perkin-Elmer Series 
200 HPLC cuplted to 
an AB Sciex API 2000 
triple quadrupole mass 
spectrometer 
Quantitative 
Hair  
LOD:0.2 - 2.8 
ng/ml 
LOQ: 0.5 - 5 
ng/ml 
Oral fluid 
LOD: 0.1 – 1.1 
ng/ml  
LOQ: 0.2 – 3.7 
ng/ml 
(Sergi et al., 
2009) 
BZE, MOR 
Human 
serum, 
urine and 
post-
mortem 
(PM) 
blood 
Protein 
precipitation  
Luna C18 column 
(150 x 2 mm, 5 
µm) 
Solvent A: 10 mM 
ammonium acetate 
in 95:5 (v/v) 
water/methanol + 
0.1% acetic acid 
Solvent B: 10 mM 
ammonium acetate 
in 97:3 (v/v) 
methanol/water + 
0.1% acetic acid 
Shimadzu HPLC 
coupled to an API 4000 
Qtrap mass 
spectrometer 
Shimadzu HPLC 
coupled to an AP 5500 
Qtrap mass 
spectrometer 
Qualitative 
Serum: 0.01 - 
0.67 ng/ml 
Urine: 0.10 - 2.7 
ng/ml  
PM blood: 0.01 
- 1.7 ng/ml  
(Dziadosz et 
al., 2018) 
COC: cocaine; BZE: benzoylecgonine; EME: ecgonine methyl ester; AME: anhydromethylecgonine; CE: cocaethylene; NCOC: norcocaine; HER: heroin; MOR: morphine; 6-
AM: 6-acetylmorphine 
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Table 1.2 continued…  
Analytes Sample type 
Extraction 
method Column type Mobile phase Instrumentation 
Type of 
measurement 
Limit of 
detection Ref. 
COC, BZE, 
EME, ECG, 
NCOC, CE, 
EEE, NCE, 
NEEE 
Whole 
blood SPE 
Atlantis® T3 C18 
column (150 x 2.1 
mm, 3 µm) 
Solvent A: 0.1% 
formic acid in water 
Solvent B: 90:10 (v/v) 
acetonitrile/water + 
0.1% formic acid 
Shimadzu HPLC 
coupled to an AB 
Sciex triple TOF™ 
mass spectrometer 
Quantitative 
0.2 - 0.9 ng/ml 
LOQ: 1.9 - 320 
ng/ml 
(Chen et al., 
2017) 
COC, BZE, 6-
AM, MOR 
including 
other analytes 
Oral fluid SPE 
Allure PFP propyl 
column (50 x 2.1 
mm, 5 µm) 
Solvent A: 0.1% 
formic acid, 2 mM 
ammonium acetate, 
and 2% acetonitrile in 
water 
Solvent B: 0.1% formic 
acid, 2 mM ammonium 
acetate, and 10% water 
in acetonitrile 
Agilent 1100 HPLC 
coupled to a Sciex 
API 3200 mass 
spectrometer 
Quantitative LOQ: 0.4 - 2.0 ng/ml  (Cone, 2012) 
HER, 6-AM, 
MOR 
including 
other analytes 
Urine SPE 
Restek Pinnacle® 
DB C18 column 
(100 x 2.1, 3 µm) 
Solvent A: 10 mM 
ammonium acetate + 
0.1% formic acid in 
water 
Solvent B: Acetonitrile 
+ 0.1% formic acid 
Shimadzu LC-20AD 
HPLC coupled to an 
MDS Sciex API 3200 
mass spectrometer 
Quantitative LOQ: 2 - 80 ng/ml 
(Knight et 
al., 2014) 
COC, BZE, 
NCOC, HER, 
MOR, 6-AM, 
M3G, M6G 
including 
other analytes 
Human 
plasma SPE 
Zorbax bonus RP 
column (150 x 4.6 
mm, 5 µm) 
Solvent A: 5 mM 
ammonium formate, 
pH 4.0 
Solvent B: acetonitrile 
Agilent 1100 HPLC 
coupled to Sciex API 
3000 mass triple 
quadrupole mass 
spectrometer 
Quantitative Not specified (Rook et al., 2005) 
COC: cocaine; BZE: benzoylecgonine; EME: ecgonine methyl ester; ECG: ecgonine; CE: cocaethylene; NCOC: norcocaine; EEE: ecgonine ethyl ester; NCE: norcocaethylene; 
NEEE: norecgonine ethyl ester; HER: heroin; MOR: morphine; 6-AM: 6-acetylmorphine; M3G: morphine-3glucuronide; M6G: morphine-6-glucuronide 
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Table 1.2 continued…  
Analytes Sample type 
Extraction 
method Column type Mobile phase Instrumentation 
Type of 
measurement 
Limit of 
detection Ref. 
COC, BZE, 
EME, NCOC, 
ECG 
Whole 
blood and 
urine 
SPE 
Zorbax SB-C18 
column (30 x 2.1 
mm, 3 µm) 
Solvent A: 5% 
acetonitrile + 0.05% 
formic acid 
Solvent B: acetonitrile + 
0.05% formic acid 
Agilent 1100 HPLC 
coupled to a Waters 
Quattro micro 
quadrupole mass 
spectrometer 
Quantitative 
Whole blood 
LOD: 0.001 - 
0.003 mg/kg  
LOQ: 0.05 - 
0.008 mg/kg 
(Johansen & 
Bhatia, 2007) 
HER, 6-AM, 
MOR, M3G, 
M6G 
including 
other analytes 
Human 
plasma 
Protein 
precipitation  
X-Bridge phenyl 
column (150 x 4.6 
mm, 5 µm) 
Solvent A: 5 mM 
ammonium formate, pH 
3.0 
Solvent B: Acetonitrile + 
0.1% formic acid 
Waters Alliance 
2795 HPLC 
coupled to a 
Quatrro Premier 
mass spectrometer 
Quantitative LLOQ: 10 ng/ml 
(Moreno-
Vicente et 
al., 2015) 
COC, BZE, 
CE, HER, 6-
AM, MOR 
including 
other analytes 
Breast and 
bovine 
milk 
Protein 
precipitation  
Purospher star 
RP-18 (125 x 2.0 
mm, 5 µm) 
Solvent A: aceonitrile 
Solvent B: Water + 20 
mM formic 
acid/ammonium formate 
buffer (pH 3.8) 
Symbiosis™ Pico 
HPLC coupled to a 
AB Sciex 4000 
Qtrap mass 
spectrometer 
Quantitative 
0.2 - 5 ng/ml 
LOQ: 0.5 - 10 
ng/ml 
(López-
García et al., 
2018) 
BZE, EME, 6-
AM, MOR, 
M3G, M6G 
Urine 
Dilution or 
enzymatic 
cleavage 
AQUASIL C18 
(100 x 2.1 mm, 5 
µm)  
Solvent A: 10 M 
ammonium acetate in 
water 
Solvent B: 10 mM 
ammonium acetate in 1:1 
(v/v) methanol: 
acetonitrile  
Shimadzu 
Prominence UFLC 
coupled to an AB 
Sciex 5500 Qtrap 
mass spectrometer 
Quantitative LLOQ: 5 - 25 ng/ml 
(de Jager & 
Bailey, 2011) 
COC, BZE, 
EME, NCOC, 
CE, MOR, 6-
AM including 
other analytes 
Hair SPE 
Synergi hydro RP 
column (150 x 2.0 
mm, 4 µm) 
Solvent A: 10 mM 
ammonium acetate in 
water + 0.001% formic 
acid (pH 4.5) 
Solvent B: Acetonitrile 
Shimadzu LC-
20AD HPLC 
coupled to an MDS 
Sciex API 3000 
triple quadrupole 
mass spectrometer 
Quantitative LOQ: 17 - 83 pg/mg 
(Scheidweiler 
& Huestis, 
2004) 
COC: cocaine; BZE: benzoylecgonine; EME: ecgonine methyl ester; CE: cocaethylene; NCOC: norcocaine; HER: heroin; MOR: morphine; 6-AM: 6-acetylmorphine; M3G: 
morphine-3glucuronide; M6G: morphine-6-glucuronide 
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Table 1.2 continued…  
Analytes Sample type 
Extraction 
method Column type Mobile phase Instrumentation 
Type of 
measurement 
Limit of 
detection Ref. 
COC and BZE Hair 
Molecular 
imprinted 
polymers 
SymmetryShield 
RP18 column 
(150 x 2.1 mm, 
3.5 µm) 
Isocratic: 80% 
ammonium formate 
(5 mM, pH 3.2) and 
20% acetonitrile 
Agilent 1200 HPLC 
coupled to a triple 
quadrupole mass 
spectrometer 
Quantitative 
0.01 - 0.02 
ng/mg 
LOQ: 0.04 - 
0.07 ng/mg 
(Thibert et 
al., 2012) 
6-AM, MOR 
including 
other analytes 
Hair Solvent extraction 
Porosell 120 EC-
C18 column (50 x 
3.0 mm, 2.7 µm) 
Solvent A: 5 mM 
ammonium formate 
and 0.01% formic 
acid in water  
Solvent B: 
Acetonitrile + 0.01% 
formic acid 
Agilent 1260 Infinity 
HPLC coupled to a 
6460 triple 
quadrupole mass 
spectrometer 
Quantitative 
0.05 - 0.25 
ng/10 mg 
LOQ: 0.05 - 0.5 
ng/10 mg 
(Kim et al., 
2014) 
M3G, MOR, 
BZE, COC Urine SPE 
Xterra® MS C18 
column (50 x 3.0 
mm, 2.5 µm) 
Solvent A: 5 mM 
ammonium acetate 
with 0.05% acetic 
acid 
Solvent B: 
Acetonitrile 
Agilent 1100 HPLC 
coupled to a API 
4000 mass 
spectrometer 
Quantitative 9.00 - 2.29 pg/ml 
(Feng et al., 
2007) 
COC, BZE, 
EME, NCOC 
Rat brain, 
peripheral 
organs and 
plasma 
solvent 
extraction 
and 
centrifugatio
n 
LiChropher 60-
RP select B (125 
x 4.6 mm, 5 µm) 
Solvent A: 0.1% 
formic acid in water 
Solvent B: 0.1% 
formic acid in 
acetonitrile 
Agilent 1100 coupled 
to a API 2000 mass 
spectrometer 
Quantitative 0.05 µg/g (Bystrowska et al., 2012) 
COC, BZE, 
NCOC, CE Hair 
Protein 
precipitation  
Kinetex C18 (50 x 
3 mm, 2.6 µm) 
Solvent A: 2MM 
ammonium acetate in 
5% acetonitrile with 
0.02% formic acid 
Solvent B: 2 mM 
ammonium acetate in 
95% actonitrile 
Agilent 1290 coupled 
to an Sciex 6500 
Qtrap mass 
spectrometer 
Quantitative 
0.0202 - 0.005 
ng/mg 
LLOQ: 0.01 
ng/mg 
(Franz et al., 
2018) 
COC: cocaine; BZE: benzoylecgonine; EME: ecgonine methyl ester; NCOC: norcocaine; CE: cocaethylene; MOR: morphine; 6-AM: 6-acetylmorphine; M3G: morphine-3-
glucuronide
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Hair is another matrix that has been used to determine drug use. It enables a determination 
of the history of drug exposure (Negrusz & Cooper, 2013; Caplan & Goldberger, 2001). 
Hair analysis allows for a longer detection window (weeks to months), depending on the 
length of hair used for analysis. The collection of a hair sample is easy, non-invasive and 
not easily substituted (Negrusz & Cooper, 2013). However, the main limitation is that it 
cannot be used to determine recent drug use (Negrusz & Cooper, 2013; Dasgupta, 2010). 
Additionally, the influence of cosmetic treatment and potential for external contamination 
pose a concern for hair drug testing (Negrusz & Cooper, 2013). 
1.2.6 Fingerprints and drug testing 
Fingerprint samples have been used for the detection of different drugs of abuse. A few 
studies have shown the potential use of fingerprints to determine the presence of drugs using 
liquid chromatography – mass spectrometry (LC-MS) procedures (Zhang et al., 2015; 
Kuwayama et al., 2014; Kuwayama et al., 2013; Goucher et al., 2009; Jacob et al., 2008). 
These LC-MS methods have successfully detected methadone, lorazepam, 
methamphetamine, caffeine, and a cold medicine containing ibuprofen, dihydrocodeine, 
methylephedrine and chlorpheniramine in fingerprints. A summary of LC-MS methods used 
for the analysis of drugs in fingerprints, including extraction method and performance 
characteristics is detailed in Table 1.3. In most studies, the participants administered the 
drug prior to fingerprint deposition (Kuwayama et al., 2014; Kuwayama et al., 2013; 
Goucher et al., 2009). The remaining two utilised participants who had a known history of 
drug abuse to determine the presence of methadone and methamphetamine in fingerprints, 
respectively (Zhang et al., 2015; Jacob et al., 2008). In this PhD project, fingerprint samples 
were collected from individuals who had a known history of drug abuse, rather than carrying 
out an administration study. 
Another method has been reported for the detection of cocaine in fingerprints from 
individuals seeking treatment for drug dependency using paper spray mass spectrometry 
(Costa et al., 2017). The method has previously been used for the analysis of dried blood 
spots (Espy et al., 2014; Su et al., 2013; Manicke et al., 2011). Although the method offers 
similar sensitivity to LC-MS and high throughput analysis, it lacks chromatographic 
separation which results in lower selectivity and precision than LC-MS.  
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Table 1.3: LC-MS procedures and performance characteristics for the analysis of drugs in fingerprints. 
 
  
Analytes Extraction method Type of measurement Instrumentation Limit of detection % Recovery Ref. 
Amphetamine and 
methamphetamine 
Fingermark swabbed with cotton 
swab (moistened with 50 µl 
MeOH:H2O) 60 times. Swab 
placed in tube with 0.25 ml 
MeOH and sonicated for 4 min. 
Mixture was centrifuged for 5min 
and 20 µl of supernatant used for 
analysis 
Quantitative 
Finnigan Surveyor 
liquid chromatography 
and LXQ ion trap mass 
spectrometer 
1.5 ng/fingermark 
swab 
LOQ: 5.0 ng/ 
fingermark swab 
70 - 87 (Zhang et al., 2015) 
Caffeine, 
theobromine, 
paraxanthine and 
theophylline 
Paper substrate containing 
fingerprint was placed in plastic 
dish with extractoin solvent (1.9 
ml of MeOH:H2O, 1:4 (v/v)). Dish 
was shaking for 3 min and the 
sample extract transferred to a 
tube and centrifuged for 1 min, 25 
µl of the supernatant was used for 
analysis.  
Quantitative 
Shiseido Nanospace 
SI-2 and Thermo 
Fisher Scientific TSQ 
Quantum Ultra mass 
spectrometer 
LLOQ: 0.5 - 5 
ng/fingerprint 67 - 81 (Kuwayama et al., 2013) 
Ibuprofen, 
dihydrocodeine, 
chlorpheniramine, 
methylephedrine 
and ephedrine 
Paper substrate containing 
fingerprint was placed in a tube 
with 1 ml extraction solution 
(MeOH:H2O, 1:4 (v/v)). Tube was 
shaken for 1 min and centrifuged 
for 1 min, 50 µl of the supernatant 
was used for analysis.  
Quantitative 
Waters AQUITY 
UPLC I-Class and a 
Xevo TQ-S LC–mass 
spectrometer 
0.1 - 10 pg/fingerprint 
LOQ: 0.1 - 100 
pg/fingerprint 
58 - 95 (Kuwayama et al., 2014) 
Chapter 1: Introduction 
21 
 
Table 1.3 continued…  
Analytes Extraction method Type of measurement Instrumentation Limit of detection % Recovery Ref. 
Methadone and 
EDDP 
Glass cover slip containing 
fingerprint was placed in a glass 
vial with a solvent mixture 
(MeOH:DCM, 2:5 (v/v)). Vial 
was sonicated for 15 min. The 
sample extract transferred to an 
LC-MS vial, evaporated to 
dryness and reconstituted, 20 µl 
of the sample was used for 
analysis. 
Quantitative 
Waters AQUITY 
UPLC and Waters 
Micromass Quattro 
Premier mass 
spectrometer 
0.01 ng/fingerprint Not specified (Jacob et al., 2008) 
Lorazepam and 
lorazepam-
glucuronide 
Glass cover slip containing 
fingerprint was placed in a glass 
vial with a solvent mixture 
(MeOH:DCM, 1:1 (v/v)). Vial 
was sonicated for 1 min and 
shaken for 15 min. Sample extract 
was transferred to a clean glass 
vial, evaporated to dryness and 
reconstituted before being vortex-
mixed and transferred to an LC-
MS vial (10 µl used for analysis). 
Quantitative 
Thermo Scientific 
Accela LC and Thermo 
TSQ Quantum Access 
mass spectrometer 
1.5 - 8 pg 
LOQ: 5 - 30 pg 96 - 100 (Goucher et al., 2009) 
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Fingerprints offer the advantage that it is easy to collect, non-invasive and can be used for 
identification purposes. The use of a non-invasive sample collection places a smaller mental 
and physical burden on the individual (Kuwayama et al., 2014). Additionally, fingerprints 
can be collected on-site by a non-specialist. Fingerprint sample preparation is simple 
because there is a smaller amount of matrix component present in fingerprints (Kuwayama 
et al., 2014). However, the detection of drugs of abuse in fingerprints does require sensitive 
analytical instrumentation. Although oral fluid drug testing is non-invasive, proper sample 
storage of the sample matrix is required to prevent drug degradation due to digestive 
enzymes present (Kuwayama et al., 2014). Furthermore, the use of a buffer solution in oral 
fluid collection devices, dilutes the oral fluid sample and thus affects sensitivity or requires 
a sample preparation method.  
In the reviewed methods, a fingerprint collection protocol is commonly performed to 
produce as similar fingerprint depositions as possible. Jacob et al. (2008) and Goucher et al. 
(2009) performed a grooming procedure after cleaning the hands, which involved rubbing 
the fingers against the forehead and face prior to deposition. This method results in a sebum-
rich fingerprint.  Kuwayama et al. (2013) and Kuwayama et al. (2014) utilised a different 
method, which included a 30 s. waiting period with the hands open prior to fingerprint 
deposition. This method produces an eccrine-rich fingerprint. Both of these methods do not 
necessarily represent the actual composition of fingerprints, as this is an unknown proportion 
of eccrine and sebaceous secretions. However, the sebum-rich fingerprint is possibly more 
frequently encountered due to human behaviour (touching of the face).  
The sample preparation steps for the extraction of fingerprint samples typically use an 
extraction solution containing either methanol and dichloromethane or water, and an internal 
standard. After addition of the extraction solution, the sample matrix is normally sonicated, 
evaporated to dryness and reconstituted in the mobile phase (Goucher et al., 2009; Jacob et 
al., 2008). However, some studies performed another sample preparation step, which only 
included shaking and centrifugation of the sample matrix after which the supernatant was 
injected into the injector system (Zhang et al., 2015; Kuwayama et al., 2014; Kuwayama et 
al., 2013). In the reviewed methods, the extraction efficiency from glass cover slips 
produced a better recovery (90 – 100%) (Goucher et al., 2009). The recovery of analytes 
from wetted filter paper produced recoveries of 57.7 – 95.5% (Kuwayama et al., 2014; 
Kuwayama et al., 2013).  
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Zhang et al. (2015) used a cotton swab to collect fingerprints for drug testing purposes 
(Zhang et al., 2015). Results showed that even without employing a washing procedure prior 
to fingerprint collection, methamphetamine and amphetamine could be detected in 
fingerprints (Zhang et al., 2015). The advantage of detecting the main metabolite 
(amphetamine) in fingerprints is that it shows that the drugs were present due to misuse of 
the drug. However, the paper does not mention the use of internal standards as a reference 
for the matrix effects (ion suppression/enhancement) or recovery studies performed.  
1.2.6.1 Challenges associated with fingerprint testing 
The use of fingerprints for chemical analysis (e.g. drug testing) is a relatively new area of 
research. Previous research has shown the possibility to detect drugs in fingerprints, but no 
research has investigated the reliability of the sample matrix itself. Fingerprint testing 
requires advances in the standardisation of a fingerprint sampling procedure and validation 
procedures, together with the evaluation of measurement uncertainty and its impact on 
interpretation criteria (Wille, 2018). The variable nature of a fingerprint sample, including 
amount of volume deposited and sample size varies between individuals as well as within 
an individual. This influences the interpretive value of the amount of drug detected in a 
sample. Additionally, in the absence of a validated fingerprint standard, artificial eccrine 
sweat has been used in validation procedures to simulate a fingerprint matrix and this is 
investigated further in Chapter 2. However, at present, quantification has been attempted 
using nonmatrix-matched calibration curves, which can pose a problem if matrix effects 
occur in the presence of fingerprints. Reporting results in terms of analyte-to-internal 
standard ratio also possess a concern as it is non-universal and dependent on the amount of 
internal standard used.  
One of the major concerns and challenges associated with fingerprint testing is the possible 
presence of contamination either from contact with contaminated surfaces or handling the 
drug, which are less likely to be encountered in other biological matrices. It is known that 
traces of cocaine can be found on banknotes (Armenta & de la Guardia, 2008; Carter et al., 
2003). Additionally, traces of cocaine (50 ng/swab) have been found on the skin of non-
cocaine users or individuals living with drug users (20 µg/swab)  (Kidwell et al., 2003). This 
highlights the importance of the interpretation of results and differentiation between the 
presence of drugs from external contact residue (non-drug users) and active use (drug users). 
Advances in hair analysis have led to the use of cut-off levels, which are used as a decision 
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criterion to determine whether levels are observed above external exposure levels (Cooper 
et al., 2012). This could potentially be applied to fingerprint testing if environmental 
exposure poses a problem. Another important factor to consider for fingerprint testing is the 
detection time of drugs. No research (to our knowledge) has evaluated the detection window 
of drugs in fingerprint samples and this is an important aspect that should be evaluated to 
advance fingerprint drug testing. 
1.3 Introduction to Tuberculosis  
The use of fingerprints for drug testing can have a multitude of applications, including the 
use of therapeutic drug monitoring. Using fingerprints to monitor compliance has the 
potential to increase adherence to treatment and improve success rates. This is of particular 
interest for tuberculosis treatment, where drug resistant tuberculosis can emerge with 
inadequate adherence or suboptimal adsorption of the antibiotics. Conventional methods to 
monitor compliance to treatment can include the use of a blood sample, which has associated 
biohazard risks. An alternative approach using fingerprints is investigated in this PhD 
project to evaluate treatment adherence to tuberculosis medication. 
1.3.1 Tuberculosis and human health 
Tuberculosis is an infectious disease caused by the bacteria Mycobacterium tuberculosis 
(World Health Organisation, 2017). It primarily affects the lungs but can also affect other 
parts of the body. The disease is easily spread by individuals affected by expelling the 
bacteria into the air (e.g. by coughing) (World Health Organisation, 2017). Tuberculosis is 
a curable infectious disease, yet is one of the top 10 leading cause of death worldwide (World 
Health Organisation, 2017). In 2016, an estimated 1.7 million deaths were attributed to 
tuberculosis (World Health Organisation, 2017). Most of these deaths could be prevented 
by early diagnosis and appropriate treatment. An estimated 10.4 million cases of latent 
(inactive) tuberculosis were reported in 2016 (World Health Organisation, 2017). The 
majority of the cases in 2016 occurred in countries in South-East Asia, including India, 
Indonesia, China, the Philippines and Pakistan (World Health Organisation, 2017).  
In the UK, 5,664 cases of tuberculosis were recorded in 2016 of which 59% were male 
(Public Health England, 2017). Seventy-four percent (4096 cases) of tuberculosis incidences 
were from non-UK born individuals (Public Health England, 2017). In 2016, the rate of 
tuberculosis in non-UK born population was 15 times higher than that of the UK born 
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population (Public Health England, 2017). Additionally, the majority of tuberculosis in the 
non-UK born population was observed for individuals aged >75 years and older, followed 
by those aged between 25 – 29 years (Public Health England, 2017). 
1.3.2 Treatment and adherence 
The World Health Organisation (WHO) has initiated the End of TB strategy 2016 – 2035, 
with the aim of ending the global tuberculosis epidemic (World Health Organisation, 2017). 
The recommended treatment for individuals diagnosed with tuberculosis is a combination 
of four antibiotics for 6 months as the first-line treatment drugs. These include isoniazid, 
rifampicin, ethambutol and pyrazinamide (World Health Organisation, 2017; Wang et al., 
2016; Reynolds & Heysell, 2014). The combination of the four drugs are taken for two 
months, followed by the use of isoniazid and rifampicin only for the subsequent four months. 
The dose prescribed for the course of treatment is dependent on the weight of the individual.   
Drug resistant tuberculosis is a continuing threat to treatment programmes to eradicate the 
disease. Drug resistant tuberculosis can emerge because individuals are resistant to a 
particular antibiotic (primary drug resistance) or can develop resistance (acquired resistance) 
(Public Health England, 2017; Reynolds & Heysell, 2014). Acquired drug resistant 
tuberculosis can be attributed to non-adherence as well as suboptimal drug concentrations 
in treatment regimens (Reynolds & Heysell, 2014). A number of 490,000 million cases 
emerged worldwide in 2016 with multidrug-resistant tuberculosis (World Health 
Organisation, 2017; Reynolds & Heysell, 2014; Jnawali & Ryoo, 2013). In the UK, 68 cases 
of drug-resistant tuberculosis were confirmed (Public Health England, 2017). Treatment for 
multidrug resistant tuberculosis is longer and requires more expensive and toxic drugs as the 
second-line drugs (World Health Organisation, 2017; Jnawali & Ryoo, 2013).  The second-
line drugs often cause severe side effects and thus make adherence for patients more difficult 
(Parliamentary Office of Science and Technology, 2012). Treatment of multidrug-resistant 
tuberculosis can last more than 20 months and success rates can be as low as 33% (Reynolds 
& Heysell, 2014). The cost of treatment for tuberculosis varies between countries, but is 
around £5,000 per patient in the United Kingdom (Parliamentary Office of Science and 
Technology, 2012). However, for drug resistant tuberculosis the overall cost can be between 
£50,000 - £70,000 per patient (Parliamentary Office of Science and Technology, 2012). 
There are a number of methods that can be applied to test or monitor for adherence to 
tuberculosis medication. Directly observed treatment, short-course (DOTS) is the World 
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Health Organisation tuberculosis control strategy (World Health Organisation, 1999). In 
DOTS, patients are observed taking their medication to ensure the drugs are taken and for 
the appropriate duration (World Health Organisation, 1999). DOTS is primarily considered 
for individuals who have a higher social risk factors (e.g. drug and alcohol related problems, 
and homelessness) (World Health Organisation, 1999). With the use of DOTS the 
responsibility to adhere to treatment is not solely reliant on the patient. The use of DOTS 
therefore improves compliance with tuberculosis treatment and completion rates (London 
Health Programmes, 2011). However, it has been reported that DOTS is not always available 
for the patients who would benefit or require the assistance (London Health Programmes, 
2011). Other methods rely on clinical improvement, tablet counts and engagement with 
tuberculosis nursing teams to help assess adherence. Additionally, a urine dipstick test is 
used on the spot if there are any concerns or doubts about the patient. However, these are 
not readily used by clinicians due to a limited shelf life (12 months) and cost of the urine 
dipstick test (£7 per sample), which is not effective in terms of cost-benefit analysis. 
Furthermore, the urine dipstick test is based on a colorimetric test and cannot provide 
information on the drug levels present in the urine sample. An alternative strategy to improve 
tuberculosis treatment completion by monitoring compliance and absorption of the drug 
would therefore be advantageous. 
1.3.3 Isoniazid and chemistry 
Isoniazid is the most widely used drug for tuberculosis treatment (Starke, 2012). This is 
because the drug is effective in killing Mycobacterium tuberculosis, inexpensive and easily 
administered (Starke, 2012). There are little to no side effects associated with the use of 
isoniazid (Blomberg, 2009). However, mild elevation in liver enzymes and on rare occasion 
hepatitis have been reported as side effects from the use of isoniazid in tuberculosis 
treatment (Blomberg, 2009). The standard treatment dose of isoniazid (adult dose) is 5 
mg/kg with a maximum dose of 300 mg taken daily (Van Crevel & Hill, 2017). The duration 
of treatment is generally 6 months for drug-susceptible tuberculosis (Van Crevel & Hill, 
2017).  The molecular structure of isoniazid is illustrated in Figure 1.7. It is a small water-
soluble molecule and has a molecular weight of 137.14 g/mol. 
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Figure 1.7: Molecular structure of heroin. 
1.3.3.1 Metabolism 
Once isoniazid is administered orally, it is primarily metabolised through enzymatic 
pathways (Tostmann et al., 2008). Isoniazid is converted to acetylisoniazid through 
acetylation and subsequent hydrolysis forms acetylhydrazine and isonicotinic acid (Figure 
1.8) (Tostmann et al., 2008; Ellard & Gammon, 1976). Acetylhydrazine is further 
metabolised into diacetylhydrazine (through acetylation) or hydrolysed to form hydrazine 
(Tostmann et al., 2008). The rate of acetylation in humans is genetically determined and can 
be divided into two groups, namely slow and fast acetylators (Ellard & Gammon, 1976). 
Approximately half the population of African and Caucasian descent are fast acetylators 
with elimination half-lives of 0.5 – 1.5 h (Blomberg, 2009).  
 
Figure 1.8: Metabolic pathway of isoniazid (Tostmann et al., 2008). 
For slow acetylators, the half-lives of isoniazid is between 2 – 4 h. The majority (80 – 90%) 
of individuals from Chinese and Japanese descent are fast acetylators (Blomberg, 2009). The 
acetylation status of an individual has no influence on the medication dose of isoniazid that 
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is prescribed during tuberculosis treatment (Blomberg, 2009). However, individuals with 
slow acetylation have an increased risk to certain side effects associated with isoniazid, such 
as hepatotoxicity (liver damage) and peripheral neuropathy (damage to the peripheral 
nervous system) (Wang et al., 2016; Blomberg, 2009; Tostmann et al., 2008).  
1.3.3.2 Detection of isoniazid in biological matrices 
Different methods have been applied for the detection of isoniazid in biological matrices, 
such as urine and blood (plasma and serum). No study (to our knowledge) has investigated 
the detection time of isoniazid in biological matrices. However, the use of LC-MS is most 
commonly used for the analysis of isoniazid, particularly in pharmacokinetic studies as it 
can provide quantitative information (Want et al., 2003).  A number of studies have reported 
the use of LC-MS analysis for the detection of isoniazid and its respective metabolite 
acetylisoniazid in urine and blood (plasma and serum) (Seng et al., 2015; Mukherjee et al., 
2015; Amlabu et al., 2014; Thee et al., 2011; McIlleron et al., 2009). However, the majority 
of studies utilised a colorimetric test (referred to as the Arkansas method) to determine the 
presence of isoniazid in urine using a number of reagents which produce a blue colour in the 
presence of isoniazid metabolites (Nicolau et al., 2012; Guerra et al., 2010; Schmitz et al., 
2010; Hanifa et al., 2007; Eidlitz-Markus et al., 2003). Although this is a low-cost 
alternative, this method is not as selective compared to mass spectrometry methods. The use 
of LC-MS analysis for the detection of isoniazid and its respective metabolite acetylisoniazid 
in fingerprints is investigated in this research, due to the high selectivity associated with the 
use of mass spectrometry analysis which allows qualitative identification of the analytes of 
interest.  
1.4 Aim and Objectives 
The primary aim of this research is to investigate the forensic potential of detecting drugs 
(in particular cocaine, heroin and their respective metabolites) in human fingerprints. A 
liquid chromatography – mass spectrometry (LC-MS) method will be developed and 
validated for the qualitative confirmation/identification of cocaine, benzoylecgonine, heroin 
and 6-acetylmorphine. The application of this method to determining any substance misuse 
using fingerprint samples will be explored. Important aspects of using a fingerprint as a new 
sampling matrix will be investigated, including (i) the impact of a hand cleaning procedure 
(washing hands or wiping hands with alcohol free wipes), (ii) sampling issues in relation to 
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environmental contamination (through the collection of fingerprints from a background 
population of non-drug users), and (iii) the potential of secondary transfer of drugs. The 
impact of these on the interpretation of results is important to consider in order to allow for 
a correct application of a fingerprint test. Additionally, the presence of cocaine and heroin 
after dermal contact with the parent drug will be explored (including the use of hand cleaning 
procedures) to evaluate whether a fingerprint test is suitable to determine substance misuse. 
The secondary aim of this research is to explore the potential use of fingerprints in a clinical 
application, in particular monitoring compliance with tuberculosis medication (isoniazid). 
The final aim of this research includes a pilot research study to evaluate the use of a portable 
screening system for drug testing purposes in well-established and conventional matrices, 
such as, urine and an oral fluid (saliva).  
1.4.1 Objectives 
The objectives of this study are to: 
• review the literature on methods and procedures used for the detection of cocaine 
and heroin; 
• obtain ethical approval from the NHS REC and the University of Surrey for the 
collection of biological samples from study participants; 
• develop and validate an extraction method for the preparation of fingerprint samples 
for LC-MS analysis according to the Scientific Working Group for Forensic 
Toxicology guidelines; 
• determine the detection rates of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine in fingerprint samples from (i) individuals seeking treatment for 
drug dependency at NHS drug and alcohol services, and (ii) a negative control group 
(background population of non-drug users) using different fingerprint sampling 
strategies, including (a) natural fingerprints, (b) wiping hands with alcohol free 
wipes, (c) washing hands with soap and water, and (d) secondary transfer through 
handshaking; 
• determine the detection rates of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine in fingerprint samples after dermal contact with 2 mg of the parent 
drug using different fingerprint sampling strategies, including (a) natural 
fingerprints, (b) wiping hands with alcohol free wipes, (c) washing hands with soap 
and water, and (d) secondary transfer through handshaking; 
Chapter 1: Introduction 
30 
 
• evaluate the detection of cocaine, benzoylecgonine, heroin and 6-acetylmorphine in 
fingerprints and the requirement for a decision level (i.e. to differentiate non-drug 
user and drug users); 
• determine the detection rates of isoniazid and acetylisoniazid in fingerprint samples 
from individuals (i) receiving treatment for tuberculosis, (ii) who completed 
treatment (2 – 8 months prior to recruitment) and (iii) a negative control group using 
different fingerprint sampling strategies, including (a) natural fingerprints and (b) 
washing hands with soap and water;  
• evaluate the suitability of fingerprint samples to monitor compliance with 
tuberculosis treatment by investigating the elimination profile (T = 0, T = 2 and T = 
4 days) after ceasing treatment; and to 
• evaluate the suitability of a portable mass spectrometry approach for the detection of 
cocaine and benzoylecgonine in urine and oral fluid (saliva) samples from 
individuals receiving treatment for drug dependency at NHS drug and alcohol 
services. 
The potential use of fingerprints for chemical analysis (i.e. drug testing) is increasingly 
receiving more interest due to its non-invasive approach, ease of sample collection and 
identification (embedded in the fingerprint ridge detail). Various studies have shown the 
potential of using fingerprints to determine the presence of drugs, such as methadone, 
lorazepam, caffeine, cold medicine, cocaine and methamphetamine (Zhang et al., 2015; 
Kuwayama et al., 2014; Kuwayama et al., 2013; Goucher et al., 2009; Jacob et al., 2008). 
However, no study (to our knowledge) has evaluated the potential significance of the 
detection of drugs in fingerprints. The development of an LC-MS method for the analysis 
of cocaine and heroin in fingerprints, including a fingerprint extraction method will be 
explored in Chapter 2. The detection of cocaine and heroin use in fingerprints from drug 
users and a background population of non-drug users is explored in Chapter 3. The presence 
of cocaine and heroin after dermal contact with the parent drug in fingerprints from non-
drug users is investigated in Chapter 4. The application of fingerprints to determine the 
presence of tuberculosis medication in fingerprints from patients receiving treatment is 
explored in Chapter 5. Lastly, the potential use of a portable mass spectrometer for the 
analysis of cocaine use in oral fluid and urine samples is explored in Chapter 6.  
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Chapter 2 Analytical Methodology 
2.0 Introduction 
In order to meet the proposed aim and objectives of the research study (as described in 
Chapter 1 section 1.4) an analytical sequence was set up, as illustrated in Figure 2.1. This 
chapter describes the procedures applied for the liquid chromatography – mass spectrometry 
(LC-MS) analysis used in this study at the University of Surrey. The development of a liquid 
chromatography – mass spectrometry (LC-MS) method for the analysis of cocaine, heroin 
and their respective metabolites, benzoylecgonine and 6-acetylmorphine in fingerprint 
samples is described in section 2.1. In order to evaluate the suitability of detecting these 
compounds in fingerprints, a method was developed for the extraction of the analytes of 
interest from artificial eccrine perspiration, acetonitrile and fingerprint samples deposited on 
glass cover slips and paper substrates (section 2.2). The developed extraction method was 
used for the analysis of all fingerprint samples in the proceeding chapters. The performance 
characteristics of the developed sample preparation method and LC-MS method are 
evaluated in section 2.3.  
2.1 Liquid Chromatography – Mass Spectrometry (LC-MS) 
Chromatographic techniques, such as gas chromatography (GC) and liquid chromatography 
(LC), are useful for multi-component analysis. Separation of components is based on the 
partitioning of the solutes between the mobile and stationary phase (Bogusz, 2008; Harris, 
2007). Liquid chromatography – mass spectrometry (LC-MS) is an analytical technique that 
is widely used for the identification of analytes in biological tissues and fluids, due to the 
extensive range of compounds that can be analysed. This section will detail the principles 
of LC-MS analysis and the procedures used for the optimisation of instrument parameters. 
2.1.1 Principle of chromatography 
High performance liquid chromatography (HPLC or LC) uses a high pressure to force a 
liquid mobile phase through a column containing very fine particles to produce high-
resolution separations (Harris, 2007). There are different chromatographic separation modes 
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available, namely normal-phase and reversed-phase chromatography (McMaster, 2005). In 
normal phase chromatography, a polar stationary phase is used and a non-polar mobile 
phase. In contrast, reversed-phase chromatography utilises a non-polar stationary phase and 
a more polar mobile phase. Reversed-phase chromatography is more commonly used due to 
the wide variety of compatible mobile phases, allowing greater versatility compared to 
normal-phase chromatography (McMaster, 2005).  In this study, reversed-phase LC-MS was 
used for the analyses of all samples. 
The core of an LC system is the column, as this is where chromatographic separation occurs. 
The sample is injected and mixed with the mobile phase before it is passed on to the column, 
where the stationary phase is found. Separation of analytes is determined by the affinity of 
these chemicals to the stationary phase. The greater the affinity, the longer it takes for the 
analytes to pass through the column. The time at which the compound elutes is called the 
retention time. The retention time is characteristic for a given analyte under specific 
conditions (such as type of column, mobile phase and flow rate). Analytes eluting from the 
column are then introduced into the mass spectrometer for analysis. LC systems can be run 
using an isocratic or gradient elution mode. In isocratic elution, the mobile phase 
composition is kept constant. In contrast, for gradient elution the mobile phase composition 
is continuously changing during the analysis to increase the eluent strength to elute more 
strongly retained analytes. In this study gradient elution was applied for the separation of 
the analytes of interest. Additionally, there are different column phases available to 
maximise the separation of the analytes of interest. A C18 column is widely used for the 
analysis of moderately polar to non-polar compounds and was chosen for this study for the 
analysis of cocaine, heroin and their respective metabolites. 
2.1.2 Electrospray interface, ion focussing and ion optics 
Electrospray ionisation (ESI) is a soft ionisation technique used to produce ions in a gaseous 
phase (without fragmentation).  The eluate, which is the solvent emerging from the end of 
the column is pumped through a charged, heated metal capillary. The voltage of the capillary 
(approximately 3 – 5 kV) causes the liquid spray to be charged as it is nebulised, creating an 
aerosol of charged droplets (Ho et al., 2003) . The droplets evaporate under a stream of 
nitrogen (carrier gas) and applied heat. As the solvent evaporates, the droplet decreases in 
size, the analytes are forced closer together, repel each other and break up the droplets 
forming individually charged analyte ions (Thermo Scientific, 2014; Harris, 2007). 
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Figure 2.1: Analytical sequence for this study.
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In the ion source interface, the analyte ions are extracted into the ion transfer tube and the 
stacked ring ion guide (called S-lens) region (Thermo Scientific, 2014). Figure 2.2 displays 
a schematic of the Orbitrap mass spectrometer used in this study. The main function of the 
S-lens is to focus the ions into a tight beam after exiting the ion transfer tube. The S-lens 
operates in radio frequency (RF) mode only, to move ions into the ion optics region of the 
mass spectrometer (Thermo Scientific, 2014). The ion optics transmit the ions from the S-
lens to the Orbitrap. The ion optics remove any remaining neutrals or ions of the opposite 
polarity before entering the quadrupole for mass selection (Thermo Scientific, 2014). The 
quadrupole mass filter consists of four cylindrical or hyperbolic rods. The mass analyser is 
positioned between the ion optics and the detector and acts as a mass filter. A combination 
of a direct current (DC) and radio frequency (RF) voltage is applied to the rods to allow for 
the transmission of ions of a specific mass or mass range to the detector (Glish & Vachet, 
2003). By varying the voltage applied with time, ions with a specified range of mass-to-
charge (m/z) ratios will be transmitted to the detector.  
After the quadrupole, the ions are introduced into the curved linear trap (C-trap) which is 
filled with nitrogen and operates at 10-6 mbar. The C-trap is a RF-only curved quadrupole 
used to cool down the ions after exiting the quadrupole mass analyser and compress them 
into a tight ion package before entering the Orbitrap, which is held at 10-10 mbar (Thermo 
Scientific, 2014). In addition to the use of voltage differentials, the Orbitrap mass 
spectrometer also utilises a pressure differential to focus ions through the ion optics before 
being introduced into the Orbitrap (Thermo Scientific, 2014). 
 
Figure 2.2: Schematic of the Q-Exactive Plus mass spectrometer used for the analysis of 
all samples in this study (Thermo Scientific, 2014). 
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2.1.3 Orbitrap analyser 
The main purpose of the Orbitrap mass analyser is to separate and detect ions based on their 
oscillation frequencies. The Orbitrap consists of two electrodes, a central electrode and an 
outer electrode. The outer electrode is split in half by a ceramic ring. The ions in the Orbitrap 
are trapped in an electrostatic field by applying voltages to both the outer and central 
electrode.  When the ions enter the Orbitrap, the voltage is increased to both electrodes to 
confine the ions in the Orbitrap. This forces the ions to move towards the middle of the 
central electrode and causes axial oscillations. The voltage to the central electrode is then 
stopped and this allows the ions to spin around the central electrode in a stable trajectory. 
Different masses will have different frequencies of rotation. Ions of low molecular mass will 
be kept tighter around the central electrode compared to higher molecular masses, allowing 
for the separation of ions in the Orbitrap. The outer electrodes are then used to measure the 
image current observed by the axial oscillations of the ions. Fast Fourier Transform (FFT) 
is used to convert the oscillation frequency measured by the outer electrodes, a time domain 
signal, to a frequency domain function and then into a mass spectrum (Zubarev & Makarov, 
2013).  
2.1.4 Development of a liquid chromatography method 
High performance liquid chromatography (HPLC) method development is an important 
process in an analytical sequence as it will determine the quality of the results obtained. The 
use of Kinetex XB-C18 column (100 x 2.1 mm, 5 µm) was recommended by Phenomenex 
for the analysis of cocaine, heroin and their respective metabolites. The Kinetex column 
utilises a core shell technology which improves the column efficiency, providing narrower 
peaks and thus improved sensitivity compared to a fully porous column.  
The initial conditions for the chromatographic separation used in this study was based on a 
general method used in the Department of Chemistry at the University of Surrey. This LC 
method utilised a mobile phase composition containing water (H2O) + 0.1% formic acid and 
acetonitrile (ACN) + 0.1% formic acid using a gradient elution over a run time of 7 min. 
The LC method used in this study was optimised on a Waters Acquity ultra high 
performance liquid chromatography (UHPLC) system combined with a quadrupole – time 
of flight (Q-ToF) mass spectrometer. A 250 ng/ml standard (in 20% (v/v) ACN in H2O) was 
used for the optimisation of the chromatographic separation of cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine. Using the general method, separation was achieved for the 
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analytes of interest. However, the last compound (cocaine) eluted at 3.35 min. The LC 
method was therefore modified by creating a steeper gradient to produce a 3 min method 
with chromatographic separation for cocaine, heroin and respective metabolites 
benzoylecgonine and 6-acetylmorphine. 
Multiple mobile phase compositions have been used for the LC-MS analysis of cocaine and 
heroin in various biological matrices, including ammonium acetate, water, methanol and 
acetonitrile (see Table 1.2). Both the retention time and selectivity will change depending 
on the solvents used due to differences in the chemical properties. In this study, two organic 
and two aqueous solvents were evaluated, including the use of (A1) water + 0.1% formic 
acid and (A2) 20 mM ammonium acetate in 5% (v/v) ACN in H2O. For the organic solvent, 
(B1) ACN + 0.1% formic acid and (B2) MeOH + 0.1% formic acid were evaluated. A 
combination of A1 + B1, A2 + B1 and A2 + B2 as mobile phase compositions were 
evaluated at two different initial mobile phase conditions, using a 3 min gradient elution 
method. This included an initial mobile phase composition starting at (i) 5% organic solvent 
or (ii) 20% organic solvent. The results obtained for the chromatographic separation of 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine using these methods are shown in 
Appendix A. 1 – A. 6. The use of a higher percentage (95%) aqueous solvent in the mobile 
phase resulted in narrower peaks, especially for 6-acetylmorphine (first eluted compound). 
Additionally, no significant difference was observed between the use of the different mobile 
phases (A1, A2, B1, B2), when starting the initial mobile phase composition at 5% organic 
and 95% aqueous solvent. Overall, the use of a mobile phase including H2O + 0.1% formic 
acid as the aqueous solvent and ACN + 0.1% formic acid as the organic solvent provided 
the best results, as the artefact observed for 6-acetylmorphine was minimised using these 
solvents (see Appendix A. 5).  
The LC method developed on the Waters Acquity UHPLC was later transferred to the 
Dionex Ultimate 3000 HPLC without modification for the analysis of cocaine, 
benzoylecgonine, heroin and 6-acetymorphine, where the same separation was achieved for 
all the analytes. An example of an overlay of extracted ion chromatograms of cocaine, 
benzoylecgonine, heroin, 6-acetylmorphine extracted from paper (at 10 µL of 50 ng/ml in 
ACN) and analysed using the developed LC-MS method is shown in Figure 2.3. 
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Figure 2.3: An example of an overlay of extracted ion chromatograms of a drug standard 
at 50 ng/ml containing cocaine (m/z 304.1543), benzoylecgonine (m/z 
290.1387), heroin (m/z 370.1649) and 6-acetylmorphine (m/z 328.1543) in 
5% (v/v) ACN in H2O analysed using the LC-MS method developed.   
2.1.5 Optimisation of electrospray settings 
Most electrospray source conditions, including sheath gas, auxiliary gas, capillary 
temperature and probe position are dependent on the flow rate used in the chromatographic 
separation. In this study, Thermo Fisher recommended settings were used for the sheath gas 
(45 psi), auxiliary gas (10 au), capillary temperature (320 º C) and probe position (C) for a 
flow rate of 0.250 ml/min. The spray voltage is a more analyte specific parameter and was 
optimised for the analysis of cocaine, benzoylecgonine, heroin and 6-acetylmorphine. The 
spray voltage was optimised using a 50 ng/ml standard containing all analytes of interest in 
5% (v/v) ACN in H2O at a flow rate of 0.250 ml/min. The optimised spray voltage was 3 
kV. 
2.2 Experimental 
2.2.1 Chemicals and reagents 
Certified reference materials (CRM) of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine were used to prepare drug standards (Sigma Aldrich, Dorset, UK). CRMs 
of cocaine-d3, benzoylecgonine-d3, heroin-d9 and 6-acetylmorphine-d3 were used as internal 
standards (Sigma Aldrich, Dorset, UK). Optima grade LC-MS solvents of methanol, 
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acetonitrile and water were used to prepare solutions and solvent mixtures (Fisher Scientific, 
Leicestershire, UK). Formic acid was added to the mobile phase solvents at 0.1% (v/v) 
(Fischer Scientific, Leicestershire, UK). Dichloromethane, chloroform and ethyl acetate 
were used to prepare solvent extraction mixtures and were analytical or reagent grade 
(Sigma Aldrich, Dorset, UK). A solution of artificial eccrine perspiration was used to 
simulate a fingerprint matrix in the experimental design of fingerprint experiments 
(Pickering Laboratories, Inc., Obertaufkirchen, Germany). 
2.2.2 Instrumentation and conditions 
Analysis of samples was carried out using a Dionex Ultimate 3000 HPLC module equipped 
with a binary solvent manager, column manager and autosampler, coupled to a Q-Exactive 
Plus mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK) at the University 
of Surrey. Chromatographic separation was performed on a Kinetex XB-C18 column (100 x 
2.1 mm, 5 µm) operated at 30 ºC with a flow rate of 0.25 ml/min. Gradient elution was 
performed with an initial mobile phase composition of 95% H2O (with 0.1% formic acid) 
and 5% acetonitrile (ACN, with 0.1% formic acid) increased to 80% ACN (0.1% formic 
acid) and 20% H2O (0.1% formic acid) over 2 min and kept constant for 0.5 min before 
returning to the initial mobile phase composition.  
Analysis on the Q-Exactive Plus mass spectrometer was performed in full scan mode (mass 
resolution of 70 000 and 5 ppm mass accuracy) to allow for the identification of the analytes 
of interest using the molecular ion. Table 2.1 outlines the optimised mass spectrometer (MS) 
operating conditions used for the analysis of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine in fingerprint samples.  
Table 2.1: Operating conditions of the mass spectrometer used in this research. 
Parameter Operating condition 
Source parameters 
Spray voltage 3 kV 
Capillary temperature 320 ºC 
S-lens RF level 50 
Sheath gas flow rate 45 
Aux gas flow rate 10 
Scan parameters 
Scan type Full MS 
Scan range m/z 50 - 500 
Resolution 70 000 at m/z 200 
Polarity Positive 
AGC target 106 
Maximum inject time 200 
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The [M+H] peaks for all analytes of interests and internal standards were monitored. A list 
of the m/z ratios monitored for the analytes of interests are detailed in Table 2.2. 
Table 2.2: Ions (m/z ratio) monitored for the analytes of interest and corresponding 
deuterated internal standards. 
Analyte m/z ratio 
Cocaine 304.1543 
Benzoylecgonine 290.1387 
Heroin 370.1649 
6-Acetylmorphine 328.1543 
Internal standard m/z ratio 
Cocaine-d3 307.1732 
Benzoylecgoninde-d3 293.1575 
Heroin-d9 379.2214 
6-Acetylmorphine-d3 331.1732 
2.2.3 Sample surface and extraction solutions 
The preparation of fingerprint samples for LC-MS analysis requires the use of a solvent to 
extract the fingerprint from the sample surface and into a solution. The surface and 
extraction solution used for the deposition and extraction of a fingerprint may have a 
significant effect on the ability to extract and analyse the analytes of interests. Therefore, 
comparative experiments are recommended using a range of surfaces that are representative 
of those that the method may be applied to in operational work (Sears et al., 2012). A number 
of procedures have been reported for the analysis of drugs in fingerprints using LC-MS, 
including the type of sample substrate used for collection, extraction method and extraction 
solutions used. These describe different approaches to the collection and extraction of 
fingerprints. Fingerprint samples have previously been collected on glass cover slips 
(Goucher et al., 2009; Jacob et al., 2008) or filter paper (Kuwayama et al., 2014; Kuwayama 
et al., 2013) for the detection of lorazepam, methadone, cold medicine and caffeine, 
respectively. In this research, two surfaces (chromatography paper and glass cover slips) 
previously used for fingerprint depositions were investigated in combination with a range of 
extraction solvents, including methanol, acetonitrile, dichloromethane, chloroform, ethyl 
acetate, 10% (v/v) methanol in dichloromethane and 10% (v/v) methanol in chloroform. 
This was to evaluate the suitability of the surfaces and extraction solutions for the analysis 
of cocaine, benzoylecgonine, heroin and 6-acetylmorphine in an artificial eccrine 
perspiration solution to simulate a fingerprint deposition.  
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Ten µl of analyte standard in artificial eccrine perspiration was spiked onto Whatman™ 
grade-1 chromatography paper (2 x 2 cm) or a glass cover slip (16 mm diameter) and left to 
dry overnight to produce 5 ng of analyte residue on the surface. The sample (paper or glass 
cover slip) was placed in a scintillation vial (outer diameter 27 mm) (Fisher Scientific, 
Leicestershire, UK) with 0.5 ml of one of the extraction solutions mentioned above and 
sonicated for 15 min. Next, the sample extract was vortex-mixed for 15 sec and transferred 
to an LC autosampler vial. The sample extract was evaporated to dryness under a stream of 
nitrogen at room temperature (20 ºC) and reconstituted in 100 µl mobile phase solution (5% 
acetonitrile in water with 0.1% (v/v) formic acid) containing 50 ng/ml internal standard 
solution and vortex-mixed again for 30 sec prior to LC-MS analysis. The extraction 
efficiency for the analytes of interest was evaluated in an artificial eccrine perspiration 
solution to produce a similar sample matrix to eccrine fingerprint samples. These were 
compared against an analyte standard at 50 ng/ml) in 5% (v/v) acetonitrile in water with 
0.1% formic acid and 50 ng/ml internal standard solution at the same concentration as the 
final sample extract. 
2.2.3.1 Internal standard 
Certified reference material (CRM) of cocaine-d3, benzoylecgonine-d3, heroin-d9 and 6-
acetylmorphine-d3 (100 µg/ml, Sigma Aldrich, Dorset, UK) were used as internal standards. 
The use of an internal standard can aid quantification of analytes, especially in a multi-step 
sample preparation method. The internal standard can help to correct for any sample volume 
loss during extraction as the relative instrument response of the analyte and internal standard 
would be constant. Five replicate samples were prepared at 5 ng analyte residue on surface 
by adding 10 µl of 500 ng/ml drug standard (containing cocaine, benzoylecgonine, heroin 
and 6-acetylmorphine) in acetonitrile on the paper. The stage at which the internal standard 
was introduced during the sample preparation method was investigated by adding the 
internal standard (i) before the extraction procedure (500 ng/ml internal standard solution in 
acetonitrile spiked on paper) and (ii) during reconstitution of the sample extract in the 
injection solvent (50 ng/ml internal standard solution in 5% (v/v) acetonitrile in water with 
0.1% formic acid). The influence of the addition of the internal standard on the percentage 
recovery of cocaine, benzoylecgonine, heroin and 6-acetylmorphine was investigated using 
extraction solutions of 10, 20 and 30% (v/v) methanol (MeOH) in dichloromethane (DCM). 
The extraction was performed by placing the sample in a scintillation vial with 0.5 ml of 
extraction solution and 15 min sonication. The solvent extract was vortex-mixed for 15 sec, 
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transferred to an LC autosampler vial and evaporated to dryness under a stream of nitrogen 
at room temperature (20 °C). The subsequent sample residue was reconstituted in 100 µl 
mobile phase solution (5% acetonitrile in water with 0.1% (v/v) formic acid containing 50 
ng/ml internal standard solution) and vortex-mixed again for 30 sec prior to LC-MS analysis.  
2.2.4 Extraction procedures 
The extraction efficiency of two different procedures using paper surfaces were evaluated, 
which included (i) vials and sonication and (ii) microcentrifuge tubes and centrifugation. 
Both approaches have been used for the extraction of fingerprint material of surfaces using 
LC-MS analysis (Kuwayama et al., 2014; Kuwayama et al., 2013; Goucher et al., 2009; 
Jacob et al., 2008). In this case, screw top vials (Smith Scientific, Kent, UK) were evaluated 
for extraction (outer diameter 27.5 mm) in combination with extraction solutions containing 
different ratios (v/v) of methanol and dichloromethane (including 10, 20, 30% (v/v) 
methanol in dichloromethane and 10, 20, 30% (v/v) dichloromethane in methanol). Each 
extraction solution was evaluated using n = 5 replicate samples at 5 ng of analyte residue in 
artificial eccrine perspiration on surface. The extraction was performed by placing the 
sample in a scintillation vial with 0.5 ml of extraction solution and sonicated for 15 min. 
The solvent extract was vortex-mixed for 15 sec, transferred to an LC autosampler vial and 
evaporated to dryness under a stream of nitrogen at room temperature (20 °C). The 
subsequent sample residue was reconstituted in 100 µl mobile phase solution (5% 
acetonitrile in water with 0.1% (v/v) formic acid containing 50 ng/ml internal standard 
solution) and vortex-mixed again for 30 sec prior to LC-MS analysis.  
An alternative fingerprint extraction method has been reported in the literature (Kuwayama 
et al., 2014; Kuwayama et al., 2013), which is based on the use of a microcentrifuge tube 
and centrifugation of the sample, for the extraction of fingerprint material from a paper 
substrate. For this approach, samples were extracted by placing the paper substrate in a 
microcentrifuge tube (2 ml) with 1.5 ml of extraction solution (10, 20, 30% (v/v) methanol 
in dichloromethane and 10, 20, 30% (v/v) dichloromethane in methanol) and centrifuging 
for 2 min at 9500 x g relative centrifugal force (rcf). The paper was discarded and the sample 
extract was evaporated to dryness under a stream of nitrogen at room temperature (20 °C). 
The subsequent sample residue was reconstituted in 100 µl mobile phase solution (5% 
acetonitrile in water with 0.1% (v/v) formic acid containing 50 ng/ml internal standard 
solution) and vortex-mixed again for 30 sec prior to LC-MS analysis.  
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2.2.5 Matrix effects 
The experimental design for the fingerprint extraction method development was based on 
using an artificial eccrine sweat solution to simulate eccrine fingerprint samples in the 
absence of a validated fingerprint standard. The artificial eccrine perspiration was used in 
the evaluation of the extraction procedures to determine the suitability of the sample surface 
and extraction solutions for the analysis of cocaine and heroin use in fingerprints. 
2.2.5.1 Participant selection and sampling 
The developed extraction method was used to evaluate the effects of the matrix on the 
extraction efficiency of cocaine, heroin and respective metabolites for (i) acetonitrile, (ii) 
artificial eccrine perspiration and (iii) fingerprints at three levels, namely 1, 5 and 10 ng of 
analyte residue on surface. A favourable ethical approval was obtained from the University 
of Surrey Ethics Committee to collect samples from individuals at the University of Surrey 
who volunteered to participate. Fingerprint samples were collected from n = 5 participants 
without any preparation of the hands (natural fingerprints) and after washing hands with 
soap and water, prior to wearing nitrile gloves for 10 min to aid secretion of perspiration 
from the fingertips. Four fingerprints were collected per participant (right thumb, right 
index, left thumb and left index finger) to prepare the spiked samples and a blank. A 
minimum of five participants is recommended because this allows to incorporate variations 
in gender and other factors into the experiment (Sears et al., 2012). However, due to ethical 
considerations this information is not provided. Five replicate samples were prepared for 
each matrix at each level. For fingerprints, the analyte standard (10 µl of 100, 500 or 1000 
ng/ml) in acetonitrile was pipetted onto the fingerprint samples to produce analyte residues 
on the sample surface at 1, 5 and 10 ng. Samples were extracted by placing the paper 
substrate in a microcentrifuge tube (2 ml) with 1.5 ml of extraction solution (10% 
dichloromethane in methanol) and centrifuging for 2 min at 9500 x g rcf. The paper was 
discarded and the sample extract was evaporated to dryness under a stream of nitrogen at 
room temperature (20 °C). The subsequent sample residue was reconstituted in 100 µl 
mobile phase solution (5% acetonitrile in water with 0.1% (v/v) formic acid containing 50 
ng/ml internal standard solution) and vortex-mixed again for 30 sec prior to LC-MS analysis. 
2.2.5.2 Ionisation suppression and enhancement 
Ionisation suppression or enhancement is commonly observed in LC-MS analysis as ions 
compete for ionisation in the electrospray (ESI) source. The presence of co-eluting 
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compounds can interfere with the instrument response of the analyte of interest. This 
phenomenon is mainly a concern when ionisation suppression occurs as this can negatively 
affect the limit of detection (Polettini, 2006). The potential of ionisation suppression or 
enhancement was assessed using the post-extraction addition approach (Scientific Working 
Group for Forensic Toxicology, 2013).  
A quantitative estimate of the ionisation suppression/enhancement can be obtained by 
addition of drug standards to a blank sample matrix post extraction. Three matrices were 
evaluated, including acetonitrile, artificial eccrine perspiration and fingerprints at two 
concentration levels (20 and 80 ng/ml). Two sets of samples were prepared in order to 
compare the effects of the matrix on the analyte signal. Set one consisted of analytes in 
standard solution (5% v/v acetonitrile in water with 0.1% formic acid) at 20 ng/ml and 80 
ng/ml containing 50 ng/ml internal standard (cocaine-d3, benzoylecgonine-d3, heroin-d9 and 
6-acetylmorphine-d3). Each standard was measured five times to provide an average peak 
area at both concentration levels. Set two consisted of three different blank matrices 
(acetonitrile, artificial eccrine perspiration and natural fingerprints) spiked with drug 
standards in standard solution post extraction. Ten microlitres of blank solvent (acetonitrile) 
or matrix (artificial eccrine perspiration or natural fingerprint) was added to Whatman 1-Chr 
grade paper (2 x 2 cm) and left to dry overnight. Five replicate samples were prepared for 
both acetonitrile and artificial eccrine perspiration at each concentration level. As it is known 
that the concentration levels of analytes present in fingerprints vary from person to person, 
natural fingerprints (n = 2 per participant) were collected from 10 individuals to assess the 
potential matrix effects. Samples were extracted by placing the paper substrate in a 
microcentrifuge tube (2 ml) with 1.5 ml of extraction solution (10% dichloromethane in 
methanol) and centrifuging for 2 min at 9500 x g relative centrifugal force (rcf). The paper 
was discarded and the sample extract was evaporated to dryness under a stream of nitrogen 
at room temperature (20 °C). The samples were reconstituted with an analyte standard (at 
20 or 80 ng/ml) in the mobile phase solution (5% acetonitrile in water with 0.1% (v/v) formic 
acid containing 50 ng/ml internal standard containing cocaine-d3, benzoylecgonine-d3, 
heroin-d9 and 6-acetylmorphine-d3). Each sample was injected five times and the average 
peak area obtained was compared to those of set one, as shown in Equation 2.1.  
Ionisation suppression or enhancement (%)= #Average Peak Area of Set 2
Average Peak Area of Set 1
-1$ × 100 Eq. 2.1 
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2.2.6 Spike recovery 
The recovery of the developed extraction method was evaluated using analyte standards 
(containing cocaine, benzoylecgonine, heroin and 6-acetylmorphine) in acetonitrile at 100, 
500 and 1000 ng/ml, to produce spiked fingerprints (using n = 5 participants, with 3 
fingerprints collected per participant) at 1, 5, and 10 ng of analyte residue on surface. 
Participant selection and sampling was discussed in section 2.2.5.1. Samples were extracted 
by placing the paper substrate in a microcentrifuge tube (2 ml) with 1.5 ml of extraction 
solution (10% dichloromethane in methanol) and centrifuging for 2 min at 9500 x g rcf. The 
paper was discarded and the sample extract was evaporated to dryness under a stream of 
nitrogen at room temperature (20 °C). The subsequent sample residue was reconstituted in 
100 µl mobile phase solution (5% acetonitrile in water with 0.1% (v/v) formic acid 
containing 50 ng/ml internal standard solution) and vortex-mixed again for 30 sec prior to 
LC-MS analysis. The average percentage recovery for cocaine, benzoylecgonine, heroin and 
6-acetylmorphine at each level (1, 5 and 10 ng) in fingerprints was calculated based on the 
original spiked concentration.  
2.2.7 Data analysis 
The following section details the statistical calculations used in this research including the 
use of the statistics of repeated measurements by calculating the average, standard deviation 
and relative standard deviation. Comparison of medians was carried out by using a Mann-
Whitney U test or Kruskal-Wallis test. The calculations below are applied throughout 
Chapters 3 to 6. 
2.2.7.1 Average and standard deviation 
The average of repeated measurements was calculated for all analytes above the limit of 
detection using the following equation (Miller & Miller, 2005): %̅ = 	 )	*+,      Eq. 2.2 
where %̅ = average, Σ	%. = sum the individual measurements and / = the number of 
measurements. The standard deviation (s) evaluates the spread of all the individual 
measurements and was calculated using (Miller & Miller, 2005): 0 = 	1∑(*+3	*̅)	4(	,35	)      Eq. 2.3 
Chapter 2: Analytical Methodology 
45 
 
2.2.7.2 Relative standard deviation (RSD) 
The relative standard deviation (or coefficient of variation), used as a measure of the 
precision of the method, was calculated to evaluate the relative error of the measurements 
using the following equation (Miller & Miller, 2005): 678	 = 	 9*̅ 	× 	100     Eq. 2.4 
where s = standard deviation and %̅ = average. 
2.2.7.3 F-test 
An F-test was used to determine whether the sample standard deviations of two data sets 
were significantly different at a specific significance level (i.e. probability (p) = 0.05). In 
this research a two-sided test was performed to determine whether the sample variances were 
different in their precision at p = 0.05 (Miller & Miller, 2005). The F statistic considers the 
ratio of the two sample standard deviations and can be calculated using the following 
information, sample standard deviation s1 and sample standard deviation s2. Where 05= is the 
largest sample variance and 0== is the smallest sample variance, so that F is always > 1. 
> = 	 9?4944      Eq. 2.5 
The degrees of freedom of the numerator and denominator are n1 – 1 and n2 – 2. If the Fcalc 
exceeds Fcrit then the null hypothesis is rejected, and the two sample standard deviations are 
significantly different at that specific significance level. 
2.2.7.4 Comparison of two experimental means 
The Student t-test was used to evaluate the statistical probability of whether the experimental 
value was significantly different from a second experimental value. The t-test can be 
performed using the following information to calculate the statistic t, the average 
measurement of the sample (%̅), the known value (@), the sample standard deviation (s) 
calculated using Eq. 2.7 and the number of samples (n). The following equation can be used 
to calculate t, if the samples have standard deviations which are not significantly different 
(determined using F-test, where Fcalc<Fcrit) (Miller & Miller, 2005): 
A = (*̅?3	*̅4)91 ?B?C	 ?B4	  0= = 	 (,?35)9?4C(,435)944(,?C	,43=)  Eq. 2.6 and Eq. 2.7 
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If the calculated |t| value is above the critical value (tcrit) then the difference observed 
between the two values is significant at that significance level (i.e. p = 0.05) for n1 + n2 – 1 
degrees of freedom.  If the samples have standard deviations which are significantly different 
(Fcalc>Fcrit), Eq. 2.8 and Eq. 2.9 are used to calculate the statistic t and degrees of freedom 
(dof) (Miller & Miller, 2005). 
A = (*̅?3	*̅4)9DE?4B?C	E44B4	  FGH = 	 (,?35)9?4C(,435)944(,?C	,43=)  Eq. 2.8 and Eq. 2.9 
2.2.7.5 Mann-Whitney U-test 
The Mann-Whitney U-test is considered to be the equivalent to the Student t-test for data 
that is not normally distributed (non-parametric) (Mendes, 2008). The Mann-Whitney U-
test can be used to compare the median of the dependent variables (e.g. levels of analyte in 
a fingerprint) of two or more categories of the independent variables (e.g. collection 
methods, natural, soap or wipe). The null hypothesis for the Mann-Whitney U-test is that 
the dependent variables (e.g. level of analyte in a fingerprint) are not dependent on the 
independent variables (e.g. collection methods) and thus have the same median values. The 
test determines the number of results in one data set that exceeds each of the results in the 
second data set (Miller & Miller, 2005). The number of values that exceed the data set 
between the independent variables tested are summed up and compared (Mendes, 2008). 
The sum of the number of values that are higher is termed the U statistic (Mendes, 2008). 
The U statistic is compared to a critical U value to determine whether to reject or accept the 
null hypothesis. If the Ucalc is below the critical U value, then the difference observed 
between the data sets is significant at the specified significance level. In this research a one-
sided test was performed to determine whether the level of analyte present in a fingerprint 
was significantly lower or higher based on independent variables.  For a sample size greater 
than 20, the U distribution approximates a normal distribution and requires the use of a z 
value (Mendes, 2008). The z statistic can be calculated from the U statistic using the 
following equation (Miller & Miller, 2005):  
I = 	 J3	KLML       Eq. 2.10 
where U = the sample statistic; µu = average of the sampling distribution of sample U; σu = 
standard deviation of the sampling distribution of sample U. 
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The average (µu) and standard deviation (σu) are calculated using Eq. 2.11 and Eq. 2.12 
(Miller & Miller, 2005). 
@N = 	O?	O4=    PN = 	1O?	O4	(O?C	O4C5)5=  Eq. 2.11 and Eq. 2.12 
where N1 and N2 = sample sizes for data set 1 and 2, respectively. 
2.2.7.6 Kruskal-Wallis test 
The Kruskal-Wallis test is an extension of the Mann-Whitney U test as it allows for the 
comparison of three or more sample medians (e.g. study populations A, B and C). The 
individual results from each data set are pooled and ranked (Miller & Miller, 2005). The 
rank totals are compared by calculating the chi-squared statistic (c2) using the following 
equation (Miller & Miller, 2005): 
c2	 = 	 5=O4CO 	RST4,T +	SV4,V +	SW4,W + ⋯Y − 3(\ + 1)    Eq. 2.13 
where nA, nB, nC are the number of measurements, RA, RB and RC are the rank totals and N 
is the sum of numbers in each data set given by N = nA + nB + nC, etc. 
The calculated chi-squared statistic (c2) is then compared to tabulated values, with the 
number of degrees of freedom given by k – 1. If the calculated c2 statistic is greater than the 
tabulated values, the null hypothesis is rejected (e.g. the medians of the samples are not 
significantly different). 
2.3 Results and Discussion 
2.3.1 Effect of the sample substrate and extraction solution 
The extraction efficiency (expressed as the average percentage recovery) varied greatly 
depending on the extraction solvent and surface used, as seen for cocaine, heroin and its 
respective metabolites benzoylecgonine and 6-acetylmorphine in Figure 2.4. This is due to 
differences in the chemical structure of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine, which are fairly non-polar to moderately polar, with the respective 
metabolites being more polar (Chapter 1, section 1.2.3.2 and 1.2.4.2). A range of extraction 
solutions of different polarities were therefore evaluated to optimise the extraction efficiency 
of the analytes of interest. The use of relatively non-polar solvents, such as dichloromethane, 
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chloroform and ethyl acetate, was not suitable for the extraction of cocaine, 
benzoylecgonine, heroin and 6-aectylmorphine from both surfaces, as seen in Figure 2.4.  
 
Figure 2.4: Average percentage recovery (± standard deviation, n = 5 measurements) for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine in a spiked artificial 
perspiration standard (n = 1 sample) extracted from paper or glass cover slips 
using scintillation vials with methanol, acetonitrile, dichloromethane (DCM), 
ethyl acetate, chloroform (CHCl3), 10% (v/v) methanol (MeOH) in 
chloroform, 10% (v/v) methanol (MeOH) in dichloromethane (DCM).  
Additionally, the chromatography paper used consisted of cellulose, which contains 
hydroxyl groups that can interact with the analytes of interest. In order for the analytes of 
interest to be extracted, the affinity for the extraction solvent must be greater than the paper 
substrate. Therefore, the use of a polar solvent (such as methanol and acetonitrile) resulted 
in a higher extraction efficiency particularly for glass cover slips. The presence of a polar 
protic solvent (such as methanol) allows hydrogen bonding, compared to a polar aprotic 
solvent (such as acetonitrile). The presence of the amine and carbonyl groups in the analytes 
of interest can form hydrogen bonding with the hydroxyl present in the extraction solvent 
(methanol), unlike acetonitrile. Therefore, methanol provides better extraction of cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine (with the exception of heroin for the glass 
cover slips). However, a combination of a polar and a semi-polar solvent (e.g. methanol and 
dichloromethane or chloroform) provided the highest extraction efficiency for all analytes 
using paper as the sample substrate. The use of a combination of these solvents accounts for 
interaction with the solvent through a hydrophobic effect (with analyte hydrophobic groups), 
further increasing the affinity of the analytes of interest for the extraction solution over the 
paper substrate. The extraction solution containing 10% (v/v) methanol in dichloromethane 
was chosen for the extraction of cocaine, heroin and respective metabolites. However, the 
M
et
ha
no
l
Ac
et
on
itr
ile
D
C
M
Et
hy
l a
ce
ta
te
C
H
C
l 3
10
%
 M
eO
H
 
in
 C
H
C
l 3
10
%
 M
eO
H
 
in
 D
C
M
0
10
20
30
40
50
60
70
80
90
100
Extraction solvent
%
 R
ec
ov
er
y
 Cocaine
 Benzoylecgonine
 Heroin
 6-Acetylmorphine
Glass cover slip
M
et
ha
no
l
Ac
et
on
itr
ile
D
C
M
Et
hy
l a
ce
ta
te
C
H
C
l 3
10
%
 M
eO
H
 
in
 C
H
C
l 3
10
%
 M
eO
H
 
in
 D
C
M
0
10
20
30
40
50
60
70
80
90
100
Extraction solvent
Paper
%
 R
ec
ov
er
y
 Cocaine
 Benzoylecgonine
 Heroin
 6-Acetylmorphine
Chapter 2: Analytical Methodology 
49 
 
recoveries for all analytes were generally below 60%. This could be due to the extraction 
method used, as the sonication caused the paper to rise in the scintillation vial and not stay 
immersed in the extraction solvent. The use of dichloromethane and methanol has also been 
reported for the extraction of lorazepam and methadone from fingerprint samples on glass 
cover slips (Goucher et al., 2009; Jacob et al., 2008).  
2.3.2 Internal standard 
The point at which the internal standard was added during the extraction procedure was 
investigated to determine the influence of adding (i) the internal standard before extraction 
and (ii) in the reconstitution step (Figure 2.5). In quantitative measurements the internal 
standard is normally added to experience the entire extraction procedure, thus accounting 
for any loss of signal during the extraction. Addition of the internal standard prior to the 
extraction procedure resulted in average percentage recoveries of 25 – 29% for cocaine, 28 
– 31% for benzoylecgonine, 30 – 33% for heroin and 35 – 41% for 6-acetylmorphine using 
10, 20 and 30% methanol in dichloromethane as extraction solutions. In contrast, the 
addition of the internal standard in the reconstitution step resulted in average percentage 
recoveries of 53 – 59% for cocaine, 50 – 52% for benzoylecgonine, 52 – 56% for heroin and 
49% for 6-acetylmorphine.  
 
Figure 2.5: Evaluation of the addition of the internal standard (IS) during the sample 
preparation method using 10, 20 and 30% (v/v) methanol (MeOH) in 
dichloromethane (DCM) as extraction solutions. Internal standard was added 
before the extraction method or during reconstitution of the sample extract. 
Data represented as average percentage recovery (± standard deviation, n = 
5 measurements). 
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The results indicate that addition of the internal standard after evaporation to dryness 
provides higher recoveries for all analytes, for all three extraction solvents evaluated (10, 20 
and 30% MeOH in DCM). This is contradictory to what might have been expected. Although 
this method does not account for any volume loss during the sample preparation steps, better 
results were obtained adding the internal standard in the reconstitution step. In addition, no 
significant difference was observed in the extraction efficiency of cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine for the three extraction solutions evaluated (10, 20 or 30% 
methanol in dichloromethane).  
In light of the results presented in Figure 2.5, a 50 ng/ml internal standard solution (in 5% 
(v/v) acetonitrile in water with 0.1% (v/v) formic acid) containing cocaine-d3, 
benzoylecgonine-d3, heroin-d9 and 6-acetylmorphine-d3 was added in the reconstitution step 
of the extraction procedure prior to LC-MS analysis in all proceeding experiments to correct 
for any change in signal observed due to instrument response variance. The average peak 
area ratio of analyte (A) to internal standard (IS) was calculated for data analysis. As the 
internal standard does not experience the full extraction procedure, it cannot be used for 
quantitative measurements as it does not represent the analytes of interest performance 
during the sample preparation steps. 
2.3.3 Extraction procedures 
The use of a different vial type for extraction was investigated to improve the recovery for 
the analytes of interest (at 5 ng analyte residue on surface) using 10, 20 and 30% methanol 
in dichloromethane and 10, 20 and 30% dichloromethane in methanol as extraction 
solutions. The use of a different scintillation vial was explored as the vials used previously 
were small and as a result the paper substrate did not remain immersed in the extraction 
solution. The use of different screw top vials for extraction improved the percentage 
recovery to above 60%. In addition, the percentage recovery for each analyte was higher 
using extraction solutions containing a higher percentage of methanol than dichloromethane, 
as seen in Figure 2.6, with recoveries close to 90% for all analytes. A higher percentage 
polar solvent in the extraction mixture is more efficient extracting cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine as this allows for more hydrogen bonding.   
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Figure 2.6: Average percentage recovery (± standard deviation, n = 5 measurements) for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine in a spiked artificial 
perspiration standard (n = 5) extracted from paper using scintillation vials 
using 10, 20, 30% (v/v) methanol (MeOH) in dichloromethane (DCM) and 
10, 20, 30% (v/v) dichloromethane (DCM) in methanol (MeOH). 
Two different approaches (using scintillation vials and microcentrifuge tubes) for the 
extraction of the analytes of interest (at 5 ng of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine) from paper were investigated to develop an optimised extraction method 
using 10, 20 and 30% dichloromethane in methanol. Figure 2.7 shows the percentage 
recoveries obtained for both extraction methods using (i) scintillation vials and (ii) 
microcentrifuge tubes. The percentage recoveries for all analytes improved with the use of 
Eppendorf™ microcentrifuge tubes and centrifugation compared to the use of screw top 
vials (Smith Scientific, Kent, UK) and sonication. During the extraction method 
development experiments, it was observed that the percentage recoveries obtained in Figure 
2.7 were lower than those previously observed in Figure 2.6. This was most likely caused 
by the ultrasonic bath, as the water was warm and this could have caused evaporation of the 
sample during sonication as this has been observed in previous experiments. Overall, the 
extraction method using Eppendorf™ microcentrifuge tubes using 10% (v/v) 
dichloromethane (DCM) in methanol (MeOH) as the extraction solution, provided the 
highest percentage recoveries (between 89 – 96%) for all analytes. 
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Figure 2.7: Average percentage recovery (± standard deviation, n = 5 measurements) for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine in a spiked artificial 
perspiration standard (n = 5) extracted from paper in screw top vials using 
10, 20, 30% (v/v) dichloromethane (DCM) in methanol (MeOH). 
2.3.4 Extraction method 
The developed extraction method was performed based on three steps before LC-MS 
analysis, namely sample extraction, evaporation to dryness and reconstitution. Figure 2.8 
outlines the developed extraction procedure used for the preparation of samples for LC-MS 
analysis. In order to extract the analytes from the surface, the paper surface was placed in a 
2 ml Eppendorf™ microcentrifuge tube with 1.5 ml extraction solution 10% (v/v) 
dichloromethane (DCM) in methanol (MeOH). The sample was centrifuged for 2 min at 
9500 x g relative centrifugal force (rcf). The paper was then removed from the 
microcentrifuge tube and discarded. The resulting sample extract was evaporated to dryness 
under a stream of nitrogen at room temperature (20 ºC). A 100 µl of mobile phase solution, 
5% (v/v) acetonitrile in water with 0.1% formic acid containing 50 ng/ml of internal standard 
solution (cocaine-d3, benzoylecgonine-d3, heroin-d9 and 6-monoacetylmorphine-d3) was 
added to reconstitute the extract. The sample was then centrifuged for 2 min at 9500 x g rcf 
and transferred to an autosampler vial for LC-MS analysis. This extraction method was 
applied to all fingerprint samples collected in this research. 
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Figure 2.8: Extraction procedure for the analysis of cocaine, benzoylecgonine, heroin 
and 6-acetylmorphine in fingerprint samples. 
2.3.5 Matrix effects 
The effects of the matrix on the extraction efficiency of cocaine, heroin and respective 
metabolites were evaluated for acetonitrile, artificial eccrine perspiration and fingerprints 
using analyte standards at three concentration levels, 100, 500 and 1000 ng/ml. Five replicate 
samples were prepared for each matrix at each concentration level, with 10 µl of standard 
spiked onto paper to produce 1, 5 and 10 ng of analyte residue on surface. For fingerprints, 
the analyte standard (10 µl of 100, 500 or 1000 ng/ml) in acetonitrile was pipetted onto 
fingerprint samples collected from non-drug users. Fingerprint samples were collected from 
n = 5 participants without any preparation of the hands (natural fingerprints) and after 
washing hands with soap and water, prior to wearing nitrile gloves for 10 min to aid the 
secretion of perspiration from the fingertips. All samples were extracted using the extraction 
method detailed in section 2.3.4. Figure 2.9 shows that the average peak area ratio analyte 
(A) to internal standard (IS) obtained for cocaine and benzoylecgonine was not analyte 
dependent or matrix dependent, as the ratio A/IS is similar for all concentration levels and 
matrices assessed. Results for heroin and 6-acetylmorphine also indicate that the extraction 
of an analyte standard in acetonitrile and a spiked fingerprint sample produce similar effects. 
However, the use of artificial eccrine perspiration produced matrix effects for heroin and 6-
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acetylmorphine as a higher ratio A/IS was consistently observed for both analytes at all three 
concentration levels compared to acetonitrile or fingerprints. This shows that artificial 
eccrine perspiration is not representative of a typical fingerprint matrix. Therefore, in the 
absence of a validated fingerprint standard it was chosen to not produce matrix-matched 
calibration curves. Although it is possible to report the results for cocaine and 
benzoylecgonine as an amount of analyte (e.g. in ng) per fingerprint (as no matrix effects 
are observed), this is not reported throughout the thesis as this is not possible for heroin and 
6-acetylmorphine due to differences observed for the analyte signal in the presence of a 
fingerprint sample compared to a standard in acetonitrile. Results are therefore reported as 
a ratio of analyte-to-internal standard (ratio A/IS) signal to allow for the comparison between 
the levels of analytes in fingerprint samples. 
Interestingly, the fingerprint samples (natural and after washing hands) from the five donors 
studied here show that the matrix effects observed between donors do not vary greatly 
(fingerprint variability (n = 5 participants) <15% for natural fingerprints and <10% after 
washing hands with soap).  
 
Figure 2.9: Average peak area ratio A/IS (± standard deviation, n = 5 measurements) for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine for (n = 5) in spiked 
acetonitrile, artificial eccrine perspiration and fingerprints (natural and after 
washing hands with soap). 
2.3.5.1 Ionisation suppression/enhancement 
The influence of ionisation suppression/enhancement of the sample matrix on cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine was evaluated using acetonitrile (n = 5), 
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artificial eccrine perspiration (n = 5) and natural fingerprints (n = 10). A blank solvent 
(acetonitrile), blank solution (artificial eccrine perspiration) or natural fingerprints were 
deposited on paper and extracted using the extraction method detailed in section 2.3.4. The 
sample matrices were then spiked with 20 and 80 ng/ml drug standard (containing 50 ng/ml 
internal standard solution) post extraction to assess the influence of the matrix on the 
analytes of interest. The ionisation suppression/enhancement percentages (%IS/IE) for both 
concentration levels (20 ng/ml and 80 ng/ml) are provided in Table 2.3 and Table 2.4 for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine, respectively. Results show that the 
percentage ionisation suppression/enhancement (% IS/IE) for cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine have negative values, which indicates that some ionisation 
suppression occurred, however this was < 14% for both concentration levels. Additionally, 
the same effect was observed for the drug and internal standard. As the average ionisation 
suppression did not exceed 25% (Scientific Working Group for Forensic Toxicology, 2013); 
this was acceptable. Although the average peak area showed some ionisation 
suppression/enhancement effects for the analytes of interest, the ratio A/IS was consistent 
with the reference standards for all analytes at both concentration levels. This is because the 
same effect was observed for the deuterated internal standards, therefore using the ratio 
analyte (A) to internal standard (IS) corrected for the ionisation suppression effects 
observed. 
Table 2.3: Ionisation suppression/enhancement (percentage) for the analysis of cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine at 20 ng/ml in acetonitrile, 
artificial eccrine sweat and fingerprint samples (participants 1 – 10). 
Sample 
Ionisation suppression or enhancement (IS/IE) % 
Coc Coc-d3 BZE BZE-d3 Her Her-d9 6-AM 6-AM-d3 
Acetonitrile -4 -3 -9 -8 -2 -3 -2 -3 
Artificial eccrine 
perspiration 1 1 0 1 -1 -2 2 -2 
Fi
ng
er
pr
in
t 
Participant 1 -3 -3 -8 -8 -4 -4 -4 -3 
Participant 2 -4 -3 -10 -9 -4 -5 -5 -4 
Participant 3 -5 -5 -8 -8 -6 -6 -5 -4 
Participant 4 -4 -4 -12 -11 -4 -4 -5 -5 
Participant 5 -5 -5 -11 -10 -4 -4 -5 -5 
Participant 6 -5 -4 -7 -7 -5 -5 -4 -4 
Participant 7 -6 -6 -13 -12 -5 -5 -7 -6 
Participant 8 -4 -5 -9 -8 -4 -5 -5 -5 
Participant 9 -4 -3 -6 -6 -3 -3 -4 -4 
Participant 10 -4 -3 -8 -7 -3 -3 -3 -3 
Where Coc = cocaine; Coc-d3 = cocaine-d3; BZE = benzoylecgonine; BZE-d3 = benzoylecgonine-d3; Her = 
heroin; Her-d9 = heroin –d9; 6-AM = 6-acetylmorphine; 6-AM-d3 = 6-acetylmorphine-d3 
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Table 2.4: Ionisation suppression/enhancement (percentage) for the analysis of cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine at 80 ng/ml in acetonitrile, 
artificial eccrine sweat and fingerprint samples (participants 1 – 10). 
Sample 
Ionisation suppression or enhancement (IS/IE) % 
Coc Coc-d3 BZE BZE-d3 Her Her-d9 6-AM 6-AM-d3 
Acetonitrile -1 -2 -8 -8 -2 -3 -2 -2 
Artificial eccrine 
perspiration 2 2 -5 -5 -1 -2 2 0 
Fi
ng
er
pr
in
t 
Participant 1 -1 -1 -5 -6 -4 -4 -4 -2 
Participant 2 -2 -2 -8 -8 -4 -5 -5 -2 
Participant 3 -2 -2 -5 -5 -6 -6 -5 -2 
Participant 4 -5 -5 -14 -13 -4 -4 -5 -11 
Participant 5 -3 -3 -8 -9 -4 -4 -5 -4 
Participant 6 -3 -4 -7 -7 -5 -5 -4 -3 
Participant 7 -2 -2 -5 -5 -5 -5 -7 -2 
Participant 8 -2 -2 -6 -6 -4 -5 -5 -2 
Participant 9 -2 -2 -3 -3 -3 -3 -4 -2 
Participant 10 -4 -4 -5 -5 -3 -3 -3 -2 
Where Coc = cocaine; Coc-d3 = cocaine-d3; BZE = benzoylecgonine; BZE-d3 = benzoylecgonine-d3; Her = 
heroin; Her-d9 = heroin –d9; 6-AM = 6-acetylmorphine; 6-AM-d3 = 6-acetylmorphine-d3 
2.3.6 Spike recovery  
The recovery of cocaine, benzoylecgonine, heroin and 6-acetylmorphine using the 
developed extraction method was evaluated at 1, 5 and 10 ng of analyte residue on surface 
in the presence of fingerprints (n = 5 participants). The average percentage recovery for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine are outlined in Table 2.5.  
Table 2.5: Percentage recovery range for cocaine, benzoylecgonine, heroin and 6-
monoacetylmoprhine for (n = 5 measurements) spiked fingerprints (natural 
and after washing hands with soap). 
Analyte Percentage recovery (%) Fingerprints (natural) Fingerprints (soap) 
Cocaine 85 – 90 85 – 90 
Benzoylecgonine 83 – 91 85 – 90 
Heroin 33 – 37 33 – 34 
6-Acetylmorphine 26 – 30 23 – 25 
 
The initial extraction method was performed using artificial eccrine sweat to simulate a 
fingerprint sample, however as this resulted in a higher extraction efficiency for heroin and 
6-acetylmorphine compared to fingerprints and acetonitrile (as observed in Figure 2.9, 
section 2.3.5), it was not representative of a fingerprint matrix. Therefore, the recovery was 
assessed using natural fingerprints and samples collected after washing hands, which were 
spiked with drug standard in acetonitrile. Good recoveries were obtained for cocaine (85 – 
90%) and benzoylecgonine (83 – 91%). However, lower percentage recoveries were 
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observed for heroin (26 – 30%) and 6-acetylmorphine (23 – 25%) in the presence of 
fingerprint samples. Overall, the developed fingerprint extraction method was considered to 
provide reliable and repeatable results for each analyte of interest. 
2.3.7 Method performance 
A validation study was carried out for qualitative confirmation/identification measurements 
according to the Scientific Working Group for Forensic Toxicology guidelines to evaluate 
the analytical performance of the developed method. A set of experiments were performed 
to determine the reliability of the method for its intended use and evaluate the limitations of 
the method, including the working range, sensitivity (limit of detection) and sample stability.   
2.3.7.1 Definitions 
The definitions provided below are according to the guidelines of the Scientific Working 
Group of Forensic Toxicology. 
Accuracy: 
closeness of agreement between the mean of the result of measurements of a measurand and 
the true value of a measurand. 
Blank matrix sample (blank sample): 
a biological fluid or tissue (or synthetic substitute) without target analyte or internal 
standard. 
Calibration model:  
the mathematical model that demonstrates the relationship between the concentration of 
analyte and the corresponding instrument response.  
Carry-over: 
the appearance of unintended analyte signal in a subsequent sample after the analysis of a 
positive sample. 
Fortified matrix sample (spiked sample): 
a blank matrix sample spiked with target analyte and/or internal standard using reference 
materials. 
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Interferences: 
non-target analytes (i.e. matrix components, other drugs and metabolites, internal standard, 
impurities) which may impact the ability to detect, identify, or quantitate a targeted analyte. 
Ionisation suppression/enhancement 
Limit of detection: 
an estimate of the lowest concentration of an analyte in a sample that can be reliably 
differentiated from blank matrix and identified by the analytical method. 
Precision: 
the measure of closeness of agreement between a series of measurements obtained from 
multiple samples of the same homogenous sample. 
Repeatability: 
expresses the precision under the same operating conditions over a short time interval. 
Reproducibility: 
expresses the precision under different days, by different analysts, in different laboratories 
using different instrumentation. 
Reference material: 
material, sufficiently homogenous and stable with respect to one or more specified 
properties, which has been established to be fit for intended use in a measurement process. 
Stability: 
an analyte’s resistance to chemical change in a matrix under specific conditions for given 
time intervals. 
Working range: 
the concentration range of that can be adequately determined by an instrument where the 
instrument provides a useful signal that can be related to the concentration of the analyte. 
2.3.7.2 Working range 
A linear calibration curve of analytes in a standard solution was prepared with a 
concentration range of 50 – 1000 ng/ml of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine in acetonitrile. Each calibration standard was prepared from a stock solution 
(at 5000 ng/ml in acetonitrile) containing cocaine, benzoylecgonine, heroin and 6-
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acetylmorphine. The stock solution was prepared from certified reference materials of the 
individual analytes at 1 mg/ml in acetonitrile or methanol. Calibration standards were 
prepared at 50, 100, 200, 400, 600, 800 and 1000 ng/ml in acetonitrile by appropriate dilution 
of the stock solution. Ten microlitres of the calibration standard was added to the paper 
surface (Whatman 1-Chr grade paper, 2 x 2 cm) to produce 0.5, 1, 2, 4, 6, 8, and 10 ng of 
analyte residue on surface. The samples were subsequently extracted using the method 
described in section 2.3.4. Each sample was measured five times over five consecutive days 
to evaluate the repeatability and reproducibility of the method. A blank mobile phase 
injection was performed after each calibration standard in triplicate to evaluate the potential 
for carryover at each concentration level. No carryover was observed at any calibration level 
for cocaine, benzoylecgonine, heroin and 6-acetylmorphine or the internal standards. 
Appendix A. 7 - A. 11 provides an overview of the calibration curve data obtained for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine over five separate runs. 
To evaluate the precision of the method for the retention time and peak area ratio A/IS, the 
relative standard deviation (%RSD) was calculated for the repeated measurements for each 
standard of the calibration curve. The method provided good peak area ratio A/IS 
repeatability with RSD values of 0 – 2% for the repeated measurements over five runs (n = 
25) and in a single run (n = 5). Additionally, the retention time reproducibility (%RSD) was 
<1% for all analytes over n = 5 days. The correlation coefficients (R2) were calculated with 
R2 > 0.999. This demonstrates that the method has a satisfactory level of repeatability and 
reproducibility. A summary of the instrument performance is outlined in Table 2.6. 
Table 2.6: Performance data for LC-MS analysis of cocaine, benzoylecgonine, heroin 
and 6-acetylmorphine from extracted calibration standards from paper. 
Analyte 
Retention time (min) Peak area ratio A/IS 
reproducibility %RSDa 
Linearity 
R2 mean %RSDa 
Cocaine 2.12 <1 <1 0.999 
Benzoylecgonine 2.01 <1 <1 0.999 
Heroin 2.06 <1 <1 0.999 
6-acetylmorphine 1.85 <1 <2 0.999 
a for n = 25 injections at each concentration level over 5 days. 
2.3.7.3 Limit of detection 
The limit of detection was determined by analysis of progressively more dilute extracted 
drug standards (Armbruster et al., 1994). This approach was applied, because the blank 
signal observed for heroin and 6-acetylmorphine was zero and therefore could not be used 
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to calculate the limit of detection. Standards of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine in acetonitrile were spiked on paper to produce 10, 20, 30, 40, 50, 100, 200, 
300, 400 and 500 pg of analyte residue on surface, including a blank sample substrate and 
blank solvent (acetonitrile). Ten microlitres of standard was spiked onto paper (no spike 
added to the blank paper or blank solvent) and prepared using the extraction method 
described in section 2.3.4. Using the method by Armbruster et al. (1994), the limit of 
detection was determined to be the concentration at which reproducible and reliable 
measurements were obtained for the lowest analyte concentration. The acceptance criteria 
were based on the retention time within ±2% (n = 5) and repeatability of the peak area ratio 
A/IS measurements (n = 5) ≤20%. Figure 2.10 shows the trend of the standards extracted 
from paper used to evaluate the limit of detection. The minimum detectable limit for each 
analyte of interest was determined to be; cocaine = 10 pg (ratio A/IS 0.002), 
benzoylecgonine = 30 pg (ratio A/IS 0.004), heroin = 30 pg (ratio A/IS 0.003) and 6-
acetylmorphine = 40 pg (ratio A/IS 0.003) extracted from paper. 
 
Figure 2.10: Evaluation of the limit of detection for cocaine, benzoylecgonine, heroin and 
6-acetylmorphine by analysing progressively more dilute standards using 
extracted drug standards in acetonitrile. Data represented as the average peak 
area ratio analyte (A) to internal standard (IS) (± standard deviation, n = 5 
measurements) with error bars indicating the standard deviation. 
2.3.7.4 Sample stability – processed sample 
Analyte stability in solution is an important factor to evaluate as it can influence the integrity 
of the sample for reliable detection and identification of the analytes of interest. Analyte 
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standards (containing cocaine, benzoylecgonine, heroin and 6-acetylmorphine) in 
acetonitrile were prepared to produce 0.5, 1, 2, 4, 6, 8, and 10 ng of analyte residue on 
surface. The sample stability of each analyte in standard solution (5% (v/v) acetonitrile in 
water with 0.1% formic acid) was evaluated. Each standard was measured n = 5 times, to 
provide an average peak area ratio of analyte to internal standard. The samples at each level 
were analysed after sample preparation to establish the time zero response (run 1). Each 
subsequent analysis of the samples was performed in 24-hour increments; run 1 = 0 hours, 
run 2 = 24 hours, run 3 = 48 hours; run 4 = 72 hours and run 5 = 96 hours. Figure 2.11 shows 
the level of stability maintained for cocaine, benzoylecgonine, heroin and 6-acetylmorphine 
at each concentration level. The analytes of interest were considered to be stable over 96 
hours, with an RSD less than <2% (n = 25 measurements) for all analytes. 
  
  
Figure 2.11: Evaluation of sample stability (processed sample) for cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine in standard solution (5% 
(v/v) acetonitrile in water with 0.1% formic acid and 50 ng/ml internal 
standard). Data represented as average peak area ratio analyte (A) to internal 
standard (IS) (± standard deviation, n = 5 measurements) with error bars 
indicating the standard deviation. 
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2.4 Summary 
All samples were analysed using liquid chromatography – mass spectrometry (LC-MS) at 
the University of Surrey. A fingerprint extraction method was developed for the analysis of 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine. The surface used for the deposition 
of fingerprints was evaluated using paper (Whatman 1-Chr chromatography paper) and glass 
cover slips with a range of solvent mixtures for extraction. Both sample surfaces have 
previously been used for the analysis of drugs in fingerprints (Costa, 2017; Kuwayama et 
al., 2014; Kuwayama et al., 2013; Goucher et al., 2009; Jacob et al., 2008). Results showed 
that the use of a paper surface in combination with more polar solvents resulted in higher 
extraction efficiencies for the analytes of interest (section 2.3.1). The developed extraction 
method was based on the use of microcentrifuge tubes for the extraction of cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine from paper using 10% dichloromethane in 
methanol as the extraction solvent (section 2.3.4). The effect of the matrix on the extraction 
and analysis of the analytes of interest was explored using fingerprint samples, artificial 
eccrine perspiration and acetonitrile. Matrix effects were only observed for heroin and 6-
acetylmorphine using artificial eccrine sweat compared to the use of fingerprint samples or 
acetonitrile (section 2.3.5). In light of these results and the absence of a validated fingerprint 
standard it was not possible to produce matrix-matched calibration curves, results are 
therefore stated in terms of analyte to internal standard ratio for all analytes. The recovery 
values based on spiked fingerprints (natural and after washing hands) were 85 – 90% for 
cocaine, 83 – 91% for benzoylecgonine, 26 – 30% for heroin and 23 – 25% for 6-
acetylmorphine (section 2.3.6). The experimental conditions of the LC-MS method are 
detailed in Table 2.1 (section 2.2.2). A linear response was obtained for all analytes of 
interest (for 0.5 - 10 ng of analyte residue on surface) with correlation coefficients (R2) > 
0.999 (section 2.3.7.2). Retention times and peak area ratio A/IS demonstrated excellent 
repeatability (n = 25) <1% RSD for all analytes of interest. The limit of detection for cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine was at 10, 30, 30 and 40 pg of analyte 
residue on surface (section 2.3.7.3). Additionally, the analytes of interest were stable in 
solution over 96 hours, with RSD <2% (n = 25) (section 2.3.7.4). 
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Chapter 3 Investigation into the Suitability of a Fingerprint to 
Detect Cocaine and Heroin use 
3.0 Introduction 
One of the objectives of this research was to evaluate the suitability of fingerprints for the 
analysis of drugs of abuse (namely, cocaine and heroin). The possibility of using fingerprints 
for drug testing purposes has recently been explored, as described in Chapter 1. It has been 
shown that an administered substance and its metabolite can be detected in fingerprints and 
not in negative control subjects (Costa et al., 2017; Zhang et al., 2015; Kuwayama et al., 
2014; Kuwayama et al., 2013; Jacob et al., 2008). However, the suitability of a fingerprint 
as a sampling matrix for drug testing has not yet been explored. Particularly relating to the 
significance of the detection of drugs from fingerprints, including the prevalence of cocaine 
and heroin in a background population of non-drug users has not yet been explored. The use 
of a fingerprint sample for drug testing purposes should be robust enough to provide a good 
detection rate (>80%), even if a hand cleaning procedure is used prior to sample collection, 
otherwise the test would be easily falsified. Additionally, the use of a hand cleaning 
procedure should successfully remove external contamination on the hands from 
contaminated surfaces or handling the parent drug, which may otherwise yield false positive 
results. Therefore, different sampling strategies for the collection of fingerprint samples 
were investigated, which included the collection of fingerprints (i) without any preparation 
of the hands (natural), (ii) after washing hands with soap and water and (iii) after wiping 
hands with alcohol free wipes. 
The following section will detail the specific participants recruited for the purpose of this 
study (section 3.1.1) and the sample collection and preparation methods used for fingerprint 
samples collected from (i) individuals seeking treatment at an NHS Drug and Alcohol 
Service and (ii) a background population of non-drug users (section 3.2.3). Analysis of 
fingerprint samples were performed using the procedure outlined in Chapter 2 section 2.3.4. 
The detection of cocaine, heroin and their respective metabolites (benzoylecgonine and 6-
acetylmorphine) in natural fingerprint samples from drug users and a background population 
of non-drug users are discussed in sections 3.2.2 and 3.2.3. The application of a threshold 
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level to differentiate substance misuse (drug users) from environmental exposure to drugs 
(non-drug users) is discussed in section 3.2.4. The influence of a hand cleaning procedure 
on the detection of cocaine and heroin use in fingerprints from drug users and non-drug users 
(background population) is discussed in sections 3.2.5 – 3.2.8. The potential transfer of drugs 
between individuals is outlined in section 3.2.9. The influence of the fingerprint sample 
collected on the detection rate of cocaine and heroin is outlined in section 3.2.10. 
The present chapter investigates important aspects of using a fingerprint as a new sample 
matrix, including (i) the prevalence of cocaine, heroin and their respective metabolites in a 
background population of non-drug users and (ii) the use of fingerprint collection procedures 
to understand the influence of a hand cleaning procedure on the detection of the analytes of 
interest. Additionally, the presence of contamination from environmental exposure and 
transfer of drugs between individuals is explored to determine its impact on the 
interpretation of results. 
3.1 Experimental 
3.1.1 Study populations 
Study participants were recruited from different groups to evaluate the significance of the 
detection of cocaine, benzoylecgonine, heroin and 6-acetylmorphine in fingerprints. These 
included (i) individuals seeking treatment for drug dependency (n = 15) and (ii) a 
background population of non-drug users (n = 50). Recruitment of individuals seeking 
treatment for drug dependency was held at The Xchange in Woking in collaboration with 
Surrey and Borders NHS Foundation Trust. The Xchange is an NHS Drug and Alcohol 
Service where individuals are in treatment to overcome drug and alcohol dependency. For 
drug dependency, individuals are prescribed methadone or buprenorphine to ease the 
transition to a drug free existence. However, most participants recruited in the study 
admitted to the use of illegal substances (such as cocaine and heroin) alongside the 
prescribed drugs. In this case, the target of the study was the analysis of cocaine and heroin 
use from fingerprint samples collected from individuals who admitted to the use of these 
illegal drugs in the past 24 hours. The inclusion criteria stipulated that participants needed 
to be enrolled in a drug treatment programme, aged between 18 – 65 years old (male or 
female), must have the ability to provide consent and must be able to understand enough 
English to understand the information sheet and consent form. Due to ethical considerations 
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only, the drugs administered, and the gender of the participant were recorded. Analysis of 
fingerprint samples for the detection of cocaine and heroin use was carried out using the LC-
MS method described in section 2.2.2. Fingerprints were also collected from non-drug users 
(n = 50) to investigate the prevalence of drugs of abuse in fingerprints from the background 
population. Study participants were recruited from the University of Surrey (Guildford, UK) 
who admitted to not have taken any drugs of abuse.  
Oral fluid samples were also collected from drug users using Alere™ oral fluid collection 
devices, to help corroborate the fingerprint results obtained from liquid chromatography – 
mass spectrometry (LC-MS) analysis. The procedure for the collection of oral fluid samples 
is outlined in section 3.1.3. The oral fluid samples were analysed by Claritest (a drug testing 
service) in Norwich, England, where screening tests were carried out using immunoassays, 
and confirmation test were carried out using LC-MS/MS. Additionally, no oral fluid samples 
were taken from the background population (non-drug users). 
A favourable ethical opinion was obtained from the NHS Research Ethics Service (NRES-
REC) and the University of Surrey Ethics Committee for the collection of fingerprint and 
oral fluid samples from individuals enrolled in Surrey and Borders NHS Drug and Alcohol 
Services who volunteered taking part in this study, as well as fingerprint samples from non-
drug users (background population) at the University of Surrey (NRES-REC reference 
14/LO/0346). Participants were given information sheets and informed consent forms in 
order to understand their involvement in the study. Once informed consent was obtained 
from the participants, samples were collected according to the protocols outlined in sections 
3.1.2 and 3.1.3. The standard operating procedures outlining the detailed protocol for the 
collection of oral fluid and fingerprint samples are included in Appendix B. 1 and B. 2. 
3.1.2 Fingerprints 
Fingerprint samples were collected on chromatography paper (Whatman™ 1-Chr) cut into 
2 x 2 cm. Fingerprint collection kits were prepared by taping the paper substrate onto a 
microscope glass slide labelled with a unique participant identifier, e.g. H0483210 for the 
participants recruited from NHS Drug and Alcohol Services and e.g. SUB001 for the 
background population. 
Fingerprint samples (n = 65) were collected from individuals seeking treatment for drug 
dependency under three different conditions: (i) natural; (ii) after washing hands with soap 
Chapter 3: Investigation into the Suitability of a Fingerprint to Detect Cocaine and Heroin use 
66 
 
and water; and (iii) after wiping hands with alcohol free wipes. Samples were only collected 
from participants who admitted having taken either cocaine or heroin or both within the past 
24 h. Fingerprints (n = 5) were collected from all fingers of the right hand for each 
participant. Natural fingerprint samples collected were deposited upon arrival at the clinic 
without any preparation of the hands. The fingerprint collection procedure was carried out 
as follows: 
• the fingerprint collection slide was placed on the weighing balance and tared; 
• the participant placed the finger displayed on the label onto the collection slide (e.g. 
right thumb). The fingerprint must be placed within the rectangular guidelines; 
• participant must increase the pressure until the balance reads between 800 – 1200 g 
of pressure and hold for 10 seconds; 
• participant must carefully lift the finger upwards, after providing the required 
pressure for collection; and 
• the above steps are repeated until all five fingerprints are collected. 
After the collection of natural fingerprints, the participant was asked to wash hands with 
soap and water or the researcher wiped the fingers and thumbs with an alcohol-free wipe. 
The participant then put on nitrile gloves for 10 min to induce perspiration on the fingers 
and thumbs prior to fingerprint deposition. The fingerprint collection procedure described 
above was repeated to standardise the collection of samples after the hand cleaning 
procedure.  
Each sample collected was labelled with a unique participant identifier; the finger or thumb 
that was collected and the condition under which the sample was collected (e.g. natural, 
soap, or wipe). The collected fingerprint sample was then placed into a microscope glass 
slide storage box for transport to the University of Surrey, UK. In addition, fingerprint 
samples were collected from volunteers (non-drug users, n = 5) before and after contact 
(shaking hands) with participants (n = 5) recruited in the study who admitted having taken 
either cocaine or heroin (or both) to determine the potential of secondary transfer of the 
drugs between individuals.  
Fingerprint samples (n = 100) were collected from n = 50 participants (background 
population) at the University of Surrey. Fingerprint samples collected from the background 
population were collected (i) natural and (ii) after washing hands with soap and water to 
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determine the prevalence of cocaine and heroin in the background population. Only the right 
thumb and right index finger were collected for each participant. A more detailed protocol 
used for the collection of fingerprint samples is described in the SOP in Appendix B. 2. 
3.1.3 Oral fluid 
Oral fluid samples were collected from participants at NHS drug and alcohol services only, 
using Quantisalä oral fluid collection devices. One oral fluid sample was collected per 
participant. The collection of oral fluid samples was carried out as follows: 
• research personnel took the swab used for the collection of oral fluid from the pre-
labelled kit; 
• the participant was asked to churn saliva; 
• the swab was placed between the teeth and cheek or under the tongue of the 
participant until the indicator on the swab turned blue. This indicates enough saliva 
was collected (ca. 1 ml); 
• once the indicator turned blue, the swab was removed from the mouth and placed in 
the collection tube provided in the kit, end first; and 
• the lid of the tube was pressed until sealed. 
A more detailed description of the standard operating procedure for the collection of oral 
fluid samples is detailed in Appendix B. 1. Oral fluid samples collected were sent to Claritest 
(Norwich, UK) for analysis, where screening and confirmation tests were carried out using 
immunoassay and LC-MS analysis, respectively. 
A summary of the study participants and samples collected for each population is provided 
in Table 3.1. 
Table 3.1: Recruitment information for the study populations and type of sample 
collected. 
Study 
population N Fingerprint samples collected Oral fluid sample collected 
Background 
population 50 Right thumb and index finger No 
Drug-users 15 Right thumb, index, middle, ring and little finger Yes 
Secondary 
transfer 5 
Right thumb, index, middle, ring and 
little finger No 
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3.2 Results and Discussion 
3.2.1 Comparison between study populations 
3.2.1.1 Cocaine 
Fingerprint samples were collected from non-drug users (background population, n = 49) 
and cocaine users (n = 13). Samples were collected using different collection procedures, 
including (i) natural fingerprints, (ii) after handwashing and (iii) after wiping hands with 
alcohol free wipes, to determine whether (a) cocaine and benzoylecgonine were prevalent 
in a background population of non-drug users and (b) the levels observed were different 
depending on the study population. Figure 3.1 shows the average peak area ratio analyte (A) 
to internal standard (IS) for cocaine and benzoylecgonine in fingerprints collected from 
cocaine users and non-drug users for the different sample collection procedures (e.g. natural, 
soap or wipe). Note that for the background population samples were only collected as 
natural fingerprints and after washing hands with soap and water.  
 
Figure 3.1: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine from a 
background population (non-drug users) and cocaine users for samples 
collected as natural fingerprints, after washing hands with soap and water, 
and after wiping hands with alcohol free wipes. 
Results show that cocaine and benzoylecgonine were present in nearly all fingerprint 
samples collected from cocaine users. However, fingerprint samples from the background 
population also showed traces of cocaine and benzoylecgonine. One of the main sources of 
cocaine in fingerprint samples from non-drug users is through environmental exposure (e.g. 
with banknotes) (Zuccato & Castiglioni, 2009; Armenta & de la Guardia, 2008; Carter et 
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al., 2003). There is a significant difference in distribution of the level (ratio A/IS) of cocaine 
(U = 0, p < 0.001) and benzoylecgonine (U = 27, p = 0.001) present in fingerprint samples 
from non-drug users compared to drug users (Appendix E. 1). The median cocaine level 
(ratio A/IS) was 0.004 for non-drug users compared to 0.900 for cocaine users. For 
benzoylecgonine the median level present in fingerprints from non-drug users was 0.009 
compared to 0.028 for cocaine users. The background population admitted not having taken 
cocaine, suggesting that environmental exposure is the most likely explanation for the 
presence of these analytes in their fingerprints. 
Fingerprints (n = 98) collected after washing hands with soap and water from non-drug users 
showed that no traces of cocaine and benzoylecgonine were detected (with one false positive 
for cocaine). This suggests that the use of a hand cleaning procedure prior to sample 
collection is advantageous to remove possible presence of cocaine and benzoylecgonine 
from environmental exposure, which could otherwise lead to false positive tests. 
Additionally, fingerprints (n = 40) collected after washing hands from cocaine users showed 
that the majority of samples remained positive for both cocaine (40 samples) and 
benzoylecgonine (34 samples). However, a significant difference is observed in the level of 
cocaine (U = 819, p = 0.002) and benzoylecgonine (U = 461, p < 0.001) present in natural 
fingerprints compared to samples collected after handwashing (Appendix E. 1). The median 
cocaine level (ratio A/IS) was 0.900 for natural fingerprints but reduced to 0.282 after 
handwashing. Similarly, for benzoylecgonine, the median level (ratio A/IS) present in 
natural fingerprints was 0.028 compared to 0.009 after handwashing.  This suggests that the 
use of a handwashing procedure did remove some cocaine and benzoylecgonine present on 
the fingers. Interestingly, no significant difference (at p = 0.05) was observed for cocaine (U 
= 603, p = 0.059) and benzoylecgonine (U = 609, p = 0.144) between natural fingerprints 
compared to samples collected after wiping hands with alcohol free wipes (Appendix E. 1). 
The median cocaine level (ratio A/IS) for natural fingerprints was 0.900 compared to 0.513 
after wiping hands. For benzoylecgonine the median level (ratio A/IS) was 0.028 compared 
to 0.023 after wiping hands. This suggests that the use of a hand wiping procedure was most 
likely not as effective in the removal of cocaine and benzoylecgonine in fingerprints 
(resulting in similar levels between both sampling methods) compared to a handwashing 
procedure. 
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3.2.1.2 Heroin 
Comparison between fingerprint samples collected from drug users and non-drug users 
shows that heroin and 6-acetylmorphine is not prevalent in a background population of non-
drug users (see Figure 3.2). In contrast to cocaine, heroin is not detected in any fingerprint 
sample from the background population (natural or after handwashing). 6-Acetylmorphine 
was detected in one fingerprint sample (natural) from the background population, however 
after washing hands all fingerprints were negative. Note that no samples were collected from 
the background population after wiping hands. Compared to cocaine, heroin is not prevalent 
on banknotes and is more likely to degrade (Carter et al., 2003; Jenkins, 2001). This suggests 
that heroin and 6-acetylmorphine are not commonly encountered through environmental 
exposure and therefore the presence of these analytes in samples most likely arises from 
handling the parent drug or drug administration.  
 
Figure 3.2: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine from a 
background population (non-drug users) and heroin users for samples 
collected as natural fingerprints, after washing hands with soap and water, 
and after wiping hands with alcohol free wipes.  
Figure 3.2 shows that the level of heroin present in fingerprint samples collected from heroin 
users varies depending on the sample collection procedure used. A significant difference is 
observed between the level of heroin present in natural fingerprints compared to those 
collected after washing hands (U = 0.067, p < 0.001) and after wiping hands (U= 104, p < 
0.001) (Appendix E. 1). The median heroin level (ratio A/IS) was 0.067 for natural 
fingerprints compared to 0.011 after handwashing and 0.016 after wiping hands. In contrast, 
for 6-acetylmorphine no significant difference (at p = 0.05) was observed between natural 
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fingerprints compared to fingerprints collected after washing hands with soap and water (U 
= 807, p = 0.061) or after wiping hands with alcohol free wipes (U = 557, p = 0.633) 
(Appendix E. 1). The median 6-acetylmorphine level for natural fingerprints was 0.030 
compared to 0.021 after hand washing and 0.028 after wiping hands. This suggests that the 
hand cleaning procedures were more effective in the removal of heroin in fingerprints 
compared to 6-acetylmorphine.  
3.2.2 Drug users 
3.2.2.1 Cocaine 
A total of 13 participants were recruited who admitted having taken cocaine in the past 24 
h. Samples (n = 5 per participant) were collected as natural fingerprints for all participants 
(41026, 41028 and 41036 – 41046). Cocaine and benzoylecgonine were detected in nearly 
all fingerprint samples collected, as shown in Figure 3.3. Cocaine was detected in all 
fingerprint samples for all participants, resulting in a 100% (65 samples) detection rate based 
on participant testimony. In contrast, 61 samples (94%) were positive for benzoylecgonine 
in natural fingerprint samples collected. This is because participant 41026 admitted having 
taken cocaine, but benzoylecgonine was only detected in 1 out of 5 fingerprint samples 
collected for this participant. The presence of both the parent drug and metabolite is 
significant. However, a greater significance is attributed to the presence of the metabolite as 
this indicates that the individual has administered and metabolised the parent drug in the 
body. In contrast, the sole presence of the parent drug could be due to contamination or 
contact with the parent drug.  
 
Figure 3.3: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) based on n = 5 fingerprint 
samples for participants who admitted having taken cocaine in the past 24 
hours. Solid line represents the limit of detection (LOD). 
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A similar trend is observed for cocaine and benzoylecgonine in fingerprint samples collected 
from these participants. A higher level of cocaine present in fingerprint samples also resulted 
in a higher level of benzoylecgonine, e.g. see participants 41045 and 41040. Interestingly, 
results for participant 41026 showed the lowest levels of cocaine which was paired with a 
low detection rate for benzoylecgonine. Overall, the spread in the levels of cocaine and 
benzoylecgonine observed in fingerprint samples is narrow for each participant, which 
suggests that although fingerprint variability (sample size and volume) is not accounted for, 
similar concentrations are present in the samples. 
An overview of the oral fluid confirmation and fingerprint test results are shown in Table 
3.2. There is a discrepancy observed between the oral fluid and fingerprint screening results 
for 3 participants, namely participants 41026, 41036 and 41040. In these cases, a negative 
oral fluid result was obtained, despite a positive fingerprint result for both cocaine and 
benzoylecgonine in all samples for participants 41036 and 41040. Interestingly, the levels 
of cocaine and benzoylecgonine observed in fingerprints for participants 41036 and 41040 
are similar to those of other participants whose oral fluid samples were positive for cocaine 
use.  
Table 3.2: Oral fluid confirmation and fingerprint results based on n = 5 natural 
fingerprint samples collected for participants who admitted having taken 
cocaine in the past 24 hours. 
Participant 
Oral fluid confirmation test 
(concentration ng/ml) 
Fingerprint screening test (n = 5) 
Number of values >LOD 
Cocaine Benzoylecgonine Cocaine Benzoylecgonine 
41026 Negative Negative 5 5 
41028 >64 >64 5 1 
41036 Negative Negative 5 5 
41037 64 64 5 5 
41038 Negative 64 5 5 
41039 >64 >64 5 5 
41040 Negative Negative 5 5 
41041 >64 >64 5 5 
41042 >64 >64 5 5 
41043 >64 >64 5 5 
41044 >64 >64 5 5 
41045 >64 >64 5 5 
41046 >64 >64 5 5 
*LOD = limit of detection (see section 2.3.7.3) 
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As mentioned previously, for participant 41026, cocaine was present in all fingerprint 
samples, but benzoylecgonine was only present in one fingerprint sample (right ring finger). 
Although a high detection rate was observed for cocaine and benzoylecgonine in fingerprint 
samples, these results should be treated with caution given that these findings are based on 
natural fingerprint samples collected. The presence of cocaine and benzoylecgonine could 
arise from external contamination rather than from secretion of drugs from the eccrine 
glands of the fingertips after ingestion and absorption of the drug. Alternatively, it is possible 
that the detection window of cocaine and benzoylecgonine in fingerprints is greater than in 
oral fluid, resulting in negative oral fluid results.  
A total of 2 participants admitted having taken heroin only in the past 24 hours. However, 
fingerprint samples collected from these participants also showed traces of cocaine and 
benzoylecgonine (see Figure 3.4). All fingerprint samples (natural) collected for participants 
41033 and 41035 were positive for cocaine. Additionally, benzoylecgonine was present in 
all fingerprint samples for participant 41033, but not for participant 41035. The oral fluid 
results for these participants were negative for both cocaine and benzoylecgonine. This 
suggests that the detection window of cocaine and benzoylecgonine in fingerprints is >24 h. 
However, as natural fingerprint samples were collected, contamination present on the hands 
could also be the source of the presence of these analytes. Overall, the levels of cocaine and 
benzoylecgonine observed in the fingerprint samples from these participants were lower 
than those observed for participants who admitted using of cocaine in the past 24 h (see 
Figure 3.3). 
 
Figure 3.4: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for cocaine and 
benzoylecgonine for natural fingerprints collected from individuals admitted 
having taken heroin only. Solid line represents limit of detection (LOD). 
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3.2.2.2 Heroin 
A total of 12 participants were recruited who admitted to the use of heroin in the past 24 h. 
Natural fingerprint samples (n = 5) were collected for all participants (41033, 41035 – 41039 
and 41041 – 41046). Figure 3.5 shows the ratio A/IS obtained for heroin and 6-
acetylmorphine in the fingerprint samples collected. Heroin was detected in all fingerprint 
samples for all participants, with the exception of participant 41036, where heroin was not 
detected in the right little finger, resulting in a detection rate of 98% (59 samples) based on 
participant testimony. Additionally, 6-acetylmorphine was detected in all fingerprint 
samples (n = 60) resulting in a 100% detection rate. The results show that similar levels of 
heroin and 6-acetylmorphine are present in the fingerprint samples. In contrast, an order 
magnitude difference was observed between the levels of cocaine and benzoylecgonine in 
fingerprint samples (section 3.2.2.1). Overall, a similar pattern is observed for the amount 
of parent drug and metabolite present in each fingerprint. For example, the level of heroin 
present in fingerprint samples for participant 41033 decreases from right index finger > right 
thumb > right middle finger > right little finger > right ring finger. A similar pattern is 
observed for the metabolite 6-acetylmorphine. Additionally, a greater intra-donor variability 
is observed for this participant for both analytes compared to other participants.  
 
Figure 3.5: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) based on n = 5 natural 
fingerprint samples collected for participants who admitted having taken 
cocaine in the past 24 hours. Solid line represents limit of detection (LOD). 
Comparison between the oral fluid confirmation and fingerprint results are shown in Table 
3.3. There is a disagreement between the oral fluid and fingerprint results obtained for 
participants 41036 – 41038 and 41046, as the oral fluid results do not confirm opiate use for 
these participants. In contrast, the fingerprint results conform to the participant testimony. 
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Interestingly, the highest levels of heroin were present in fingerprint samples from 
participant 41033 and the oral fluid sample for this participant also resulted in the highest 
morphine concentration. It is possible that this is observed due to recent heroin use. 
However, a limitation of monitoring morphine is that is it not solely indicative of heroin use. 
Morphine could be present if the individual has administered morphine itself or codeine or 
heroin (as metabolism of these substances forms morphine) (Bogusz, 2008).  
Table 3.3: Oral fluid confirmation and fingerprint results based on n = 5 natural 
fingerprint samples collected from participants who admitted having taken 
heroin in the past 24 hours. 
Participant 
Oral fluid confirmation test 
(concentration ng/ml) 
Fingerprint screening test (n = 5) 
Number of values >LOD 
Morphine 6-Acetylmorphine Heroin 6-Acetylmorphine 
41033 >240 32 5 5 
41035 138 32 5 5 
41036 Negative Negative 4 5 
41037 Negative  Negative 5 5 
41038 Negative Negative 5 5 
41039 Negative >32 5 5 
41041 69 >32 5 5 
41042 >189 >32 5 5 
41043 60 >32 5 5 
41044 Negative 22.6 5 5 
41045 90 Negative 5 5 
41046 Negative Negative 5 5 
*LOD = limit of detection (see section 2.3.7.3) 
A total of 3 participants (41026, 41028 and 41040) admitted to the sole use of cocaine in the 
past 24 h. Furthermore, the oral fluid samples for these participants were negative for opiate 
use. No heroin or 6-acetylmorphine were detected in the fingerprint samples for participant 
41026. However, the results showed that the fingerprint samples for participant 41028 were 
positive for heroin in all natural samples collected (see Figure 3.6). 6-Acetylmorphine was 
also present in all fingerprint samples for this participant, except for the right thumb. 
Additionally, for participant 41040, heroin was detected in the right middle finger only, 
whereas the right index, middle and ring finger were positive for 6-acetylmorphine. It is 
possible that these traces of heroin and 6-acetylmorphine were present due to heroin use >24 
h, which suggests that the detection window is longer than 24 h.  
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Figure 3.6: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for heroin and 6-
acetylmorphine for natural fingerprints collected from individuals admitted 
having taken cocaine only. Solid line represents limit of detection (LOD). 
3.2.2.3 Relationship between the parent drug and metabolite 
The relationship between the parent drug and metabolite was evaluated in natural fingerprint 
samples by comparing the average peak area A/IS (n = 5) as a ratio of parent drug-to-
metabolite. Figure 3.7 shows the ratio of cocaine-to-benzoylecgonine for cocaine users and 
heroin users in natural fingerprint samples. The results show that the ratio of cocaine-to-
benzoylecgonine varies within a participant based on the different fingerprint samples 
collected as well as between participants. The difference between participants is not 
surprising as the dose and time of drug administration is likely to vary from participant to 
participant. However, the difference observed within a participant suggests that there are 
different levels of cocaine and benzoylecgonine present in each of the fingerprint samples. 
This can be a result of the different sample size between fingerprints and the amount of 
sample collected, which were not controlled.  
For participants 41026, 41036 and 41040, the oral fluid tests were negative for cocaine. 
However, cocaine and benzoylecgonine were present in the natural fingerprint samples 
collected. The ratio cocaine-to-benzoylecgonine for participant 41036 is lower than those 
observed for the other participants. However, for participants 41026 and 41040, the ratio of 
cocaine-to-benzoylecgonine falls within the range of the participants whose oral fluid 
samples were positive for cocaine. This demonstrates that it is not possible to use the 
relationship between cocaine and benzoylecgonine to make a distinction between 
participants whose oral fluid were positive and negative for cocaine in natural fingerprint 
samples.  
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Participants 41033 and 41035 admitted having taken heroin only. However, for participant 
41033, both cocaine and benzoylecgonine were detected in all natural fingerprint samples 
collected. The ratio cocaine-to-benzoylecgonine observed for participant 41033 is in the 
lower range of the ratios observed for cocaine users. For participant 41035, the ratio of 
cocaine-to-benzoylecgonine could not be determined, as benzoylecgonine was not detected 
in any of the fingerprint samples. 
 
Figure 3.7: Average peak area ratio of cocaine-to-benzoylecgonine for cocaine and 
heroin users in natural fingerprint samples collected.  
The relationship between the presence of heroin and 6-acetylmorphine for individuals who 
admitted having taken heroin in the past 24 h is shown in Figure 3.8. The results show that, 
similarly to cocaine, variability is observed in the natural fingerprint samples collected from 
the same participant and between participants. For participant 41026, heroin and 6-
acetylmorphine were not detected in any fingerprint sample, therefore the ratio heroin-to-6-
acetylmorphine could not be calculated. Similarly, for participant 41040, the ratio heroin-
to-6-acetylmorphine could only be calculated for the right ring finger. However, this 
fingerprint sample still falls within the heroin-to-6-acetylmorphine range observed for 
heroin users. For participants 41036, 41037, 41038 and 41046, the oral fluid test was 
negative for opiates. This despite the presence of both heroin and 6-acetylmorphine in all 
(natural) fingerprints collected for these participants. The ratio heroin-to-6-acetylmorphine 
observed for these participants is similar to those observed in fingerprint samples from 
participants whose oral fluid samples were positive. No clear distinction can be made using 
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the relationship between heroin and 6-acetylmorphine between these participants based on 
the collection of natural fingerprints. The ratio heroin-to-6-acetylmorphine for the 
participants (41026, 41028 and 41040) who admitted having taken cocaine only shows that 
no distinction can be made between fingerprint samples from cocaine users and heroin users 
in natural fingerprints (see Figure 3.8). 
 
Figure 3.8: Average peak area ratio of heroin-to-6-acetylmorphine (n = 5 measurements) 
for heroin and cocaine users in natural fingerprint samples collected.  
3.2.3 Background population (non-drug users) 
To evaluate the significance of the detection of trace cocaine, benzoylecgonine, heroin and 
6-acetylmorphine in fingerprint samples from individuals seeking treatment for drug 
dependency, fingerprint samples were also collected from a background population (non-
drug users). This should help to determine the prevalence of the analytes of interest in 
fingerprint samples from the background population. In a multiple donor study, fingerprints 
should be collected from as many different people (preferably >40) to represent the study 
population (Sears et al., 2012). In this study, natural fingerprint samples (n = 2 per 
participant, right thumb and right index finger) were collected from 50 participants 
(SUB003-SUB053). For one participant SUB016, the right index finger failed during LC-
MS analysis. Therefore, it was decided not to include the data for SUB016 due to an 
incomplete set of fingerprint samples.  
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3.2.3.1 Cocaine 
For the majority of the fingerprint samples collected (natural) from the non-drug users, 
cocaine and benzoylecgonine were not detected. Figure 3.9 shows the fingerprint for cocaine 
and benzoylecgonine in the background population. Thirteen fingerprint samples (13%) 
collected from non-drug users (49 participants), were positive for cocaine. In contrast, 
benzoylecgonine was detected in 5 fingerprint samples (5%) of the background population. 
A combination of cocaine and benzoylecgonine in fingerprint samples was only detected in 
4% (4 samples) of the background population.  
 
Figure 3.9: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for cocaine and 
benzoylecgonine from the background population for natural fingerprints 
collected (n = 2 fingerprint per participant). Solid line represents the limit of 
detection (LOD). 
For participants SUB013 and SUB014, both cocaine and benzoylecgonine were detected in 
the right thumb, whereas the right index finger was negative for both analytes. In contrast, 
for participant SUB037, cocaine and benzoylecgonine were detected in the right index finger 
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but not the right thumb. For participant SUB043, both the right thumb and right index were 
positive for cocaine.  However, benzoylecgonine was only detected in the right index finger 
for this participant. Overall, the level of cocaine present in the fingerprint samples from the 
background population (ratio A/IS 0.004 – 0.061) were lower than those observed for drug 
users (ratio A/IS 0.069 – 22.981). In contrast, similar levels of benzoylecgonine were 
observed in the fingerprints of non-drug users (ratio A/IS 0.005 – 0.015) compared to those 
found in fingerprints from drug users (ratio A/IS 0.004 – 0.426). These results suggest that 
the collection of natural fingerprint samples can lead to false positive results for non-drug 
users, due to the prevalence of cocaine in the environment if no threshold level is applied. 
This demonstrates that the choice of sampling regime is an important consideration for 
fingerprint testing. 
3.2.3.2 Heroin 
The fingerprint results from the background population were all negative for the presence 
of heroin. 6-Acetylmorphine was present in 1% (1 sample) of the background population 
(for SUB037 right index finger). However, no heroin was present in the right index finger 
for this participant. Additionally, the right thumb was negative for both heroin and 6-
acetylmorphine. All fingerprint samples (n = 98) from the background population were 
negative for the combination of heroin and 6-acetylmorphine. This is contrary to the 
prevalence of cocaine in the background population, where 4% (4 samples) was positive for 
both cocaine and benzoylecgonine. Compared to cocaine, heroin is not prevalent on 
banknotes and is more likely to degrade (Carter et al., 2003; Jenkins, 2001). The possible 
presence of heroin in fingerprint samples due to environmental exposure is therefore less 
likely to occur. 
3.2.4 Threshold level 
3.2.4.1 Cocaine 
The results obtained for natural fingerprint samples collected (n = 98) from the background 
population showed that cocaine can readily be detected in fingerprint samples from non-
drug users (13%), whereas benzoylecgonine was detected in 5% of the background 
population. This indicates that there is a requirement to establish a threshold level for natural 
fingerprint samples to differentiate non-drug users from drug users. A key concept in drug 
testing is the use of a cut-off level. A threshold level is chosen which will maximise the 
detection rate, but also minimise the number of false positive results obtained in drug testing. 
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The use of this concept (threshold level) should help to differentiate between fingerprint 
samples from individuals who admitted taking a substance and the background population 
(non-drug users). It must be noted that with the use of a threshold level, a negative screening 
result does not necessarily indicate no substance was taken. It might contain drugs which 
are below the proposed threshold level. 
The influence of various threshold levels on the detection rate of cocaine and 
benzoylecgonine in natural fingerprint samples collected from drug users and non-drug users 
were evaluated per analyte at the limit of detection (ratio A/IS 0.002 for cocaine and 0.004 
for benzoylecgonine) and ratio A/IS of 0.005 – 0.030, in increments of 0.005.  The threshold 
levels were proposed to lower the false positive detection rate of cocaine and 
benzoylecgonine in fingerprint samples from the background population, which could 
otherwise produce false positive fingerprint results. For the background population, only the 
right thumb and index finger (n = 2) were collected for the purpose of this study. In contrast, 
n = 5 fingerprint samples (right thumb to right little finger) per participant were collected 
from the drug users.  
The detection rates for cocaine and benzoylecgonine based on the proposed threshold levels 
for both groups, drug users and non-drug users (background population) are shown in Table 
3.4 (cocaine) and Table 3.5 (benzoylecgonine). In order for all fingerprint samples from the 
background population to be negative (0% positive detection rate), a threshold level at ratio 
A/IS 0.65 is required for cocaine. This is because a high level of cocaine was present in the 
right thumb for participant SUB014 (non-drug user). In contrast, a threshold level at ratio 
A/IS 0.020 results in a 0% false positive detection rate for benzoylecgonine in the 
background population. As the level of cocaine in fingerprint samples collected from drug 
users are significantly higher than those of the background population (non-drug users), a 
100% positive detection rate is still observed in all fingerprints at this threshold level. In 
contrast, a threshold level (ratio A/IS) at 0.020 for benzoylecgonine results in a 63% positive 
detection rate for drug users (based on all 5 fingerprints), but 77% based on n = 2 fingerprints 
(right thumb and index). Therefore, caution should be taken when proposing a high threshold 
level as this can negatively affect the detection rate of the analyte in fingerprint samples 
from drug users.  
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Table 3.4: Comparison of the detection rate of cocaine in fingerprint samples collected 
from participants admitted having taken cocaine in the past 24 h and the 
background population based on the proposed threshold levels.  
Sample 
 
 
 
Threshold           
level 
Cocaine detection rate (%) 
Clinic samples (n = 13) Background samples (n = 98) 
Right 
thumb 
Right 
index 
finger 
Right 
middle 
finger 
Right 
ring 
finger 
Right 
little 
finger 
Right 
thumb 
Right 
index 
finger 
0.002 100 100 100 100 100 7 6 
0.005 100 100 100 100 100 4 2 
0.010 100 100 100 100 100 1 2 
0.015 100 100 100 100 100 1 2 
0.020 100 100 100 100 100 1 2 
0.025 100 100 100 100 100 1 2 
0.030 100 100 100 100 100 1 0 
0.065 100 100 100 100 100 0 0 
The use of threshold levels has a greater influence on the detection rate of benzoylecgonine 
compared to cocaine, due to the fact that similar levels of benzoylecgonine were present in 
fingerprints from drug users and non-drug users. The differences in the levels present in 
fingerprints correlates with previous findings by Jacob et al. (2008), who found that 
fingerprints taken from the same individual could vary  up to 3-fold in the amount of 
substance detected from each finger (Jacob et al., 2008). This suggests that a threshold level 
cannot be applied to all fingerprint samples but has to be evaluated separately for each 
fingerprint sample and per analyte, unless a standardised fingerprint sampling procedure has 
been used to account for fingerprint variability (sample size and volume). 
Table 3.5: Comparison of the detection rate of benzoylecgonine in fingerprint samples 
collected from participants admitted having taken cocaine in the past 24 h 
and the background population based on the proposed threshold levels. 
Sample 
 
 
 
Threshold          
level 
Benzoylecgonine detection rate (%) 
Clinic samples (n = 13) Background samples (n = 98) 
Right 
thumb 
Right 
index 
finger 
Right 
middle 
finger 
Right 
ring 
finger 
Right 
little 
finger 
Right 
thumb 
Right 
index 
finger 
0.004 92 92 92 100 92 2 3 
0.005 92 92 92 100 92 1 3 
0.010 92 85 92 77 77 0 2 
0.015 85 85 62 77 54 0 1 
0.020 85 69 54 69 38 0 0 
0.025 77 54 46 62 23 0 0 
0.030 46 54 38 54 23 0 0 
In drug testing an emphasis is put on the detection of drug metabolites, because this is 
indicative of administration of a substance rather than contact with a contaminated surface. 
A combination of cocaine and benzoylecgonine was only detected in 4% (4 samples) of 
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fingerprint samples from the background population. However, by applying a threshold level 
at ratio A/IS 0.005 for both cocaine and benzoylecgonine and the requirement for the 
presence of both cocaine and benzoylecgonine in fingerprint samples from the background 
population, only results in a false positive rate of 1% (1 sample). At this threshold level, a 
92% detection rate is obtained in fingerprints from drug users (based on the right thumb and 
index finger) which relates to an 8% false negative detection rate. 
3.2.4.2 Heroin 
The results obtained for natural fingerprint samples collected from the background 
population showed that there is no significant environmental exposure to heroin. From n = 
98 fingerprint samples, only 1% (1 sample) was positive for 6-acetylmorphine, whereas none 
were positive for heroin. In contrast to cocaine, this shows that there is no requirement to 
impose a threshold level for natural fingerprint samples for the analysis of heroin. The 
detection limit can be used as the decision level instead, as the detection of heroin and 6-
acetylmorphine above the detection limit would be significant. However, there is a limitation 
to the evaluation of natural fingerprint samples, as mentioned previously. Although there is 
no false positive rate observed for the background population, the presence of heroin and 6-
acetylmorphine in natural fingerprints collected might still provide false positive results if 
the participant touched a contaminated surface or handled the parent drug. In this instance, 
the presence of heroin and 6-acetylmorphine would not necessarily indicate administration 
of a drug.   
3.2.5 Effect of wiping hands: drug users 
The fingerprint sampling strategy was evaluated by comparing the collection of natural 
fingerprints to samples collected after wiping hands with alcohol free wipes. This is 
particularly important, as external contamination of drugs on the hands can result in false 
positive results if natural fingerprints are collected. Comparison in the distribution of 
cocaine and benzoylecgonine between natural fingerprints and samples collected after 
wiping hands with alcohol free wipes is shown in Figure 3.10. No significant difference (at 
p = 0.05) is obtained for cocaine (U = 231, p = 0.114) and benzoylecgonine (U = 258, p = 
290) between natural fingerprints and samples collected after wiping hands with alcohol free 
wipes for same participants (Appendix E. 2). The median cocaine level (ratio A/IS) was 
0.850 for natural fingerprints and 0.513 after wiping hands. For benzoylecgonine, the 
median benzoylecgonine level in natural fingerprints was 0.030 compared to 0.023 after 
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wiping hands. This could mean that the use of a hand wiping procedure was not effective in 
the removal of cocaine and benzoylecgonine, therefore resulting in similar levels for both 
sample collection procedures.  
 
Figure 3.10: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine between 
natural fingerprints and samples collected after wiping hands with alcohol 
free wipes for the same participants. 
Comparison in the distribution of the levels of heroin and 6-acetylmorphine present in 
natural fingerprints and after handwashing for the same participants is shown in Figure 3.11. 
The results show that a similar distribution is observed for heroin in natural fingerprints 
compared to samples collected of wiping hands. However, the two hand cleaning procedures 
result in a difference in the median level of heroin present.  
 
Figure 3.11: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine between natural 
fingerprints and samples collected after wiping hands with alcohol free wipes 
for the same participants. 
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In comparison to natural fingerprint samples, the heroin levels are significantly lower after 
wiping hands with alcohol free wipes based on a Mann-Whitney U test (U = 42, p < 0.001). 
The median heroin level (ratio A/IS) present in natural fingerprints was 0.050 compared to 
0.016 after wiping hands. This suggests that the alcohol-free wipes removed heroin present 
on the hands, resulting in lower analyte levels. For 6-acetylmorphine, a closer distribution 
is observed after wiping hands compared to natural fingerprints. However, no significant 
difference is observed in the levels present based on the two sample collection procedures. 
The median 6-acetylmorphine level (ratio A/IS) was 0.019 in natural fingerprints compared 
to 0.028 after wiping hands for the same participants. A higher median level is observed 
after wiping hands, which could be due to new sweat secretion. 
3.2.5.1 Cocaine 
A number of participants (n = 5) were recruited who admitted having taken cocaine in the 
past 24 h and whose fingerprint samples (n = 5) were collected as natural fingerprints and 
after wiping hands with alcohol free wipes. Figure 3.12 shows the fingerprint results (ratio 
A/IS) for cocaine and benzoylecgonine after wiping hands for each participant. Both cocaine 
and benzoylecgonine were detected in all fingerprints for all participants after wiping hands 
with alcohol free wipes (100% detection rate). The results show a narrow spread in the levels 
of cocaine and benzoylecgonine present in the fingerprint samples, which suggests that the 
inter- and intra-donor variability is small, similar to the natural fingerprints collected from 
these participants. 
 
Figure 3.12: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) based on n = 5 fingerprint 
samples collected after wiping hands with alcohol free wipes for participants 
who admitted having taken cocaine in the last 24 h. Solid line represents limit 
of detection (LOD). 
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An overview of the oral fluid confirmation and fingerprint results after wiping hands with 
alcohol free wipes is shown in Table 3.6. A disagreement is observed between the fingerprint 
screening results and oral fluid results for participant 41040. A negative oral fluid 
confirmation result was obtained, but both cocaine and benzoylecgonine were detected in 
all fingerprint samples after wiping hands with alcohol free wipes. This is consistent with 
the results obtained from natural fingerprints collected for this participant. It is possible that 
the use of alcohol free wipes was not effective in the removal of external contamination of 
the fingers and thumbs or that the discrepancy is observed due to a difference in detection 
time window between the two matrices. The detection window for cocaine in fingerprints is 
unknown. This has been evaluated for sweat using sweat patches, which showed that cocaine 
use can be determined using two-week sweat patches (Liberty & Johnson, 2004). However, 
it must be noted that this is not representative of a fingerprint sample as the patches are used 
to accumulate sweat over a number of days. It has been reported that sweat (patch) has a 
longer detection window than oral fluid (United Nations Office on Drug and Crime, 2014). 
Cocaine can be detected in oral fluid for 5 – 12 h, whereas benzoylecgonine can be detected 
for 12 – 24 h after a single dose, but this can be up to 10 days for chronic users (Verstraete, 
2004). 
Table 3.6: Oral fluid confirmation and fingerprint results based on n = 5 fingerprint 
samples collected after wiping hands with alcohol free wipes from 
participants who admitted having taken cocaine in the past 24 hours. 
Participant 
Oral fluid confirmation test 
(concentration ng/ml) 
Fingerprint screening test (n = 5) 
Number of values >LOD 
Cocaine Benzoylecgonine Cocaine Benzoylecgonine 
41039 >64 >64 5 5 
41040 Negative Negative 5 5 
41041 >64 >64 5 5 
41042 >64 >64 5 5 
41043 >64 >64 5 5 
*LOD = limit of detection (see section 2.3.7.3)  
3.2.5.2 Heroin 
A number of participants (n = 4) were recruited who admitted having taken heroin in the 
past 24 h and whose fingerprint samples were collected (i) natural and (ii) after wiping hands 
with alcohol free wipes. Figure 3.13 shows the fingerprint results (ratio A/IS) for heroin and 
6-acetylmorphine after wiping hands with alcohol free wipes for each participant. Both 
heroin and 6-acetylmorphine were detected in all fingerprints for all participants after wiping 
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hands with alcohol free wipes, which is consistent with the natural fingerprint samples 
collected for these participants (100% detection rate). Similar to the results of cocaine, a 
narrow spread is observed in the levels of heroin and 6-acetylmorphine in fingerprint 
samples after wiping hands. Overall, the results show that the levels of analytes present 
between participants after wiping hands is more similar compared to natural fingerprints 
from these participants (see Figure 3.5). The use of alcohol free wipes has reduced the inter-
donor variability. 
 
Figure 3.13: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) based on n = 5 fingerprint 
samples collected after wiping hands with alcohol free wipes for participants 
who admitted having taken heroin in the last 24 h. Solid line represents limit 
of detection (LOD). 
The fingerprint results after wiping hands with alcohol free wipes are compared to the oral 
fluid confirmation results in Table 3.7. There is an excellent agreement between the oral 
fluid and fingerprint results obtained as both matrices were consistent with the participant 
testimony, indicating heroin use. 
Table 3.7: Oral fluid confirmation and fingerprint results based on n = 5 fingerprint 
samples collected after wiping hands with alcohol free wipes from 
participants who admitted having taken heroin in the past 24 hours. 
Participant 
Oral fluid confirmation test 
(concentration ng/ml) 
Fingerprint screening test (n = 5) 
Number of values >LOD 
Morphine 6-Acetylmorphine Heroin 6-Acetylmorphine 
41039 Negative >32 5 5 
41041 69 >32 5 5 
41042 >189 >32 5 5 
41043 60 >32 5 5 
*LOD = limit of detection (see section 2.3.7.3) 
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Participant 41040 admitted to the sole use of cocaine in the past 24 hours, however traces of 
heroin and 6-acetylmorphine were present in the natural fingerprints collected for this 
participant. Although the levels of heroin and 6-acetylmorphine present in the natural 
fingerprint samples were similar to those of heroin users, after wiping hands with alcohol 
free wipes, no heroin or 6-acetylmorphine was present in any fingerprint sample for this 
participant. It is possible that these traces were present due to external contamination present 
on the hands, which were removed with the hand cleaning procedure. It is also possible that 
the levels of analytes were present due to heroin use >24 h and after wiping hands were 
below the limit of detection and therefore produced negative fingerprint results. The oral 
fluid sample for this participant was negative for opiates. 
3.2.5.3 Relationship between parent drug and metabolite 
The distribution in the level of parent drug-to-metabolite for natural fingerprints compared 
to samples collected after wiping hands with soap and water for the same participants is 
shown in Figure 3.14. The results show that a close distribution is observed between the 
cocaine-to-benzoylecgonine ratio between participants, especially for natural fingerprints.  
 
Figure 3.14: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of cocaine-to-benzoylecgonine ratio for 
cocaine users for samples collected as natural fingerprints and samples 
collected after wiping hands with alcohol free wipes. 
No significant difference was observed in the level of cocaine and benzoylecgonine between 
natural fingerprints and samples collected after wiping hands. Similarly, the cocaine-to-
benzoylecgonine ratio showed no significant difference (at p = 0.05) between the two sample 
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collection procedures (U = 295, p = 0.734) (Appendix E. 3). The median level of cocaine-
to-benzoylecgonine ratio in natural fingerprints was 37.621 compared to 32.834 after wiping 
hands. 
The individual ratio of cocaine-to-benzoylecgonine for each participant for natural 
fingerprints and samples collected after wiping hands with alcohol free wipes from 
participants admitted having taken cocaine in the past 24 h is shown in Figure 3.15. Although 
a negative oral fluid result was obtained for participant 41040, the cocaine-to-
benzoylecgonine ratio is similar to those for participants whose oral fluid samples were 
positive. The relationship between cocaine and benzoylecgonine could not be used to 
differentiate between those who had positive and negative oral fluid results. 
 
Figure 3.15: Average peak area ratio of cocaine-to-benzoylecgonine (n = 5 measurements) 
for cocaine and heroin users in natural fingerprint samples and samples 
collected after wiping hands.  
Comparison of the relationship between heroin and 6-acetylmorphine present in natural 
fingerprints and samples collected after wiping hands for the same participants is shown in 
Figure 3.16. Initial results already showed that the use of alcohol free wipes resulted in 
significantly lower heroin levels for samples collected after wiping hands compared to 
natural fingerprints, but not for 6-acetylmorphine (see section 3.2.5.2). This translates to a 
significant difference in the heroin-to-6-acetylmorphine ratio present in fingerprints between 
the two sample collection procedure (U = 40, p < 0.001), resulting in lower levels after 
wiping hands (Appendix E. 3). 
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Figure 3.16: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of heroin-to-6-acetylmorphine ratio for 
heroin users for samples collected as natural fingerprints and samples 
collected after wiping hands with alcohol free wipes. 
The individual ratio of heroin-to-6-acetylmorphine for natural fingerprints and samples 
collected after wiping hands with alcohol free wipes for the same participants is shown in 
Figure 3.17. The intra-donor variability between fingerprint samples is smaller for 
participants 41042 and 41043 compared to the remaining participants. Compared to the 
natural fingerprint samples collected from these participants, the ratio heroin-to-6-
acetylmorphine decreased for nearly all participants after wiping hands with alcohol free 
wipes, due to a decreased signal for heroin.  
 
Figure 3.17: Average peak area ratio of heroin-to-6-acetylmorphine (n = 5 measurements) 
for heroin and cocaine users in natural fingerprint samples and samples 
collected after wiping hands. 
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3.2.6 Effect of washing hands: drug users 
In addition to the use of a hand wiping procedure (with alcohol free wipes), the influence of 
a handwashing procedure on the detection rate of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine in fingerprints was also evaluated. Comparison of the levels of cocaine and 
benzoylecgonine in natural fingerprints and after handwashing for the same participants is 
shown Figure 3.18. A Mann-Whitney U test showed that a significant difference was 
observed for cocaine (U = 516, p = 0.006) and benzoylecgonine (U = 260, p < 0.001) 
between the two sample collection procedures (Appendix E. 4). The median cocaine level 
(ratio A/IS) in natural fingerprints was 1.030 compared to 0.292 after handwashing. For 
benzoylecgonine, the median level (ratio A/IS) in natural fingerprints was 0.029 compared 
to 0.009 after handwashing. This suggests that the use of a handwashing procedure removed 
cocaine and benzoylecgonine present on the hands, resulting in lower levels. 
 
Figure 3.18: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine between 
natural fingerprints and samples collected after wiping hands with alcohol 
free wipes for the same participants. 
The influence of a handwashing procedure on the level of heroin and 6-acetylmorphine 
present in fingerprint samples for the same participants is shown in Figure 3.19. The results 
show that a greater variability is observed in the level of heroin in fingerprints after 
handwashing, resulting in an uneven box plot size. Based on a Mann-Whitney U test, a 
significant difference is observed in the level of heroin (U = 290, p < 0.001) and 6-
acetylmorphine (U = 450, p = 0.008) present in natural fingerprints compared to samples 
collected after wiping hands (Appendix E. 4). The median heroin level (ratio A/IS) in natural 
fingerprints was 0.118 compared to 0.011 after handwashing. For 6-acetylmorphine, the 
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median (ratio A/IS) was 0.037 in natural fingerprints compared to 0.021 after handwashing. 
This suggests that the use of a handwashing procedure removed heroin and 6-
acetylmorphine present on the hands, resulting in lower analyte levels. 
 
Figure 3.19: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine between natural 
fingerprints and samples collected after wiping hands with alcohol free wipes 
for the same participants. 
3.2.6.1 Cocaine 
A total of 8 participants were recruited who admitted having taken cocaine and whose 
fingerprint samples were collected after washing hands with soap and water. Natural 
fingerprint samples (n = 5) were collected from each participant 41026, 41028, 41036 – 
41038 and 41044 – 41046 and after hand washing. The fingerprint results obtained for 
cocaine and benzoylecgonine after handwashing are shown in Figure 3.20. Cocaine was 
detected in all fingerprint samples for each participant after handwashing, resulting in a 
100% detection rate based on participant testimony. In contrast, benzoylecgonine was 
detected in 87% (35 samples) after washing hands with soap and water. This is because 
benzoylecgonine was not detected in any fingerprint samples for participant 41026 after 
handwashing. This is consistent with results obtained from natural fingerprint samples 
collected for this participant. Additionally, the lowest level of cocaine in fingerprint samples 
was observed for this participant. Furthermore, the oral fluid result for participant 41026 
was negative for cocaine use. It is possible that cocaine was not removed completely after 
the handwashing procedure or that not enough sweat had been secreted for benzoylecgonine 
Chapter 3: Investigation into the Suitability of a Fingerprint to Detect Cocaine and Heroin use 
93 
 
to be detected, or the drug administration was too recent for it to produce a positive oral 
fluid or fingerprint test.  
 
Figure 3.20: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) based on n = 5 fingerprint 
samples collected after handwashing for participants who admitted having 
taken cocaine in the last 24 h. Solid line represents limit of detection (LOD). 
A comparison between the oral fluid and fingerprint screening results (after handwashing) 
is shown in Table 3.8. It must be noted that a discrepancy is still observed between the 
fingerprint and oral fluid results for participant 41036. A negative oral fluid confirmation 
result was obtained, but cocaine and benzoylecgonine were detected in all fingerprints after 
washing hands with soap and water. This could possibly be observed due to a difference in 
detection window between the matrices or the handwashing procedure was not sufficient in 
the removal of external contamination from the fingers. 
Table 3.8: Oral fluid confirmation and fingerprint results based on n = 5 fingerprint 
samples collected after handwashing from participants who admitted having 
taken cocaine in the past 24. 
Participant 
Oral fluid confirmation test 
(concentration ng/ml) 
Fingerprint screening test (n = 5) 
Number of values >LOD 
Cocaine Benzoylecgonine Cocaine Benzoylecgonine 
41026 Negative Negative 5 0 
41028 >64 >64 5 5 
41036 Negative Negative 5 5 
41037 64 64 5 5 
41038 Negative 64 5 5 
41044 >64 >64 5 5 
41045 >64 >64 5 5 
41046 >64 >64 5 5 
*LOD = limit of detection (see section 2.3.7.3) 
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Fingerprint samples collected from participants 41033 and 41035 who admitted to the sole 
use of heroin, showed traces of cocaine and benzoylecgonine in natural fingerprints (see 
Figure 3.4). It is possible that these participants had taken cocaine >24 h and therefore 
resulted in positive fingerprint samples or that these traces were present from external 
contamination. Figure 3.21 shows that after washing hands with soap and water, cocaine 
was still detected in all fingerprint samples for both participants. In contrast to the natural 
fingerprint samples collected for participant 41033, benzoylecgonine was not detected in 
any fingerprint sample after handwashing. For participant 41035, one fingerprint sample 
(right little finger) was positive for benzoylecgonine, whereas none were positive in natural 
fingerprint samples collected. The oral fluid results for these participants were negative for 
both cocaine and benzoylecgonine. Comparison of the cocaine levels detected in natural 
fingerprint samples collected and fingerprints collected after handwashing showed a 
decrease in signal, which suggests that the hand washing procedure removed some external 
contamination that was present on the hands or that not enough sweat was secreted to allow 
for similar levels to be detected (<LOD). 
 
Figure 3.21: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for cocaine and 
benzoylecgonine from fingerprints collected after handwashing from 
individuals admitted having taken heroin only. Solid line represents limit of 
detection (LOD).  
3.2.6.2 Heroin 
A total of n = 8 participants were recruited who admitted having taken heroin the past 24 h. 
Fingerprint samples (n = 5) were collected from participants 41036 – 41038 and 41044 – 
41046 (i) natural and (ii) after washing hands with soap and water. The fingerprint results 
obtained for heroin and 6-acetylmorphine after washing hands are shown in Figure 3.22. 
Eighty-five percent (34 samples) of the fingerprint samples were positive for heroin, 
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whereas 90% (36 samples) were positive for 6-acetylmorphine based on participant 
testimony. For participant 41036, both heroin and 6-acetylmorphine were not detected in the 
right middle, ring or little finger. For participant 41038, no heroin was detected in the right 
middle finger and no 6-acetylmorphine in the right little finger. Additionally, the right ring 
finger was negative for both analytes for participant 41037, whereas no heroin was detected 
in the right middle finger for participant 41035 after washing hands. This could be due to 
lower concentrations of analytes present in these fingers compared to the right thumb and 
index finger. The natural fingerprint samples collected for these participants, however were 
all positive for heroin and 6-acetylmorphine. In contrast to the use alcohol free wipes, the 
detection rate of heroin and 6-acetylmorphine is decreased by using this handwashing 
procedure from 98% for heroin and 100% for 6-acetylmorphine to 85% and 90%, 
respectively.  
 
Figure 3.22: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) based on n = 5 fingerprint 
samples collected after handwashing for participants who admitted having 
taken heroin in the past 24 h. Solid line represents limit of detection (LOD). 
The oral fluid confirmation and fingerprint results after handwashing are shown in Table 
3.9. There still is a discrepancy between the oral fluid and fingerprint results. In particular 
for participants 41037, 41038 and 41046 as heroin and 6-acetylmorphine were still detected 
in nearly all fingerprints even after washing hands with soap and water.  It is possible that 
the participants did not thoroughly wash their hands and as a result the external 
contamination of heroin was not effectively removed. Another possibility is that a difference 
in detection window between the matrices can result in these discrepancies observed. The 
results obtained for participant 41036 suggest that the detection of heroin and 6-
acetylmorphine was due to external contamination. Especially compared to the natural 
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fingerprint samples collected for this participant which were all positive, however after 
handwashing only the right thumb and index finger remained positive for heroin and 6-
acetylmorphine.  
Table 3.9: Oral fluid confirmation and fingerprint results based on n = 5 fingerprint 
samples collected after washing hands with soap and water from participants 
who admitted having taken heroin in the past 24 h. 
Participant 
Oral fluid confirmation test 
(concentration ng/ml) 
Fingerprint screening test (n = 5) 
Number of values >LOD 
Morphine 6-Acetylmorphine Heroin 6-Acetylmorphine 
41033 >240 32 5 5 
41035 138 32 4 5 
41036 Negative Negative 2 2 
41037 Negative  Negative 4 4 
41038 Negative Negative 4 5 
41044 Negative 22.6 5 5 
41045 90 Negative 5 5 
41046 Negative Negative 5 5 
*LOD = limit of detection (see section 2.3.7.3)  
Fingerprint samples collected from participants (41026 and 41028) who admitted to the sole 
use of cocaine showed that traces of heroin and 6-acetylmorphine were present for 
participant 41028 in natural fingerprints (as seen in Figure 3.23). For participant 41026, no 
heroin or 6-acetylmorphine was detected in any natural fingerprint sample or after 
handwashing.  
 
Figure 3.23: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for heroin and 6-
acetylmorphine for fingerprints collected after handwashing or wiping hands 
from individuals admitted having taken cocaine only. Solid line represents 
limit of detection (LOD). 
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For participant 41028, heroin was still detected in all fingerprint samples after handwashing. 
In contrast, only 2 out of 5 fingerprints were positive for 6-acetylmorphine after 
handwashing, which could be due to the low levels of analytes present (<LOD). Although 
the oral fluid samples were negative for opiate use, it is possible that traces of these analytes 
could be present from heroin use >24 h or possible external contamination on the hands 
which was not removed by the handwashing procedure. 
3.2.6.3 Relationship between parent drug and metabolite  
Comparison of the cocaine-to-benzoylecgonine ratio for natural fingerprints and samples 
collected after washing hands with soap and water is shown in Figure 3.24. The results show 
a similar distribution of the cocaine-to-benzoylecgonine ratio for both sample collection 
procedures. No significant difference (at p = 0.05) is observed between the cocaine-to-
benzoylecgonine ratio after washing hands compared to natural fingerprints (U = 588, p = 
0.778) (Appendix E. 5). The median level for the cocaine-to-benzoylecgonine ratio in 
natural fingerprints was 37.621 compared to 32.834 after handwashing. This suggests that 
although the handwashing procedure resulted in significantly lower results for cocaine and 
benzoylecgonine compared to natural fingerprints (section 3.2.6.1), the cocaine-to-
benzoylecgonine ratio remained similar. 
 
Figure 3.24: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of cocaine-to-benzoylecgonine ratio for 
cocaine users for samples collected as natural fingerprints and samples 
collected after washing hands with soap and water. 
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The individual ratio cocaine-to-benzoylecgonine for natural fingerprints and samples 
collected after washing hands for each participant is shown in Figure 3.25. For participants 
41026, 41036 and 41040 (whose oral fluid samples were negative for cocaine), the 
handwashing procedure still resulted in a ratio cocaine-to-benzoylecgonine similar to those 
of participants whose oral fluid samples were positive.  This suggests that it is not possible 
to differentiate these participants by using the ratio cocaine-to-benzoylecgonine. It is 
possible that a difference in detection window can result in these differences observed, or 
that external contamination remaining on the hands can produce similar results between the 
presence of cocaine and benzoylecgonine. 
 
Figure 3.25: Average peak area ratio of cocaine-to-benzoylecgonine (n = 5 measurements) 
for cocaine and heroin users in fingerprint samples collected after washing 
hands with soap and water.  
In contrast to the cocaine-to-benzoylecgonine ratio, the heroin-to-6-acetylmorphine ratio is 
significantly lower for samples collected after handwashing (U = 353, p = 0.001) compared 
to natural fingerprints as seen in Figure 3.26 (Appendix E. 5). The use of the handwashing 
procedure resulted in significantly lower levels for heroin and 6-acetylmorphine (section 
3.2.6.2). The median level of heroin-to-6-acetylmorphine ratio in natural fingerprints was 
2.854 compared to 1.317 after handwashing. In contrast to cocaine, this suggests that the 
amount of heroin and 6-acetylmorphine removed by washing hands varied, resulting in a 
lower heroin-to-6-acetylmorphine ratio after handwashing. 
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Figure 3.26: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of heroin-to-6-acetylmorphine ratio for 
heroin users for samples collected as natural fingerprints and samples 
collected after washing hands with soap and water. 
The individual ratio of heroin-to-6-acetylmorphine for natural fingerprints compared to 
samples collected after washing hands with soap and water is shown in Figure 3.27. The use 
of a hand cleaning procedure has not reduced the variability observed between fingerprints 
within a participant and between participants.  
 
Figure 3.27: Average peak area ratio of heroin-to-6-acetylmorphine (n = 5 measurements) 
for heroin and cocaine users in natural fingerprints and samples collected 
after washing hands with soap and water. 
For participants 41037, 41038 and 41046, negative oral fluid results were obtained. 
However, the heroin-to-6-acetylmorphine ratio is similar to those for participants with 
positive oral fluid samples. This indicates that the relationship between the parent drug and 
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metabolite could not be used to provide a clear distinction between participants whose oral 
fluid samples were positive or negative for heroin use. 
3.2.7 Effect of washing hands: background population (non-drug users) 
3.2.7.1 Cocaine 
The collection of natural fingerprint samples from the background population resulted in the 
presence of cocaine and benzoylecgonine in 13% and 5% of samples, respectively. To 
reduce the detection of cocaine and benzoylecgonine from environmental exposure, a 
different sampling strategy was evaluated, which included washing the hands thoroughly 
with soap and water prior to sample collection. Fingerprint samples (n = 2 per participant, 
right thumb and index finger) were collected from 50 participants (SUB057 – SUB106) after 
washing hands with soap and water and wearing nitrile gloves for 10 min to promote the 
secretion of eccrine sweat from the fingertips. Results showed that cocaine was only detected 
in one fingerprint sample (SUB082 right thumb) and all samples were negative for 
benzoylecgonine. However, based on the presence of both the parent drug and metabolite in 
fingerprint samples, a 0% false positive rate would be obtained after handwashing, compared 
to 4% false positive rate if natural fingerprints are collected. The introduction of a 
handwashing step prior to sample collection results in a lower detection rate for both cocaine 
and benzoylecgonine from environmental contamination in the background population.  
3.2.7.2 Heroin 
The prevalence of heroin and 6-acetylmorphine in natural fingerprints from the background 
population was insignificant, as only 1% was positive for 6-acetylmorphine, whereas none 
were positive for heroin. The influence of the use of a handwashing procedure on the 
detection of heroin and 6-acetylmorphine in the background population was also evaluated. 
Fingerprint samples (n = 2 per participant, right thumb and index) were collected from 50 
participants (SUB057 – SUB106) after washing hands with soap and water and wearing 
nitrile gloves for 10 min to promote the secretion of eccrine sweat from the fingertips. From 
the 100 fingerprint samples, none were positive for heroin and 6-acetylmorphine. Similar to 
the results obtained from the background population for natural fingerprint samples 
collected, heroin is not likely observed due to environmental contamination. This suggests 
that the detection of heroin and 6-aceytlmorphine in fingerprint samples is significant above 
the detection limit as no false positive results would be observed in a background population 
of non-drug users.  
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3.2.8 Effect of a hand cleaning procedure 
3.2.8.1 Cocaine 
The fingerprint sampling strategy was evaluated by comparing the collection of fingerprint 
samples after wiping hands with alcohol free wipes or washing hands with soap and water. 
It is important to show that (i) a fingerprint test cannot be falsified by the use of a hand 
cleaning procedure and (ii) the use of a hand cleaning procedure reduces the possibility of 
external contamination on the fingers and thumbs. Comparison between the two hand 
cleaning procedures (alcohol free wipes and handwashing) showed that the same fingerprint 
results were obtained as the collection of natural fingerprints for those participants.   
The results obtained for fingerprint samples collected after handwashing (n = 100) from the 
background population showed that cocaine and benzoylecgonine were not present (with 1 
false positive for cocaine), in contrast to the results obtained for natural samples collected. 
This shows that the use of a handwashing procedure has reduced the prevalence of cocaine 
in fingerprint samples from the background population of non-drug users. This whilst 
maintaining the same detection rate for cocaine (100%) and benzoylecgonine (87%) for 
cocaine users after handwashing compared to natural fingerprint samples collected. This 
suggests that there is no requirement to impose a threshold level for fingerprints if samples 
are collected after washing hands, implying that the detection limit can then be used as the 
decision level, with a 1% false positive rate for cocaine in the background population (non-
drug users). 
3.2.8.2 Heroin 
The majority of the natural fingerprint samples collected from individuals admitted having 
used heroin in the past 24 h were positive for heroin (85% detection rate) and 6-
acetylmorphine (100% detection rate). However, comparison between the two hand cleaning 
procedures (wiping hands with alcohol free wipes and handwashing) showed that there is a 
difference observed between the two approaches, as 100% detection rate is observed using 
alcohol free wipes for both heroin and 6-acetylmorphine. The collection of fingerprint 
samples after handwashing indicates that it is possible that the detection of heroin and 6-
acetylmorphine could have been due to contamination of heroin on the hands of the 
participants. This is suggested by the results obtained after handwashing, which reduced the 
overall detection rate to 85% and 90% for heroin and 6-acetylmorphine, respectively and 
additionally were inconsistent with corresponding oral fluid samples. However, as the 
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detection window for heroin in fingerprints is unknown, it is possible that this could also be 
a result of a difference in detection window for drugs of abuse between oral fluid and 
fingerprints. Another possibility is that not enough sweat was secreted for these samples to 
produce a positive result or the levels were below the limit of detection. These results 
highlight the challenges associated with the use of fingerprints for drug testing purposes and 
the need of a standardised fingerprint collection procedure. It is possible that external 
contamination present on the hands even after a hand cleaning procedure can result in false 
positive tests. Furthermore, it is also possible that the hand cleaning procedure used was not 
effective in the removal of external contamination, which would still result in a false positive 
fingerprint result.  
The results obtained for heroin and 6-acetylmorphine from the background population in 
natural fingerprints and after handwashing suggest that these analytes are not commonly 
observed due to environmental exposure. This implies that the detection of heroin and 6-
acetylmorphine is significant above the detection limit and there is no requirement to impose 
a threshold level for fingerprint analysis. However, the use of a hand cleaning procedure is 
advantageous as this could help to reduce the possibility of the presence of analytes on the 
hands from contamination. 
3.2.9 Secondary transfer of drugs 
The potential transfer of drugs between individuals was investigated between non-drug users 
and drug users through shaking hands. This was investigated because it is important to 
understand if drugs can be present in fingerprints from non-drug users through secondary 
transfer and what the influence of this is on the interpretation of results. Comparison between 
the distribution of cocaine and benzoylecgonine in samples collected from non-drug users 
before and after shaking hands, with those from cocaine users is shown in Figure 3.28. A 
significant difference was observed between the levels of cocaine (c2 = 46.29, p < 0.001) 
and benzoylecgonine (c2 =12.95, p = 0.002) in non-drug users (before and after shaking 
hands) compared to natural fingerprints from cocaine users based on a Kruskal-Wallis test 
(Appendix E. 6). The median cocaine level (ratio A/IS) was 0.802 for cocaine users in 
natural fingerprints compared to 0.003 for non-drug users. The median cocaine level (ratio 
A/IS) for non-drug increased to 0.023 after shaking hands. This suggests that by shaking 
hands, cocaine was transferred between the individuals resulting in an increase in the median 
cocaine level detected. However, no significant difference (at p = 0.05) was observed 
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between the samples collected from non-drug users before and after secondary transfer based 
on a Mann-Whitney U test (U = 147, p = 0.005) (Appendix E. 7). For benzoylecgonine, the 
median level (ratio A/IS) in natural fingerprints was 0.026 for cocaine users compared to 
0.006 for non-drug users. After shaking hands, the median benzoylecgonine level (ratio 
A/IS) for non-drug users remained 0.006. No significant difference (at p = 0.05) was 
observed between the benzoylecgonine levels before and after shaking hands for non-drug 
users (U = 6, p = 1) (Appendix E. 7). This suggests that although benzoylecgonine was more 
prevalent in the fingerprints of non-drug users after shaking hands, the amount of analyte 
transferred was similar to those present in natural fingerprints for those participants (possibly 
from environmental exposure). 
 
Figure 3.28: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine between 
cocaine users and non-drug users before and after shaking hands. 
The distribution of heroin and 6-acetylmorphine in fingerprints samples collected from non-
drug users before and after secondary transfer compared to samples collected from heroin 
users is shown in Figure 3.29. The results show that no heroin or 6-acetylmorphine was 
present in natural fingerprints from non-drug users. This is consistent with the results 
obtained from a background population of non-drug users (section 3.2.3.2). A significant 
difference is observed between the levels of heroin (c2 = 17.57, p < 0.001) and 6-
acetylmorphine (c2 = 11.12, p < 0.001) from non-drug users (natural and after shaking 
hands) compared to natural fingerprints from heroin users (Appendix E. 6). This suggests 
that although the act of shaking hands has resulted in secondary transfer of heroin and 6-
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acetylmorphine, the analyte levels present were lower than those normally observed for 
heroin users. 
 
Figure 3.29: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine between 
cocaine users and non-drug users before and after shaking hands. 
3.2.9.1 Cocaine 
Natural fingerprint samples (n = 5 per participant) were collected from non-drug users 
(SUB001, SUB002, and SUB054 – 56) to determine the presence of drugs prior to contact 
with drug users (at an NHS Drug and Alcohol Service). Additional fingerprint samples were 
collected from the volunteers (non-drug users) after shaking hands once with participants 
who admitted to the use of cocaine in the past 24 h. Details of the secondary transfer 
experiment are outlined in Table 3.10. 
Table 3.10: Details of the secondary transfer experiment carried out between non-drug 
users (volunteers) and cocaine users. 
Volunteer Hands shaken with participant Participant testimony 
SUB001 41026 Cocaine  
SUB002 41028 Cocaine 
SUB054 41044 Cocaine and heroin  
SUB055 41045 Cocaine and heroin 
SUB056 41046 Cocaine and heroin 
Figure 3.30 shows the fingerprint results for samples collected from the volunteers (i) natural 
and (ii) after secondary transfer with participants admitted to cocaine use in the past 24 h. 
Cocaine was detected in 7 out of 25 natural fingerprint samples collected from the volunteers 
(non-drug users). This is not surprising as it is known that traces of cocaine can be found in 
the environment (Zuccato & Castiglioni, 2009; Armenta & de la Guardia, 2008; Carter et 
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al., 2003). Additionally, the results obtained from natural fingerprint samples collected from 
the background population (section 3.2.3.1) showed that cocaine was present from 
environmental exposure in 13% of the background population. In contrast, benzoylecgonine, 
was only detected in 2 out of 25 fingerprint samples collected (natural) from the non-drug 
users. After shaking hands with a participant from the Xchange (drug users), all 25 
fingerprint samples (100%) from the non-drug users were positive for cocaine and 5 
fingerprint samples (20%) for benzoylecgonine. This demonstrates that cocaine can readily 
be transferred between individuals through contact and to a lesser extent for 
benzoylecgonine. These findings demonstrate that the collection of natural fingerprint 
samples can result in a false positive test, as secondary transfer of cocaine can be a potential 
source for the presence of these analytes. This also further highlights the importance of the 
sampling strategy for fingerprint testing and the importance of carful interpretation of the 
results obtained.   
 
Figure 3.30: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for volunteers before and after 
secondary transfer with participants admitted having taken cocaine in the past 
24 hours. Solid line represents limit of detection (LOD). 
A threshold level was required to differentiate non-drug users from drug users for natural 
fingerprint samples (section 3.2.4.1). The influence of the same proposed threshold levels 
on the detection rate of cocaine and benzoylecgonine before and after secondary transfer 
was explored. Threshold levels were evaluated per analyte at the limit of detection (ratio 
A/IS 0.002 for cocaine and 0.004 for benzoylecgonine) and ratio A/IS of 0.005 – 0.030 in 
increments of 0.005. Figure 3.31 shows the detection rate for cocaine and benzoylecgonine 
in fingerprint samples from (n = 5) non-drug users before and after secondary transfer based 
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on the proposed threshold levels. The results show that the detection rate for cocaine before 
secondary transfer with a drug user can be reduced to 0% for the right index, middle, ring 
and little finger, by imposing a cut-off level at ratio A/IS 0.005. However, for the right thumb 
the detection rate remains 20% at all proposed cut-off levels. This is a result of participant 
SUB056 where cocaine was present at ratio A/IS 0.075 in the right thumb collected (natural 
fingerprint). In contrast, the detection rate for benzoylecgonine in all natural fingerprint 
samples collected from non-drug users, is readily reduced to 0% by imposing a cut-off level 
at ratio A/IS 0.010. 
 
Figure 3.31: Detection rate (percentage) of cocaine and benzoylecgonine in natural 
fingerprint samples collected from (n = 5) non-drug users before and after 
shaking hands with a cocaine user (based on n = 5 fingerprint samples per 
participant) for each proposed cut-off level. 
The collection of natural fingerprint samples from non-drug users after contact with a 
participant who admitted having taken cocaine, resulted in a 100% detection rate for cocaine 
based on the limit of detection. Although the use of various threshold levels was explored, 
it was not possible to obtain a 0% detection rate for cocaine for non-drug users after hands 
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were shaken with a cocaine user. This is due to the higher levels of cocaine transferred 
between the participants. However, the levels of benzoylecgonine transferred between the 
participants were lower and therefore the use of a threshold level at ratio A/IS 0.010 results 
in a 0% detection rate for all fingerprint samples. If both analytes were required to be present 
and a threshold level of ratio A/IS 0.010 was imposed for benzoylecgonine, no false positive 
tests would be obtained even after secondary transfer. 
3.2.9.2 Heroin 
Natural fingerprint samples (n = 5 per participant) were collected from non-drug users 
(SUB054 – 56) to determine the presence of heroin in fingerprint samples prior to contact 
with participants recruited from the Xchange (NHS Drug and Alcohol Service) who 
admitted having taken heroin. An additional set of fingerprint samples were collected from 
the non-drug users after shaking hands. Details of the secondary transfer experiment are 
outlined in Table 3.11. 
Table 3.11: Details of the secondary transfer experiment carried out between non-drug 
users (volunteers) and heroin users. 
Volunteer Hands shaken with participant Participant testimony 
SUB054 41044 Cocaine and heroin  
SUB055 41045 Cocaine and heroin 
SUB056 41046 Cocaine and heroin 
Figure 3.32 shows that no heroin and 6-acetylmorphine were detected in natural fingerprint 
samples collected from the volunteers (non-drug users), which is consistent with the results 
obtained for the background population in section 3.2.3.2. However, after shaking hands 
with participants who admitted to the use of heroin in the past 24 h, both heroin and 6-
acetylmorphine were detected in 7 fingerprint samples (28%) of the volunteers (n = 3 
participants).  
It is important to determine whether after contact with an individual who administered a 
drug, these traces can be transferred onto the hands of a non-drug user. More importantly 
because this will result in a positive result if natural fingerprint samples are collected. This 
also further highlights the importance of a hand cleaning procedure prior to fingerprint 
collection to remove external contamination which could be present. As the results from the 
background population of non-drug users showed that heroin and 6-acetylmorphine were 
not prevalent, there was no requirement to impose threshold levels for heroin and 6-
acetylmorphine for natural fingerprint samples collected. However, if the same principle is 
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applied here, the results indicate that a false positive fingerprint test could be obtained due 
to secondary transfer between individuals. This highlights that the sampling strategy for a 
fingerprint test is particularly important, as it is possible that the source of the presence of 
the analytes could come from contact with an individual rather than administration of the 
drug. 
 
Figure 3.32: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for volunteers before and after 
secondary transfer with participants admitted having taken heroin in the past 
24 hours. Solid line represents limit of detection (LOD). 
3.2.9.3 Relationship between parent drug and metabolite 
Comparison of the distribution of the cocaine-to-benzoylecgonine ratio in fingerprint 
samples from non-drug users (before and after shaking hands with cocaine user) and cocaine 
users is shown in Figure 3.33. The results show a significant difference is observed in the 
distribution of the cocaine-to-benzoylecgonine ratio between the non-drug users (before and 
after shaking hands) and cocaine users based on a Kruskal-Wallis test (c2 = 8.46, p = 0.015) 
(Appendix E. 8). The median cocaine-to-benzoylecgonine ratio in natural fingerprints for 
cocaine users was 29.901 compared to 6.007 for non-drug users. After shaking hands with 
a cocaine user, the median cocaine-to-benzoylecgonine ratio for non-drug users increased to 
17.25. Additionally, the results show a close distribution of the cocaine-to-benzoylecgonine 
ratio for non-drug users after shaking hands, suggesting similar levels of drugs were 
transferred between the individuals. 
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Figure 3.33: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of cocaine-to-benzoylecgonine ratio for 
natural fingerprints collected from cocaine users and non-drug users before 
and after shaking hands with cocaine users. 
The individual cocaine-to-benzoylecgonine ratio for fingerprint samples collected from 
cocaine users (n = 13) and non-drug users (n = 3) before and after shaking hands with 
cocaine users is shown in Figure 3.34. For participants SUB054 and SUB056, the right 
thumbs were positive for cocaine and benzoylecgonine before hands were shaken with the 
participant. In contrast, for the remaining participants, no benzoylecgonine was present, and 
therefore the ratio cocaine-to-benzoylecgonine could not be calculated.  
 
Figure 3.34: Average peak area ratio of cocaine-to-benzoylecgonine (n = 5 measurements) 
for fingerprint samples collected from non-drug users after shaking hands 
with participants admitted having taken cocaine. 
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After shaking hands with a cocaine user, the prevalence of cocaine and benzoylecgonine in 
fingerprint samples from non-drug users increased. Although a significant difference is 
observed in the distribution of the cocaine-to-benzoylecgonine ratio between non-drug users 
(before and after shaking hands) and cocaine users (Figure 3.33), the individual values 
observed are in the range of those of natural fingerprint samples collected for participants 
admitted having taken cocaine (Figure 3.34). This suggests that the ratio cocaine-to-
benzoylecgonine in natural fingerprint samples is not able to differentiate between 
participants who have taken cocaine and participants who have come into contact with a 
cocaine user. 
A comparison of the distribution of the heroin-to-6-acetylmorphine ratio in fingerprints from 
heroin users and non-drug users (before and after shaking hands with heroin users) is shown 
in Figure 3.35. A significant difference is observed in the distribution of the heroin-to-6-
acetylmorphine ratio between heroin users and non-drug users (before and after 
handshaking) based on a Kruskal-Wallis test (c2 = 6.01, p = 0.014) (Appendix E. 8). The 
median heroin-to-6-acetylmorphine ratio for heroin users was 2.691 compared to 0.871 for 
non-drug users after shaking hands.  
 
Figure 3.35: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of heroin-to-6-acetylmorphine ratio for 
natural fingerprints collected from heroin users and non-drug users before 
and after shaking hands with heroin users. 
Chapter 3: Investigation into the Suitability of a Fingerprint to Detect Cocaine and Heroin use 
111 
 
The individual ratio heroin-to-6-acetylmorphine for fingerprint samples collected from 
heroin users (n = 12) and non-drug users (n = 3) before and after shaking hands with 
participants admitted having taken heroin in the past 24 h is shown in Figure 3.36. The 
results show that heroin and 6-acetylmorphine are not present in fingerprint samples 
collected before contact with a heroin user, and therefore the ratio heroin-to-6-
acetylmorphine could not be calculated. This is consistent with the results obtained from the 
background population in section 3.2.3.2, which showed that heroin was not prevalent in 
non-drug users. However, after contact with a heroin user, fingerprint samples for SUB055 
(right middle and ring finger) and SUB056 (right middle and little finger) were positive for 
heroin and 6-acetylmorphine. The individual ratio heroin-to-6-acetylmorphine observed for 
non-drug users after contact with a heroin user, were similar to the levels observed for than 
heroin users. Therefore, is not possible to determine the difference between a participant 
who has taken heroin and a participant who has been in contact with a heroin user based on 
the ratio heroin-to-6-acetylmorphine. 
 
Figure 3.36: Average peak area ratio of cocaine-to-benzoylecgonine (n = 5 measurements) 
for fingerprint samples collected from non-drug users after shaking hands 
with participants admitted having taken cocaine. 
3.2.10 Effect of the finger on the detection rate  
3.2.10.1 Cocaine 
The level of cocaine and benzoylecgonine present in fingerprint samples collected from drug 
users varied depending on the fingerprint sample collected (right thumb to right little finger). 
However, in natural fingerprint samples collected the same detection rate (100%) was 
observed for cocaine in all fingers (see Table 3.12). Therefore, the use of the finger to collect 
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a sample from for drug testing purposes did not influence the interpretation of the results. 
However, for benzoylecgonine the highest detection rate was observed for the right ring 
finger (100% detection rate), compared to the other fingerprint samples (92% detection rate). 
This is caused by participant 41026, whose natural fingerprint samples (were negative for 
benzoylecgonine in all samples, except for the right ring finger. In light of the different 
results obtained, it would therefore be good practice to collect more than one fingerprint 
sample to confirm the results obtained. In addition, the detection rates of cocaine and 
benzoylecgonine after using a hand cleaning procedure (e.g. washing hands or wiping hands 
with alcohol free wipes) were consistent for all fingerprints. This shows that the finger used 
to test for illicit substances is not dependent on the fingerprint sample collected. 
Table 3.12: Positive detection rate (percentage) of cocaine and benzoylecgonine (BZE) 
above the detection limit from participants admitted to the use of cocaine in 
the past 24 h, per fingerprint sample based on participant testimony and 
collection method. 
Collection  
method 
 
Sample 
Detection rate (%) 
Natural (n = 13) Soap (n = 8) Wipe (n = 5) 
Cocaine BZE Cocaine BZE Cocaine BZE 
Right thumb 100 92 100 87 100 100 
Right index finger 100 92 100 87 100 100 
Right middle finger 100 92 100 87 100 100 
Right ring finger 100 100 100 87 100 100 
Right little finger 100 92 100 87 100 100 
 
3.2.10.2 Heroin 
The level of heroin and 6-aceytlmoprhine detected in fingerprint samples from heroin users 
varied for each finger. An overview of the detection rates per finger for heroin and 6-
acetylmorphine based on participant testimony and fingerprint collection method is shown 
in Table 3.13. The detection rates of the analytes were not dependent on the finger collected 
for natural fingerprint and fingerprints collected after wiping hands as the same detection 
rates were observed (with one false positive due to participant 41036, where heroin was not 
detected in the right little finger).  
Interestingly, the results varied for fingerprints collected after washing hands with soap and 
water. The highest detection rates were observed for the right thumb and index finger and 
reduced for the middle, ring and little finger. This suggests that lower levels of heroin and 
6-acetylmorphine were present after handwashing for these fingers which resulted in 
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negative results. The results indicate that the use of the right thumb and right index finger 
for fingerprint drug testing would provide the highest detection rates. 
Table 3.13: Positive detection rate (percentage) of heroin and 6-acetylmorphine (6-AM) 
above the detection limit from participants who admitted to the use of heroin 
in the past 24 h, per fingerprint sample based on participant testimony and 
collection method. 
Collection 
method 
 
Sample 
Detection rate (%) 
Natural 
(n = 12) 
Soap  
(n = 8) 
Wipe  
(n = 4) 
Heroin 6-AM Heroin 6-AM Heroin 6-AM 
Right thumb 100 100 100 100 100 100 
Right index finger 100 100 100 100 100 100 
Right middle finger 100 100 62 87 100 100 
Right ring finger 100 100 75 75 100 100 
Right little finger 92 100 87 87 100 100 
3.3 Summary 
Cocaine, benzoylecgonine, heroin and 6-acetylmorphine can be detected in natural 
fingerprints from cocaine and heroin users (section 3.2.1.1). However, traces of cocaine and 
benzoylecgonine were also detected in natural fingerprints from a background population of 
non-drug users (section 3.2.3). With the use of a threshold level (at ratio A/IS 0.005), the 
false positive detection rate of cocaine and benzoylecgonine can be reduced to 1% for non-
drug users (based on the presence of both analytes), with an 8% false negative detection rate 
for cocaine users (section 3.2.4.1). No threshold level was required for heroin and 6-
acetylmorphine, as these analytes were not prevalent in fingerprints form non-drug users 
(section 3.2.4.2). Additionally, threshold levels are not required if a hand washing procedure 
is used prior to sample collection, as cocaine and benzoylecgonine were not commonly 
observed in fingerprints from non-drug users after handwashing (1% false positive detection 
rate for cocaine) (section 3.2.7). The hand washing procedure did result in significantly 
lower levels (ratio A/IS) for cocaine, benzoylecgonine and heroin compared to natural 
fingerprints (but not for 6-acetylmorphine). Compared to washing hands with soap and 
water, the use of alcohol free wipes (as an alternative hand cleaning procedure) did not result 
in significantly lower analyte levels (sections 3.2.5 and 3.2.6). This suggests that washing 
hands is more effective in removal of analytes from the fingers compared to wiping hands 
with alcohol free wipes. In addition, traces of cocaine, benzoylecgonine, heroin and 6-
acetylmorphine can be transferred between non-drug users and drug users by shaking hands 
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(section 3.2.9). However, the trace levels are significantly lower compared to those of drug 
users. With the use a of threshold level (at ratio A/IS 0.010) for cocaine and 
benzoylecgonine, only a 1% false positive detection rate for cocaine is observed. The use of 
a hand washing procedure prior to sample collection would be a good approach to reduce 
the possible presence of drugs in fingerprints from non-drug users from secondary transfer. 
The finger used for analysis resulted in different analyte levels, but the detection rate for 
cocaine, benzoylecgonine, heroin and 6-acetylmorphine was not dependent on the finger 
(section 3.2.10). However, for testing purposes the collection of two samples would be 
favourable to allow for confirmation. 
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Chapter 4 Investigation into the Presence of Cocaine and 
Heroin in Fingerprints from Contact Residue 
4.0 Introduction 
The main objective of this chapter was to explore the possible presence of cocaine and heroin 
and their respective metabolites in fingerprint samples after physical contact with the parent 
drug. In the Chapter 3, the presence of cocaine, heroin and their respective metabolites 
(benzoylecgonine and 6-acetylmorphine) in fingerprint samples from participants who 
admitted having taken the substance in the past 24 h was evaluated. This showed that if a 
decision level is set at an appropriate value, it is possible to distinguish between drug use 
and environmental exposure, as well as secondary transfer from shaking hands. This then 
rules out an accidental contamination of the hands with cocaine or heroin. For a fingerprint 
test to be useful in certain operational scenarios, it is also beneficial to determine whether 
the test can distinguish between drug administration and drug contact. Whilst contact with 
a reasonable quantity of cocaine or heroin may imply direct involvement with illicit drugs 
rather than environmental exposure, this has a different legal implication to consuming a 
drug and being under its influence. No study (to our knowledge) has explored the influence 
of the possible presence of drugs from contact residue in relation to that of drug users. In 
collaboration with Forensic Science Ireland (FSI), the possibility to distinguish the presence 
of drugs in fingerprints from drug use and drug contact is investigated in this chapter. To 
evaluate the presence of cocaine or heroin due to physical contact with the parent drug, 
fingerprint samples were collected under four different conditions: 
• scenario 1: after physical contact with the parent drug; 
• scenario 2: after wiping hands with alcohol free wipes; 
• scenario 3: after washing hands with soap and water; and 
• scenario 4: after secondary transfer of drugs between participants (non-drug users).  
Fingerprint samples were collected from individuals (non-drug users) who volunteered to 
participate in the study. Four fingerprints were collected for each participant (right thumb, 
index finger, middle finger and ring finger). The presence of cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine in fingerprint samples collected after contact with the parent 
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drug was determined by liquid chromatography – mass spectrometry (LC-MS, section 
2.2.2). The fingerprint samples were extracted using the previously described sample 
preparation method (section 2.3.4). The sample collection method for each scenario is 
described in section 4.1. The presence of cocaine and heroin in fingerprint samples after 
each scenario is discussed in section 4.2. 
The presence of cocaine, benzoylecgonine, heroin and 6-acetylmorphine in fingerprints after 
drug administration has been explored in Chapter 3. In this chapter, the presence of cocaine 
and heroin after dermal contact with the parent drug is evaluated using different sampling 
strategies to determine its impact on the suitability of a fingerprint test to determine drug 
use. This will help to understand whether a fingerprint test can differentiate contact residue 
from drug administration. 
4.1 Experimental 
Fingerprint samples were collected after contact with seized street drugs under four different 
scenarios. The seized drugs were analysed at FSI using their standard analysis protocol using 
gas chromatography – mass spectrometry (GC-MS). The cocaine and heroin used were 
determined to have a purity of 41% and 11%, respectively. Results obtained for the GC-MS 
analysis of cocaine and heroin are provided in Appendix C.1 and Appendix C.2.  
Figure 4.1 illustrates the conditions under which fingerprint samples were collected for 
scenarios 1 to 4. Three participants (non-drug users) volunteered to participate in the study. 
Four fingerprint samples were collected per participant, namely the right thumb, index, 
middle and ring finger. Each step details the preparation for the collection of fingerprint 
samples after dermal contact with 2 mg of drug (cocaine or heroin). Scenario 2 and 3 utilised 
a hand cleaning procedure to explore whether dermal contact with the parent drug could be 
removed by washing hands or wiping hands with alcohol free wipes. In contrast, scenario 4 
investigated the potential secondary transfer of drugs between individuals after dermal 
contact with the parent drug. Each sample collected was labelled with a unique participant 
identifier; the finger or thumb that was collected and the condition under which the sample 
was collected. All samples were prepared for LC-MS analysis according to the protocol 
developed in Chapter 2, section 2.3.4. 
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Figure 4.1: Fingerprint collection procedure used at Forensic Science Ireland to 
determine the presence of drugs (cocaine and heroin) after contact, washing 
hands with soap and water, wiping hands with alcohol free wipes and 
secondary transfer (through shaking hands). 
4.2 Results and Discussion 
4.2.1 Comparison between scenarios 1 – 4 
4.2.1.1 Cocaine 
The collection of fingerprint samples (n = 12) after dermal contact with 2 mg of cocaine 
(scenario 1) resulted in the presence of both cocaine and benzoylecgonine in all samples. 
The presence of benzoylecgonine in fingerprint samples was due to the cocaine used in this 
experiment, which was confirmed by GC-MS analysis at Forensic Science Ireland (see 
Appendix C.1). Even after using a hand cleaning procedure (i) wiping hands with alcohol 
free wipes (scenario 2) and (ii) washing hands with soap and water (scenario 3), all 
fingerprint remained positive for cocaine and benzoylecgonine. Figure 4.2 shows the 
distribution of the level (ratio A/IS) of cocaine and benzoylecgonine in fingerprints for each 
scenario.  A significant difference is observed in the level of cocaine (c2 = 25.61, p < 0.001) 
and benzoylecgonine (c2 = 26.67, p < 0.001) between the scenarios based on a Kruskal-
Wallis test (Appendix E. 9). The median level (ratio A/IS) was 72.790 for cocaine and 5.714 
for benzoylecgonine after direct dermal contact with 2 mg of cocaine.  
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Figure 4.2: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine in non-drug 
users after dermal contact with 2 mg of cocaine (scenario 1), after wiping 
hands with alcohol free wipes (scenario 2) and after washing hands with soap 
and water (scenario 3). Dots represent outliers. 
Additionally, after washing hands the median cocaine level (ratio A/IS) was 0.431 compared 
to 2.516 after wiping hands with alcohol free wipes. For benzoylecgonine, the median level 
(ratio A/IS) after handwashing was 0.022 compared to 0.101 after wiping hands. This 
suggests that the use of a handwashing procedure is more effective in the removal of external 
contamination on the hands. However, the results indicate that both analytes can be present 
from external contamination on the hands if a large quantity (2 mg) of drug has been handled 
and cannot be removed by the hand cleaning procedures evaluated here. A more thorough 
hand cleaning procedure needs to be implemented (including more participants) to help 
exclude external contamination as a possible source for a positive fingerprint test. In addition 
to the presence of cocaine from handling the parent drug (dermal contact), the influence of 
secondary transfer of cocaine after dermal contact was evaluated.  
Figure 4.3 shows the distribution of cocaine and benzoylecgonine after shaking hands and 
after washing hands with soap and water. A Mann-Whitney U test showed that a significant 
difference is observed between the level of cocaine (U = 1, p < 0.001) and benzoylecgonine 
(U = 0, p < 0.001) present in samples after shaking hands and washing hands (Appendix E. 
10). The median cocaine level (ratio A/IS) was 0.761 after shaking hands compared to 0.030 
after washing hands with soap and water. For benzoylecgonine the median level (ratio A/IS) 
was 0.055 after shaking hands and 0.007 after handwashing. This shows that after shaking 
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hands with an individual who has handled 2 mg of cocaine, the levels are decreased by 
washing hands with soap and water, but not completely removed. 
 
Figure 4.3: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine in non-drug 
users after shaking hands with a participant with dermal contact of cocaine 
and after washing hands with soap and water. 
4.2.1.2 Heroin 
Fingerprints collected in scenario 1 after dermal contact with 2 mg of heroin showed that 
both heroin and 6-acetylmorphine were detected in all fingerprint samples (n = 12). The GC-
MS results from FSI confirmed that 6-acetylmorphine was already present in the heroin used 
in this experiment (see Appendix C.2). After using a hand cleaning procedure, such as 
wiping hands with alcohol free wipes (scenario 2) or washing hands with soap and water 
(scenario 3), both heroin and 6-acetylmorphine remained present in all fingerprints. Figure 
4.4 shows the distribution of the level of heroin and 6-acetylmorphine for each scenario. A 
significant difference is observed in the level of heroin (c2 = 28.76, p < 0.001) and 6-
acetylmorphine (c2 = 30.71, p < 0.001) between the three scenarios (Appendix E. 9). The 
median level (ratio A/IS) was 48.312 for heroin and 10.405 for 6-acetylmorphine after 
dermal contact with 2 mg of heroin. The use of alcohol free wipes lowered the median levels 
of heroin and 6-acetylmorphine present in the fingerprint samples to 0.360 and 0.137, 
respectively. Compared to wiping hands with alcohol free wipes, the use of a handwashing 
procedure was more effective in the removal of heroin and 6-acetylmorphine as lower 
median levels (ratio A/IS) were observed (heroin 0.028 and 6-acetylmorphine 0.009). 
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Figure 4.4: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine in non-drug 
users after dermal contact with 2 mg of heroin (scenario 1), after wiping 
hands with alcohol free wipes (scenario 2) and after washing hands with soap 
and water (scenario 3). Dots represent outliers.  
The act of shaking hands with a participant who has handled 2 mg of heroin resulted in 
secondary transfer of both heroin (7 out of 8 samples) and 6-acetylmorphine (7 out of 8 
samples) as seen in Figure 4.5. Interestingly, no heroin and 6-acetylmorphine are present 
after washing hands with soap and water. This suggests that although dermal contact with 2 
mg of heroin cannot be removed by washing hands, it is possible to remove secondary 
transfer of heroin and 6-acetylmorphine. 
 
Figure 4.5: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine in non-drug 
users after shaking hands with a participant with dermal contact of heroin and 
after washing hands with soap and water. Dots represent outliers. 
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4.2.2 Comparison of natural fingerprints: drug administration and drug contact 
4.2.2.1 Cocaine 
Fingerprint samples (n = 12) were collected from non-drug users (n = 3) after dermal contact 
with 2 mg of cocaine. Fingerprint samples (n = 65) were also collected from cocaine users 
(n = 13) (Chapter 3, section 3.2.2.1). All fingerprint samples collected after dermal contact 
with 2 mg of cocaine were positive for cocaine (12/12 samples) and benzoylecgonine (12/12 
samples).  Figure 4.6 shows the distribution of cocaine and benzoylecgonine in fingerprints 
from non-drug users after dermal contact with cocaine compared to cocaine users. A 
significantly higher level (ratio A/IS) is observed for cocaine (U = 777, p < 0.001) and 
benzoylecgonine (U = 732, p < 0.001) after dermal contact with 2 mg of cocaine compared 
to cocaine users (Appendix E. 11). The median cocaine level (ratio A/IS) was 0.900 for 
cocaine users compared to 72.790 for non-drug users after dermal contact with cocaine.  
 
Figure 4.6: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine in fingerprints 
from non-drug users after dermal contact with 2 mg of cocaine (scenario 1) 
and cocaine users. Dots represent outliers. 
The relationship between the presence of cocaine and benzoylecgonine after drug contact 
and drug administration was assessed by comparison of the parent drug-to-metabolite ratio. 
Figure 4.7 shows the ratio of cocaine-to-benzoylecgonine for participants after contact with 
2 mg of cocaine (scenario 1). Significantly lower cocaine-to-benzoylecgonine ratios are 
observed for non-drug users after dermal contact with cocaine compared to cocaine users (U 
= 143, p = 0.001) (Appendix E. 12). The median cocaine-to-benzoylecgonine ratio for non-
drug users after dermal contact with cocaine was 10.296 compared to 29.901 for cocaine 
users. Although a significant difference is observed between the median levels (cocaine-to-
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benzoylecgonine ratio), no differentiation between the two groups is possible based on 
individual levels. 
 
Figure 4.7: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio cocaine-
to-benzoylecgonine in fingerprints from non-drug users after dermal contact 
with 2 mg of cocaine (scenario 1) and cocaine users. Dots represent outliers.  
4.2.2.2 Heroin 
Fingerprint samples (n = 12) were collected from non-drug users (n = 3) after dermal contact 
with 2 mg of heroin. Fingerprint samples (n = 60) were also collected from heroin users (n 
= 12) (Chapter 3, section 3.2.2.2). All fingerprint samples collected after dermal contact with 
2 mg of the parent drug were positive for heroin (12/12 samples) and 6-acetylmorphine 
(12/12 samples). Figure 4.8 shows distribution of heroin and 6-acetylmorphine for heroin 
users and non-drug users after dermal contact with heroin. A significantly higher level (ratio 
A/IS) is observed for heroin after dermal contact with the parent drug in comparison to 
fingerprints collected from heroin users, based on a Mann-Whitney U-test (U = 707 p < 
0.001, Appendix E. 11). The median level (ratio A/IS) for heroin was 0.067 for heroin users 
compared to 48.312 for non-drug users after dermal contact with heroin.  In contrast, no 
significant difference (at p = 0.05) is observed for 6-acetylmorphine between drug users and 
non-drug users after dermal contact with 2 mg of heroin (U = 242, p = 0.073, Appendix E. 
11). The median level for 6-acetylmorphine was 0.030 for heroin users and 0.016 for non-
drug users (after dermal contact with heroin). 
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Figure 4.8: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine in fingerprints 
from non-drug users after dermal contact with 2 mg of heroin (scenario 1) 
and heroin users. Dots represent outliers. 
Based on the relationship between heroin and 6-acetylmorphine (Figure 4.9), a significantly 
lower heroin-to-6-acetylmorphine ratio is observed for heroin users compared non-drug 
users after dermal contact with 2 mg of heroin (U = 543, p = 0.004) (Appendix E. 12). The 
median heroin-to-6-acetylmorphine ratio was 2.691 for heroin users compared to 4.625 after 
dermal contact with 2 mg of heroin.  
 
Figure 4.9: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio heroin-
to-6-acetylmorphine in fingerprints from non-drug users after dermal contact 
with 2 mg of heroin (scenario 1) and heroin users. Dots represent outliers. 
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Additionally, a closer distribution is observed for the ratio heroin-to-6-acetylmorphine after 
dermal contact compared to heroin users. This is most likely attributed to the same amount 
of drug handled and distributed between fingers. Although a significant difference is 
observed in the median level (heroin-to-6-acetylmorphine ratio), it is not possible to 
differentiate heroin users and participants who have handled the parent drug based on 
individual levels observed for each participant. 
4.2.2.3 Threshold level 
The previous chapter explored the significance of the detection of cocaine, benzoylecgonine 
heroin and 6-acetylmorphine in natural fingerprint samples based on the prevalence of these 
analytes in a background population of non-drug users (section 3.2.3). As cocaine and 
benzoylecgonine were present in 13% (13 samples) and 5% (5 samples) of fingerprint 
samples collected from the background population, there was a requirement to impose a 
threshold level to differentiate non-drug users from drug users (section 3.2.4). In this chapter 
the influence of those same proposed threshold levels on the detection rate of cocaine and 
benzoylecgonine after dermal contact with the drug are evaluated. Threshold levels were 
evaluated per analyte at the limit of detection (ratio A/IS cocaine 0.002 and benzoylecgonine 
0.004, see section 2.3.7.3) and ratio A/IS of 0.005 – 0.030, in increments of 0.005 for 
fingerprint samples collected after dermal contact with 2 mg of cocaine (scenario 1). The 
results showed that due to the large amount of cocaine handled (2 mg), the levels of cocaine 
and benzoylecgonine present in the fingerprint samples were higher than the proposed 
threshold levels. Therefore, all samples remained positive for cocaine (12/12 samples) and 
benzoylecgonine (12/12 samples), independent of the threshold level proposed. This means 
that a threshold level cannot be successfully applied to natural fingerprints collected in order 
to distinguish drug administration from drug contact. In contrast, heroin and 6-
acetylmorphine were not prevalent in samples from a background population of non-drug 
users therefore threshold levels were not required to differentiate non-drug users from drug 
users. However, if this same criterion is applied here, all fingerprint samples would return a 
positive test after handling the parent drug. Depending on the application of the fingerprint 
test, demonstrating whether someone has taken a substance or handled a substance, this 
could be significant already. 
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4.2.3 Effect of wiping hands: drug contact and drug administration 
In scenario 2, fingerprint samples were collected after dermal contact with 2 mg of parent 
drug (cocaine or heroin) and subsequently wiping hands with alcohol free wipes. The use of 
a hand wiping procedure was evaluated to determine whether external contamination from 
handling the parent drug could be removed.  
4.2.3.1 Cocaine 
Fingerprints collected after dermal contact with cocaine and wiping hands with alcohol free 
wipes showed that cocaine (12/12 samples) and benzoylecgonine (12/12 samples) were still 
present in all fingerprint samples for the three participants, after the hand cleaning 
procedure. The use of a hand cleaning procedure did lower the level (ratio A/IS) of analytes 
in fingerprints compared to samples collected directly after dermal contact with 2 mg of 
cocaine. Figure 4.10 shows the distribution in the level of cocaine and benzoylecgonine for 
cocaine users and non-drug users (after dermal contact), after wiping hands with alcohol free 
wipes. Overall, the levels of cocaine and benzoylecgonine present in non-drug users from 
dermal contact were significantly higher compared to levels present after cocaine use, even 
after the hand cleaning procedure (U = 269, p < 0.001 for cocaine and U = 292, p < 0.001 
for benzoylecgonine) (Appendix E. 13). The median cocaine level (ratio A/IS) present in 
fingerprints from non-drug users was 2.516 compared to 0.512 for cocaine users. 
 
Figure 4.10: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine in fingerprints 
collected after wiping hands with alcohol free wipes from non-drug users 
after dermal contact with 2 mg of cocaine (scenario 2) and cocaine users. 
Dots represent outliers. 
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For benzoylecgonine the median level (ratio A/IS) was 0.101 after dermal contact and 0.023 
for cocaine users. The results show that the presence of cocaine and benzoylecgonine after 
dermal contact with the parent drug cannot be completely removed from the hands by using 
alcohol free wipes. A more thorough hand cleaning procedure needs to be implemented to 
help exclude external contamination as a possible source for a positive fingerprint test. 
Comparison of the relationship between cocaine and benzoylecgonine in fingerprint samples 
collected after wiping hands with alcohol free wipes from cocaine users and non-drug users 
(after dermal contact with 2 mg of cocaine) is shown in Figure 4.11. Although a significant 
difference was observed between the level (ratio A/IS) of cocaine and benzoylecgonine 
between the two groups, no significant difference (at p = 0.05) is observed for the cocaine-
to-benzoylecgonine ratio (U = 99, p = 0.102) (Appendix E. 14). This suggests that it is not 
possible to differentiate drug contact from drug administration by evaluating the cocaine-to-
benzoylecgonine ratio. 
 
Figure 4.11: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio cocaine-
to-benzoylecgonine in fingerprints collected after wiping hands with alcohol 
free wipes from non-drug users after dermal contact with 2 mg of cocaine 
(scenario 2) and cocaine users.  
4.2.3.2 Heroin 
Fingerprints collected from non-drug users after dermal contact with heroin and 
subsequently wiping hands with alcohol free wipes still resulted in the presence of heroin 
and 6-acetylmorphine in all samples (12/12 for both analytes). Compared to the levels of 
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heroin and 6-acetylmorphine observed in scenario 1, the hand cleaning procedure has 
removed some external contamination on the hands. The distribution of heroin and 6-
acetylmorphine level in fingerprints collected after wiping hands with alcohol free wipes 
from non-drug users (after dermal contact) and heroin users is shown in Figure 4.12. No 
significant difference (at p = 0.05) is observed in the level (ratio A/IS) of heroin in 
fingerprints from non-drug users compared to heroin users (U = 88, p = 0224) (Appendix E. 
13). The median heroin level was 0.592 for drug users compared to 0.360 for non-drug users. 
In contrast, a significant difference (U = 212, p < 0.001) is observed in the level of 6-
acetylmorphine present in fingerprints between the two groups (Appendix E. 13). The 
median 6-acetylmorphine level (ratio A/IS) in non-drug users was 0.137 compared to 0.028 
for heroin users.  
 
Figure 4.12: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine in fingerprints 
collected after wiping hands with alcohol free wipes from non-drug users 
after dermal contact with 2 mg of heroin (scenario 2) and cocaine users. Dots 
represent outliers. 
Although all fingerprints samples were positive, these results demonstrate that the presence 
of these analytes does not necessarily indicate drug administration. Comparison of the 
distribution of the heroin-to-6-acetylmorphine ratio present in fingerprints after drug contact 
and drug administration, and subsequently wiping hands is shown in Figure 4.13. The 
relationship between heroin and 6-acetylmorphine shows that there is a significant 
difference (U = 222, p < 0.001) in the ratio of heroin-to-6-acetylmorphine between the two 
groups (Appendix E. 14). The median heroin-to-6-acetylmorphine ratio was 2.056 for non-
drug users (from dermal contact) and 0.582 for heroin users. Overall, the results suggest that 
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there is a difference in the relationship between heroin and 6-acetylmorphine from drug 
contact and drug administration. However, based on individual participant levels, 
differentiation between the two groups would not be possible as there is some overlap in the 
levels observed. 
 
Figure 4.13: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio heroin-
to-6-acetylmorphine in fingerprints collected after wiping hands with alcohol 
free wipes from non-drug users after dermal contact with 2 mg of heroin 
(scenario 2) and heroin users. 
4.2.4 Effect of washing hands: drug contact and drug administration 
In scenario 3, a handwashing procedure was implemented after dermal contact with the 
parent drug. This was to explore whether the use of a handwashing procedure could remove 
cocaine and heroin present on the hands after handling 2 mg of the parent drug. 
4.2.4.1 Cocaine 
Fingerprints collected after washing hands with soap and water from non-drug users after 
dermal contact with 2 mg of cocaine still resulted in the presence of cocaine (12/12 samples) 
and benzoylecgonine (12/12 samples). Comparison of the distribution of cocaine and 
benzoylecgonine in fingerprints collected after handwashing from cocaine users and non-
drug users (after dermal contact with the parent drug) is shown in Figure 4.14. No significant 
difference is observed in the level (ratio A/IS) of cocaine (U = 305, p = 0.158) present in 
fingerprints from non-drug users and cocaine users (Appendix E. 15). In contrast, a 
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significant difference is observed for benzoylecgonine (U = 393, p < 0.001) (Appendix E. 
15).  
 
Figure 4.14: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine in fingerprints 
collected after washing hands with soap and water from non-drug users after 
dermal contact with 2 mg of cocaine (scenario 3) and cocaine users. Dots 
represent outliers. 
The median cocaine level was 0.292 for drug users compared to 0.431 for non-drug users 
after handling 2 mg of cocaine. For benzoylecgonine the median level was 0.009 for drug 
users compared to 0.101 for non-drug users. Overall, this suggests that there is a difference 
between the two groups. However, when evaluating individual participant levels, 
differentiation between drug contact and administration is not possible. 
The distribution of the cocaine-to-benzoylecgonine ratio between non-drug users (after 
dermal contact) and cocaine users is shown in Figure 4.15. Although a significant difference 
is observed in the median levels (ratio A/IS) of cocaine and benzoylecgonine in fingerprints 
between non-drug users (after dermal contact) and cocaine users, individual levels could not 
be used to differentiate drug contact and drug administration. Additionally, comparison of 
the cocaine-to-benzoylecgonine ratio shows a significant difference is observed for 
fingerprints collected after handwashing between drug administration and drug contact (U 
= 172, p = 0.438) (Appendix E. 16). The median cocaine-to-benzoylecgonine ratio was 
32.834 for cocaine users and 24.318 for non-drug users after dermal contact with the parent 
drug. This suggests that the presence of cocaine and benzoylecgonine in fingerprints is not 
solely indicative of cocaine administration and the relationship between the parent drug and 
metabolite cannot differentiate the two. 
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Figure 4.15: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio cocaine-
to-benzoylecgonine in fingerprints collected after washing hands with soap 
and water from non-drug users after dermal contact with 2 mg of cocaine 
(scenario 3) and cocaine users. 
4.2.4.2 Heroin 
Fingerprints collected after washing hands with soap and water from non-drug users (after 
dermal contact with the parent drug) showed that all samples (12/12) were positive for both 
heroin and 6-acetylmorphine. The handwashing procedure was not able to remove the 
external contamination present on the hands from handling the parent drug. Comparison of 
the level (ratio A/IS) of heroin and 6-acetylmorphine in samples from non-drug users and 
heroin users after washing hands is shown in Figure 4.16. No significant difference (at p = 
0.05) is observed in the levels (ratio A/IS) of heroin (U = 267, p = 0.115) and 6-
acetylmorpine (U = 155, p = 0.180) between the two groups (Appendix E. 15). The median 
heroin level was 0.011 for heroin users compared to 0.028 for non-drug users after dermal 
contact with heroin. This suggests that similar levels of heroin and 6-acetylmorphine can be 
present (after a handwashing procedure) from drug administration and drug contact. 
Although the level of analyte present (after handwashing) from drug contact and drug 
administration was not significantly different between non-drug users (after dermal contact) 
and heroin users, a difference is observed for heroin-to-6-acetylmorphine ratio between the 
two groups. 
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Figure 4.16: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine in fingerprints 
collected after washing hands with soap and water from non-drug users after 
dermal contact with 2 mg of cocaine (scenario 3) and heroin users. Dots 
represent outliers. 
Figure 4.17 shows the distribution of the heroin-to-6-acetylmorphine ratio after washing 
hands for non-drug users (after dermal contact) and heroin users. The heroin-to-6-
acetylmorphine ratio is significantly higher (U = 329, p < 0.001) for non-drug users (after 
dermal contact) compared to heroin users (Appendix E. 16). The median heroin-to-6-
acetylmorphine ratio was 1.317 for heroin users after handwashing compared to 2.581 for 
non-drug users.  
 
Figure 4.17: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio heroin-
to-6-acetylmorphine in fingerprints collected after washing hands with soap 
and water from non-drug users after dermal contact with 2 mg of cocaine 
(scenario 3) and heroin users. 
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Based on individual participant levels, overlap is observed between the low heroin-to-6-
acetylmorphine ratio for non-drug users and high heroin-to-6-acetylmorphine ratio for 
heroin users. This shows that it is not possible to differentiate the two groups based on the 
relationship between the parent drug and metabolite. 
4.2.5 Secondary transfer of drugs 
The possible transfer of drugs between a participant who has handled cocaine and a non-
drug user was evaluated, similar to the secondary transfer experiment carried out in Chapter 
3, section 3.2.9. Fingerprint samples (n = 4) were collected from 2 participants (S4P1 and 
S4P2) after shaking hands with an individual who touched 2 mg of cocaine. An additional 
set of fingerprint samples were collected for these two participants after washing hands with 
soap and water (S4P1-1 and S4P2-2) to try and remove the possible presence of cocaine 
after shaking hands.  
4.2.5.1 Cocaine 
The results show that it is possible to transfer cocaine and benzoylecgonine through shaking 
hands with an individual who has handled 2 mg of the parent drug. Comparison in the level 
of cocaine and benzoylecgonine present in fingerprints after secondary transfer for non-drug 
users and cocaine users is shown in Figure 4.18. A significant difference is observed in the 
distribution of the level (ratio A/IS) of cocaine (c2 = 21.24, p < 0.001) and benzoylecgonine 
(c2 = 18.87, p < 0.001) between the data sets (Appendix E. 17).  
 
Figure 4.18: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for cocaine and benzoylecgonine in fingerprints 
collected after handshaking and handwashing for non-drug users and cocaine 
users. Dots represent outliers. 
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However, based on individual data for each participant, it is difficult to differentiate 
secondary transfer (after handshaking) and drug administration. The median cocaine level 
(ratio A/IS) was 0.761 after handshaking and 0.030 after handwashing for non-drug users, 
compared to 0.900 for cocaine users.  
Comparison of the distribution of the cocaine-to-benzoylecgonine ratio in fingerprint 
samples from non-drug users (after shaking hands with a participant who handled 2 mg of 
cocaine and after washing hands) and cocaine users is shown in Figure 4.19. A significant 
difference is observed in the level (cocaine-to-benzoylecgonine ratio) present from 
secondary transfer compared to cocaine use (c2 = 29.97, p < 0.001) (Appendix E. 18). The 
median cocaine-to-benzoylecgonine ratio present from secondary transfer was 13.403 after 
shaking hands and 4.495 after handwashing. In contrast, for cocaine users the cocaine-to-
benzoylecgonine ratio was 31.804. This suggests that there is an overall difference between 
the groups, however based on individual levels no differentiation is possible. 
 
Figure 4.19: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio cocaine-
to-benzoylecgonine in fingerprints collected after handshaking and 
handwashing for non-drug users and cocaine users. Dots represent outliers. 
4.2.5.2 Heroin 
Similar to the results obtained for cocaine, heroin and 6-acetylmorphine were transferred 
through shaking hands with a participant who handled 2 mg of heroin. However, after 
washing hands with soap and water no heroin and 6-acetylmorphine were present. Compared 
to the level (ratio A/IS) of heroin and 6-acetylmorphine present in fingerprints from heroin 
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users, a significant difference is observed in the distribution of the level (ratio A/IS) of heroin 
(c2 = 8.05, p = 0.018) present from secondary transfer (see Figure 4.20) (Appendix E. 17). 
The median heroin level (ratio A/IS) present in fingerprints was 0.020 for non-drug users 
after shaking hands compared to 0.067 for heroin users. No significant difference (at p = 
0.05) was observed for 6-acetylmorphine (c2 = 3.81, p = 0.148) between the two (Appendix 
E. 17). The median 6-acetylmorphine level (ratio A/IS) present in fingerprints from non-
drug users (after shaking hands) was 0.015 compared to 0.030 for heroin users. Although a 
significant difference is observed in the distribution of the analytes between the groups, no 
differentiation is possible based on individual data as there is overlap in the levels observed. 
 
Figure 4.20: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio analyte 
(A) to internal standard (IS) for heroin and 6-acetylmorphine in fingerprints 
collected after handshaking and handwashing for non-drug users and heroin 
users. Dots represent outliers. 
Comparison of the heroin-to-6-acetylmorphine ratio between fingerprints collected after 
secondary transfer (from non-drug users) and heroin use (from heroin users) is shown in 
Figure 4.21. The results show that no significant difference is observed (at p = 0.05) between 
the heroin-to-6-acetylmorphine ratio (c2 = 3.35, p = 0.188) observed after drug 
administration and secondary transfer of drugs (Appendix E. 18). The median heroin-to-6-
acetylmorphine ratio present after secondary transfer was 1.905 compared to 2.655 for 
heroin use. This suggests that a fingerprint test is not possible to differentiate the two groups 
based on the heroin-to-6-acetylmorphine ratio. 
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Figure 4.21: Box and whisker plots (median, 25 – 75th percentiles, whiskers 5 – 95th 
percentiles) showing the distribution of the average peak area ratio heroin-
to-6-acetylmorphine in fingerprints collected after handshaking and 
handwashing for non-drug users and heroin users. Dots represent outliers. 
4.3 Summary 
This research evaluated the presence of cocaine and heroin in fingerprint samples from 
dermal contact with the parent drug (2 mg). The results showed that cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine can be present in fingerprints from non-drug 
users after dermal contact with the drug, even after a hand cleaning procedure (washing 
hands and wiping hands with alcohol free wipes) (section 4.2.1). The presence of 
benzoylecgonine and 6-acetylmorphine in fingerprint samples was attributed to the cocaine 
and heroin used, which was confirmed by GC-MS analysis carried out by FSI. The use of 
both hand cleaning procedures (scenario 2: wiping hands with alcohol free wipes and 
scenario 3: washing hands with soap and water) reduced the level of cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine in fingerprint samples (section 4.2.1). The 
use of a handwashing procedure was more effective in the removal of contact residue 
compared to wiping hands with alcohol free wipes. However, all fingerprints remained 
positive. Secondary transfer of drugs (through shaking hands) is another possible source for 
the presence of these analytes in fingerprints (section 4.2.5). In contrast to cocaine and 
benzoylecgonine, secondary transfer of heroin and 6-acetylmorphine can be removed from 
the fingers by washing hands with soap and water. Overall, this chapter highlights that the 
presence of these analytes in fingerprints does not necessarily indicate drug administration, 
as these can also be present from handling the parent drug even after hand cleaning 
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procedures. Although some differences were observed in the level of analytes present from 
drug contact and drug administration, based on individual results no differentiation is 
possible (sections 4.2.2, 4.2.3 and 4.2.4).  In light of these findings, a fingerprint test would 
not be able to differentiate drug contact from drug administration. 
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Chapter 5 Monitoring Compliance with Tuberculosis 
Medication from a Fingerprint 
5.0 Introduction 
One of the objectives of this research was to evaluate the use of fingerprints to monitor 
compliance with medication to treat tuberculosis (in particular the first line drug, isoniazid). 
The detection of drugs of abuse has been explored in Chapter 3 for cocaine, heroin and their 
respective metabolites. The results obtained highlighted the challenges associated with the 
attributing presence of these compounds from administration (Chapter 3) or handling of the 
parent drug (Chapter 4). In this chapter, the use of fingerprint samples for a clinical 
application is investigated. Tuberculosis is one of the top ten causes of death globally and 
treatment of the infectious disease is confounded by the formation of drug resistant bacteria, 
which can appear if patients do not adhere to their treatment (World Health Organisation, 
2017).  
Various strategies have been employed to increase adherence to treatment and improve 
treatment success rates. Current methods to monitor adherence include regular engagement 
with medical and nursing teams, tablet counts and assessment of clinical improvement 
(Nackers et al., 2012; Osterberg & Blaschke, 2005). A urine dipstick test (based on a 
colorimetric test) can also be used on the spot if there are concerns or doubts (Guerra et al., 
2010; Hanifa et al., 2007). However, each of these approaches have their limitations: tablet 
count is ineffective as it is easily altered by the patient (Nackers et al., 2012; Osterberg & 
Blaschke, 2005) engagement with the patient through direct observation therapy (DOTS) is 
expensive to administer (Steffen et al., 2010; Osterberg & Blaschke, 2005) and a urine 
dipstick test requires clinic access.  A fingerprint may offer a simple route to confirming 
adherence to treatment and this is explored in this chapter.  
This chapter investigates the detection of tuberculosis medication (isoniazid and its 
respective metabolite acetylisoniazid) in fingerprint samples from individuals receiving 
treatment (section 5.2.5) and individuals who have completed treatment (section 5.2.6). 
Information on the chemistry and metabolism of isoniazid and acetylisoniazid is described 
in Chapter 1, section 1.3.3. The significance of the detection of these analytes of interest in 
fingerprint samples was determined by comparison with a negative control group (section 
5.2.7). Different sampling strategies were evaluated, including the collection of natural 
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fingerprints and after washing hands with soap and water (section 5.2.8). The use of a 
fingerprint sample should be robust enough to detect the analytes of interest even after a 
hand cleaning procedure is used prior to sample collection, otherwise a high false negative 
rate would be observed unless patients were instructed to avoid handwashing. Additionally, 
the elimination profile of isoniazid and acetylisoniazid in fingerprint samples was explored 
by collecting samples from a patient who was coming off treatment (section 5.2.9). This was 
to investigate the detection window of the analytes of interest in fingerprint samples after 
their treatment was completed. Some individuals will cease to take their medication once 
they start to feel better. Therefore, it is particularly important to demonstrate whether 
fingerprints can be used to determine if an individual is not compliant with their treatment 
to improve patient outcome.  
The following section details the specific participants recruited for the purpose of this study 
(section 5.1.1) and the sample collection and preparation methods used for fingerprint 
samples collected from participants. All samples were analysed on a Thermo Ultimate 3000 
HPLC coupled to an Orbitrap mass spectrometer. The instrumentation and optimisation for 
isoniazid and acetylisoniazid are described in section 5.1.4. The fingerprint extraction 
method developed for the analytes of interest is described in section 5.2.1. The performance 
characteristics of the developed LC-MS method are evaluated in section 5.2.4.  
The present chapter investigates whether a fingerprint can be used to detect tuberculosis 
medication to monitor treatment adherence. In addition, the detection window of isoniazid 
and acetylisoniazid in fingerprint is explored, to demonstrate whether a fingerprint test is 
suitable to determine if a patient is no longer compliant with their treatment.  
5.1 Experimental 
5.1.1 Study populations 
Study participants were recruited to evaluate whether isoniazid and acetylisoniazid could be 
detected in fingerprint samples from individuals prescribed tuberculosis medication. This 
was to explore the possibility of using fingerprint samples to monitor compliance with 
tuberculosis treatment. In collaboration with Frimley Health NHS Foundation Trust, 
participants who (i) were on treatment (n = 27) and (ii) completed treatment (n = 6) were 
recruited from the chest clinic at King Edward VII Hospital, to show if a distinction could 
be made between the two groups. Additionally, as part of the study, a participant who was 
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completing their treatment was recruited to monitor the elimination profile of isoniazid and 
acetylisoniazid over a number of days (T = 0, T = 2 and T = 4 days). It is important to test 
the detection window of these analytes in fingerprint samples to show if an individual is not 
complying with the treatment, a negative test result will be obtained. Furthermore, 
fingerprint samples were collected from a negative control group (n = 10) to show whether 
these specific analytes were detected in individuals not taking medication and that there are 
no interfering compounds present with the same mass and retention time.  
5.1.2 Fingerprints 
Fingerprint samples from participants were collected on chromatography paper 
(Whatman™ 1-Chr) cut into 2 x 2 cm. Fingerprint collection kits were prepared by taping 
the paper substrate onto a microscope glass slide labelled with a unique participant identifier, 
e.g. TB-2017-FP001 for participants from the chest clinic who were on treatment or 
completed treatment. For participants coming off treatment to monitor the elimination 
profile, samples were labelled as TB-2017-E001. Whereas, samples from the negative 
control group were labelled as TB-2017-N001.  For each participant, fingerprint samples 
were collected from all fingers and thumbs of the right hand as natural fingerprints and after 
washing hands with soap and water. This was to evaluate whether the analytes of interest 
could still be detected in fingerprint samples after a handwashing procedure.  
All fingerprint samples were collected as described in the fingerprint collection procedure 
outlined in Chapter 3, section 3.1.2. Natural fingerprints were collected from tuberculosis 
patients upon arrival at the chest clinic without any preparation of the hands. Afterwards the 
participant was asked to wash their hands with soap and water. The participant then put on 
nitrile gloves for 10 min to induce perspiration on the fingers and thumbs prior to fingerprint 
deposition. Each sample collected was labelled with a unique participant identifier; the 
finger or thumb that was collected and the condition under which the sample was collected 
(e.g. natural or soap). The collected fingerprint sample was then placed into a microscope 
glass slide storage box for transport to the University of Surrey, UK. 
Fingerprint samples were collected from n = 10 volunteers (as negative controls) at the 
University of Surrey. Fingerprint samples collected from the negative control group were 
collected as natural fingerprints and after washing hands with soap and water to determine 
whether the analytes of interest or any interfering compounds would be present. Fingerprint 
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samples (n = 5) were collected from the negative control group as described in Chapter 3, 
section 3.1.2. 
A favourable ethical opinion was obtained from the NHS Research Ethics Service (NRES-
REC) and the University of Surrey Ethics Committee for the collection of fingerprint 
samples from individuals receiving treatment for tuberculosis at Wexham Park Hospital 
(Frimley Health NHS Foundation Trust) who volunteered taking part in this study. 
Additionally, fingerprint samples were collected from a negative control group (background 
population) at the University of Surrey (NRES-REC reference 16/LO/1663). Participants 
were given information sheets and informed consent forms in order to understand their 
involvement in the study. Once informed consent was obtained from the participants, 
samples were collected according to the standard operating procedures outlined in Appendix 
B. 2 (fingerprints). 
5.1.3 Chemicals and reagents 
Isoniazid, acetylisoniazid and isoniazid-d4 (used as internal standard) were purchased from 
Toronto Research Chemicals (North York, Canada). Optima grade LC-MS solvents of 
methanol, acetonitrile and water were used to prepare solutions and solvent mixtures (Fisher 
Scientific, Leicestershire, UK). Formic acid was added to the mobile phase solvents at 0.1% 
(v/v) (Fischer Scientific, Leicestershire, UK). Dichloromethane, chloroform and ethyl 
acetate were used to prepare solvent extraction mixtures and were analytical or reagent grade 
(Sigma Aldrich, Dorset, UK). A solution of artificial eccrine perspiration was used to 
simulate a fingerprint matrix in the experimental design of fingerprint experiments 
(Pickering Laboratories, Inc., Obertaufkirchen, Germany). 
5.1.4 Instrumentation and conditions 
Analysis of samples was performed using the Dionex Ultimate 3000 HPLC coupled to a Q-
Exactive Plus mass spectrometer as detailed in Chapter 2, section 2.2.2. The electrospray 
source parameters (polarity, probe position, auxiliary gas flow rate and spray voltage) were 
optimised for isoniazid and acetylisoniazid using an infusion of a 100 ng/ml standard of the 
analytes of interest in 50:50 (v/v) acetonitrile (ACN) in water (H2O) + 0.1% formic acid. 
The optimised mass spectrometer parameters for the analysis of isoniazid and 
acetylisoniazid are outlined in Table 5.1.  
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Table 5.1: Operating conditions of the LC-MS for the analysis of isoniazid and 
acetylisoniazid in fingerprint samples. 
Parameter Operating condition 
Source parameters 
Spray voltage 4 kV 
Capillary temperature 320 ºC 
S-lens RF level 50 
Sheath gas flow rate 35 
Aux gas flow rate 8 
Scan parameters 
Scan type Full MS 
Scan range m/z 120 - 1000 
Resolution 70 000 at m/z 200 
Polarity Positive 
AGC target 106 
Maximum inject time 200 
The previously developed chromatography method for the analysis of cocaine, heroin and 
their respective metabolites (benzoylecgonine and 6-acetylmorphine) (section 2.2.2) was 
applied to isoniazid and acetylisoniazid. A Kinetex C18 column (100 x 2.1 mm, 5 µm) was 
used for the LC-MS analysis of all samples. Methanol and acetonitrile were evaluated as 
organic mobile phase solvents for the chromatographic separation of the analytes of interest 
in combination with water as the aqueous solvent. Interestingly, broader peak shapes were 
observed when using the initial mobile phase composition (5% (v/v) ACN in H2O + 0.1% 
formic acid) as the sample solution. However, sharper peaks were obtained using 50% (v/v) 
ACN in H2O + 0.1% formic acid. As the peaks eluted early in the chromatogram, the higher 
organic content in the mobile phase composition minimised peak broadening, resulting in 
sharper peaks. Therefore, all samples were reconstituted in that solvent mixture containing 
50 ng/ml isoniazid-d4 as the internal standard.  
Different gradients and run times were evaluated for the separation of isoniazid and 
acetylisoniazid, however none of the methods explored achieved baseline separation. An 
example of an overlaid extracted ion chromatogram for isoniazid and acetylisoniazid using 
the developed method is shown in Figure 5.1. Although baseline separation was not achieved 
for isoniazid and acetylisoniazid, the use of a high resolution mass spectrometer still allowed 
for the identification of these analytes based on their m/z ratio. The m/z ratio for isoniazid 
(138.0661), acetylisoniazid (180.0768) and isoniazid-d4 were within 2 ppm at 70,000 mass 
resolution.  
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Figure 5.1: An example of an overlaid extracted ion chromatogram of a standard (at 50 
ng/ml containing isoniazid and acetylisoniazid) in 50% (v/v) ACN in H2O 
analysed using the LC-MS method developed.   
5.1.5 Extraction method  
A range of solvents were evaluated for the extraction of isoniazid and acetylisoniazid from 
paper (Whatman™ grade-1 chromatography paper 2 x 2 cm square). The fingerprint 
extraction method was adopted from the previously developed method for the analysis of 
cocaine, heroin and their respective metabolites (section 2.3.4). The use of methanol, 
acetonitrile, dichloromethane, chloroform, ethyl acetate and 10% (v/v) methanol in 
dichloromethane and 10% (v/v) methanol in chloroform as extraction solvents were 
evaluated to determine which solvent would provide the best extraction. 
Ten microlitres of the analyte standard in methanol (at 500 ng/ml) was spiked onto 
Whatman™ grade-1 chromatography paper (2 x 2 cm square) and left to dry overnight to 
produce 5 ng of analyte residue on surface. The sample was placed in a 2 ml Eppendorf 
microcentrifuge tube with 1.5 ml extraction solvent. The sample was centrifuged for 5 min 
at 10000 x g relative centrifugal force (rcf) and the paper was subsequently removed and 
discarded. The sample extract was evaporated to dryness under a stream of nitrogen at room 
temperature (20 ºC), reconstituted in 100 µl mobile phase solution containing 50 ng/ml 
internal standard solution and vortexed-mixed for 30 sec prior to LC-MS analysis. The 
extracted sample was compared against an analyte standard (at 50 ng/ml) in 50% (v/v) ACN 
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in H2O with 0.1% formic acid and 50 ng/ml internal standard solution at the same 
concentration as the final sample extract. 
5.1.6 Matrix effects 
5.1.6.1 Participant selection and sampling 
The influence of the matrix on the extraction efficiency of isoniazid and acetylisoniazid was 
evaluated for methanol, artificial eccrine perspiration and fingerprints. Analyte standards 
were prepared at three concentration levels, 100, 500 and 1000 ng/ml, with five replicate 
samples per concentration level. Ten microlitres of analyte standard was spiked onto paper 
to produce 1, 5 and 10 ng of analyte residue on surface and extracted using the method 
described in section 5.2.1. A favourable ethical approval was obtained from the University 
of Surrey Ethics Committee to collect samples from individuals at the University of Surrey 
who volunteered to participate. Fingerprint samples were collected from n = 5 participants 
without any preparation of the hands (natural fingerprints) and after washing hands with 
soap and water, prior to wearing nitrile gloves for 10 min to aid secretion of perspiration 
from the fingertips. Four fingerprints were collected per participant (right thumb, right 
index, left thumb and left index finger) to prepare the spiked samples and a blank. A 
minimum of five participants is recommended because this allows to incorporate variations 
in gender and other factors into the experiment (Sears et al., 2012). However, due to ethical 
considerations this information is not provided. Five replicate samples were prepared for 
each matrix at each level. For fingerprints, the analyte standard (10 µl of 100, 500 or 1000 
ng/ml) in methanol was pipetted onto the fingerprint samples to produce 1, 5, and 10 ng of 
analyte residue on the sample surface. Samples were extracted by placing the paper substrate 
in a microcentrifuge tube (2 ml) with 1.5 ml of extraction solution (10% dichloromethane in 
methanol) and centrifuging for 5 min at 10000 x g rcf. The paper was discarded and the 
sample extract was evaporated to dryness under a stream of nitrogen at room temperature 
(20 °C). The subsequent sample residue was reconstituted in 100 µl mobile phase solution 
(50% acetonitrile in water with 0.1% (v/v) formic acid containing 50 ng/ml isoniazid-d4 as 
internal standard) and vortex-mixed again for 30 sec prior to LC-MS analysis. 
5.1.6.2 Ionisation suppression and enhancement 
The presence of matrix effects in the form of ionisation suppression/enhancement was 
investigated to determine whether the sample matrix contained interferences that co-eluted 
with the analytes of interest. These effects can attribute to a change in instrument response 
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of the analyte compared to a standard solution of the same concentration. The presence of 
ion suppression/enhancement was evaluated using the post-extraction addition approach as 
used in Chapter 2 section 2.2.5.2 for cocaine, heroin and their respective metabolites 
(Scientific Working Group for Forensic Toxicology, 2013). Two matrices were assessed, 
including methanol (blank solvent) and fingerprint samples collected without any 
preparation of the hands (natural) and after washing hands with soap and water. Two sets of 
samples were prepared in order to compare the effects of the matrix on the analyte signal. 
Set one consisted of a standard solution (50:50 (v/v) acetonitrile in water + 0.1% formic 
acid) of isoniazid and acetylisoniazid at 20 ng/ml and 80 ng/ml, both containing 50 ng/ml 
internal standard (isoniazid-d4). Set two consisted of the different blank matrices (methanol, 
fingerprint samples natural and after handwashing) spiked with a standard solution of 
isoniazid and acetylisoniazid post extraction at 20 ng/ml and 80 ng/ml. The effect of the 
sample matrix on ionisation suppression/enhancement was evaluated by comparing the 
average peak area of samples from set two with that of the standard solution (set one) of the 
same concentration.  
Ten microlitres of blank solvent (methanol) or matrix (fingerprint) was added to the paper 
substrate (Whatman 1-Chr grade paper 2 x 2 cm) and left to dry overnight. The right thumb 
(blanks) and index finger (spiked) were collected from n = 5 individuals, natural and after 
handwashing to assess the potential matrix effects between participants. Each sample was 
extracted using the extraction method described in section 5.2.1. After the extraction was 
performed and the sample was evaporated to dryness, the samples were reconstituted with 
an analyte standard (at 20 ng/ml or 80 ng/ml) in 50:50 (v/v) acetonitrile in water with 0.1% 
formic acid containing 50 ng/ml isoniazid-d4 as the internal standard. Each sample was 
measured five times and the average peak area obtained was compared to that of set one. 
5.1.7 Method recovery 
The recovery of the developed extraction method was evaluated using analyte standards 
(containing isoniazid and acetylisoniazid) in methanol at 100, 500 and 1000 ng/ml, to 
produce spiked fingerprints (using n = 5 participants, with 3 fingerprints collected per 
participant) at 1, 5, and 10 ng of analyte residue on surface. Participant selection and 
sampling is discussed in section 5.1.6.1. Samples were extracted by placing the paper 
substrate in a microcentrifuge tube (2 ml) with 1.5 ml of extraction solution (10% 
dichloromethane in methanol) and centrifuging for 5 min at 10000 x g rcf. The paper was 
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discarded and the sample extract was evaporated to dryness under a stream of nitrogen at 
room temperature (20 °C). The subsequent sample residue was reconstituted in 100 µl 
mobile phase solution (50% acetonitrile in water with 0.1% (v/v) formic acid containing 50 
ng/ml internal standard solution) and vortex-mixed again for 30 sec prior to LC-MS analysis. 
The average percentage recovery for isoniazid and acetylisoniazid at each level (1, 5 and 10 
ng) in fingerprints was calculated based on the original spiked concentration.  
5.2 Results and Discussion 
5.2.1 Extraction method 
The extraction efficiency (calculated by % recovery) for isoniazid and acetylisoniazid using 
methanol, acetonitrile, dichloromethane, chloroform, ethyl acetate and 10% (v/v) methanol 
in dichloromethane and 10% (v/v) methanol in chloroform as extraction solvents is shown 
in Figure 5.2.  
 
Figure 5.2: Average percentage recovery (± standard deviation n = 5 measurements) for 
isoniazid and acetylisoniazid (n = 1 sample) extracted from paper (at 5 ng) 
with methanol, acetonitrile, dichloromethane (DCM), ethyl acetate, 
chloroform (CHCl3), 10% (v/v) methanol (MeOH) in chloroform, 10% (v/v) 
dichloromethane (DCM) in methanol (MeOH).  
A higher percentage recovery for isoniazid and acetylisoniazid is observed using a polar 
protic solvent, such as, methanol compared to the other solvents evaluated. This is a result 
of the hydrogen bonding between methanol and the analytes of interest which increases the 
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affinity for the extraction from the paper substrate. A relatively high percentage recovery 
(127 – 140%) was observed for acetylisoniazid using (i) 10% (v/v) DCM in MeOH or (ii) 
MeOH. For isoniazid, the corresponding recoveries were 78 and 75%, respectively. The use 
of 10% (v/v) DCM in MeOH was chosen as the solvent for the extraction of isoniazid and 
acetylisoniazid from paper substrates as this provided the best % recovery.   
5.2.2 Matrix effects 
The effect of the matrix on the extraction of isoniazid and acetylisoniazid at each 
concentration level (1, 5 and 10 ng) is shown in Figure 5.3. For isoniazid, the methanol 
standard produced matrix enhancement compared to fingerprint samples (natural and after 
washing hands) and artificial eccrine perspiration. However, these results were consistent 
for each concentration level. The results show that there are sample matrix effects observed 
for acetylisoniazid in the presence of artificial eccrine sweat, as a higher ratio A/IS was 
consistently observed at each concentration level. Due to the differences observed between 
the matrix effects for isoniazid and acetylisoniazid and the absence of a validated fingerprint 
standard, it was decided not to produce matrix-matched calibration curves. Additionally, due 
to differences observed for the analyte signal in the presence of a fingerprint sample 
compared to standard in methanol, results are reported as a ratio of analyte-to-internal 
standard (ratio A/IS) signal. 
 
Figure 5.3: Average peak area ratio analyte (A) to internal standard (IS) (± standard 
deviation, n = 5 measurements) for isoniazid and acetylisoniazid for spiked 
acetonitrile, artificial eccrine perspiration and fingerprints (natural and after 
washing hands with soap). 
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The fingerprint samples (natural or after washing hands with soap) from the five participants 
studied here show that the matrix effects observed between participants does not vary 
greatly. The variability (n = 5 participants) between samples for isoniazid was ≤9 and ≤7% 
for natural fingerprints and after handwashing, respectively. For acetylisoniazid, the 
corresponding variability was ≤13 and ≤14% for natural fingerprint samples and after 
handwashing, respectively (see Figure 5.3).  
5.2.2.1 Ionisation suppression/enhancement 
Figure 5.4 shows the effect of the blank solvent (methanol) extracted from paper on the 
signal of isoniazid, acetylisoniazid and isoniazid-d4 at 20 ng/ml (A1) and 80 ng/ml (B1) 
compared to a standard solution of the same concentration. The results show that the signal 
of all analytes were lower in the presence of extracted compounds from the paper compared 
to the reference standard of the same concentration for both concentration levels. This 
indicates that there are matrix effects observed from the paper substrate in the form of 
ionisation suppression. The variability (%RSD) in ionisation suppression for n = 5 samples 
at 20 ng/ml was 9% for isoniazid, 5% for isoniazid-d4, and 4% acetylisoniazid. In contrast, 
at 80 ng/ml, the variability was slightly higher for all analytes (13% for isoniazid and 
isoniazid-d4 and 10% for acetylisoniazid). 
 
Figure 5.4: Average peak area (n = 5 measurements) for isoniazid, acetylisoniazid and 
isoniazid-d4 for blank solvent (methanol) extracted and spiked with (A1) 20 
ng/ml and (B1) 80 ng/ml of standard solution containing 50 ng/ml isoniazid-
d4 as internal standard. 
The effect of ionisation suppression on the analytes of interest in the presence of natural 
fingerprints at both concentration levels (20 ng/ml and 80 ng/ml) was also evaluated as seen 
in Figure 5.5 for natural fingerprints and Figure 5.6 for fingerprints collected after washing 
hands.  
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Figure 5.5: Average peak area (n = 5 measurements) for isoniazid, acetylisoniazid and 
isoniazid-d4 in natural fingerprint samples extracted and spiked with (A2) 20 
ng/ml and (B2) 80 ng/ml of standard solution containing 50 ng/ml isoniazid-
d4 as internal standard. 
Compared to the reference standard, lower signals were observed for all analytes in the 
presence of a fingerprint (natural and after handwashing) at both concentration levels. 
Interestingly, the results show that the degree of ionisation suppression for the analytes of 
interest varies greatly between participants at both concentration levels. The variability 
(%RSD) observed between the response from isoniazid, isoniazid-d4 and acetylisoniazid for 
natural fingerprint samples at 20 ng/ml was 54, 53 and 37%, respectively. At the higher 
concentration level (80 ng/ml), the variability observed was 47, 49 and 27% for isoniazid, 
isoniazid-d4 and acetylisoniazid, respectively for n = 5 participants.  
Figure 5.6 shows the effect of ion suppression in fingerprints after washing hands with soap 
and water. The results show that the ionisation suppression effects are still observed. 
However, the variability in ionisation suppression effects between (n = 5) participants for 
isoniazid, isoniazid-d4 and acetylisoniazid at 20 and 80 ng/ml were lower compared to 
natural fingerprint samples. At 20 ng/ml the variability was 25% for isoniazid and isoniazid-
d4, and 17% for acetylisoniazid. In addition, at 80 ng/ml the variability observed in ionisation 
suppression for n = 5 participants was 27% for isoniazid and isoniazid-d4, and 20% for 
acetylisoniazid. The lower variability observed after handwashing could be a result of the 
removal of fingerprint constituents by using a hand cleaning procedure, which may result in 
a lower degree of matrix effects compared to natural fingerprints. An estimation of the 
degree of ionisation suppression for isoniazid, acetylisoniazid and isoniazid-d4 was 
calculated using Equation 2.1. The negative values in Table 5.2 and Table 5.3 indicate that 
ionisation suppression is observed for the analytes of interest in blank solvent (methanol) 
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and fingerprint samples (natural and after handwashing for n = 5 participants) extracted from 
paper at both concentration levels (20 and 80 ng/ml). 
 
Figure 5.6: Average peak area (n = 5 measurements) for isoniazid, acetylisoniazid and 
isoniazid-d4 in fingerprint samples collected after handwashing extracted and 
spiked with (A3) 20 ng/ml and (B3) 80 ng/ml of standard solution containing 
50 ng/ml isoniazid-d4 as internal standard. 
The degree of ionisation suppression observed for isoniazid and acetylisoniazid ranged from 
-31 to -47% in the presence of paper substrates and -32 to -93% in the presence of fingerprint 
samples. For the internal standard, the ionisation suppression effects observed for isoniazid 
and acetylisoniazid, ranged from -43 to -50% in the presence of paper and -46 to -92% in 
the presence of fingerprints. The results highlight that the ionisation suppression effects 
observed varies significantly between participants using both fingerprint collection methods.  
Table 5.2: Ionisation suppression or enhancement (percentage) for the analysis of 
isoniazid, acetylisoniazid and isoniazid-d4 at 20 ng/ml in methanol and 
fingerprint samples natural and after washing hands with soap and water 
(participants 1 – 5). 
Sample 
Ionisation suppression or enhancement (IS/IE) % 
Isoniazid Acetylisoniazid Isoniazid-d4 
Blank 
solvent 
(methanol) 
Sample 1 -44 -35 -46 
Sample 2 -41 -34 -43 
Sample 3 -33 -33 -44 
Sample 4 -42 -31 -44 
Sample 5 -47 -38 -50 
Fingerprint 
natural 
Participant 1 -93 -79 -92 
Participant 2 -58 -43 -59 
Participant 3 -75 -56 -76 
Participant 4 -46 -32 -46 
Participant 5 -58 -41 -59 
Fingerprint 
soap 
Participant 1 -63 -44 -64 
Participant 2 -62 -46 -63 
Participant 3 -73 -58 -74 
Participant 4 -45 -32 -47 
Participant 5 -56 -40 -57 
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Table 5.3: Ionisation suppression or enhancement (percentage) for the analysis of 
isoniazid, acetylisoniazid and isoniazid-d4 at 80 ng/ml in methanol and 
fingerprint samples natural and after washing hands with soap and water 
(participants 1 – 5). 
Sample 
Ionisation suppression or enhancement (IS/IE) % 
Isoniazid Acetylisoniazid Isoniazid-d4 
Blank 
solvent 
(methanol) 
Sample 1 -58 -51 -59 
Sample 2 -62 -54 -62 
Sample 3 -57 -49 -57 
Sample 4 -60 -52 -61 
Sample 5 -47 -41 -48 
Fingerprint 
natural 
Participant 1 -89 -72 -91 
Participant 2 -59 -43 -60 
Participant 3 -76 -51 -77 
Participant 4 -51 -36 -52 
Participant 5 -68 -49 -69 
Fingerprint 
soap 
Participant 1 -74 -61 -75 
Participant 2 -57 -41 -58 
Participant 3 -70 -53 -71 
Participant 4 -49 -33 -49 
Participant 5 -62 -45 -62 
There are different approaches to minimise or correct ionisation suppression effects, 
including modification of chromatography conditions, sample preparation or use of internal 
standards (Annesley, 2003). In this study, an internal standard (isoniazid-d4) was used to 
correct for the observed degree of ionisation suppression (see Figure 5.7). In order for the 
internal standard to correct for the ionisation suppression, the internal standard must co-elute 
with the analyte of interest. The internal standard and analyte will undergo the same 
ionisation suppression effects and using the ratio A/IS will “correct” for the degree of 
ionisation suppression. The use of the ratio A/IS for isoniazid and acetylisoniazid shows that 
the use of isoniazid-d4 corrects for the ionisation suppression effects observed in the 
presence of a blank paper substrate for both concentration levels (20 ng/ml and 80 ng/ml). 
An F-test was performed to determine whether there was a significant difference in the 
sample variance between two sample sets, blank paper and fingerprints (natural and after 
handwashing) compared to the reference standard. The results suggested that the two 
standard deviations (between a sample and the reference standard) were significantly 
different, with the exception of blank paper (methanol) for acetylisoniazid at both 20 and 80 
ng/ml, and blank paper (methanol) and fingerprints (soap) for isoniazid at 20 ng/ml. 
Therefore Eq. 2.8 was used to compare the two experimental means for data sets where the 
sample variances were significantly different and Eq. 2.6 for those that were not significantly 
different (at p = 0.05).  
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Figure 5.7: Average peak area ratio analyte (A) to internal (IS) standard (± standard 
deviation, n = 5 measurements) for isoniazid and acetylisoniazid for blank 
solvent (methanol) extracted and spiked with (C1) 20 ng/ml and (D1) 80 
ng/ml of standard solution containing 50 ng/ml isoniazid-d4 as internal 
standard. 
Compared to the reference standard of the same concentration, the ratio A/IS for the 
extracted samples (fingerprints natural and after handwashing, and blank paper with 
methanol) were still significantly different (at p = 0.05) at both concentration levels 
(Appendix E. 19 and E. 20). The only exception to this was for isoniazid samples at 20 ng/ml 
and acetylisoniazid methanol samples at 20 and 80 ng/ml, no significant difference was 
observed at p = 0.05. The use of the ratio A/IS reduced the variability (%RSD) between n = 
5 samples to 1% for isoniazid and acetylisoniazid at 20 ng/ml. At the higher concentration 
level (80 ng/ml), the use of the ratio A/IS reduced the variability for n = 5 samples to 2% for 
isoniazid and acetylisoniazid. This suggests a good level of precision between samples. A 
high level of variability in the degree of ionisation suppression was initially observed for 
isoniazid and acetylisoniazid in the presence of a fingerprint. However, using the ratio A/IS 
for isoniazid and acetylisoniazid corrected for the sample matrix effects observed at both 
concentration levels (Figure 5.8 and Figure 5.9). The variability in the level of isoniazid and 
acetylisoniazid observed (at 20 ng/ml) between fingerprint samples (natural) for n = 5 
participants was reduced to 10 and 32%, respectively. After washing hands with soap and 
water the variability was reduced to 1 and 9% for isoniazid and acetylisoniazid, respectively. 
This shows that the sample matrix effects are corrected for using an internal standard, 
particularly after handwashing. However, based on a t-test, there is a still a significant 
difference observed between the levels of isoniazid in the presence of a paper substrate (at 
both concentration levels) and fingerprints (natural at 80 ng/ml and after handwashing at 20 
and 80 ng/ml) compared to a standard of the same concentration (at p = 0.05, Appendix E. 
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19). For acetylisoniazid a significant difference is observed for all matrices (blank solvent 
on paper and fingerprint samples natural and after handwashing) at both concentration levels 
(at p = 0.05, Appendix E. 20). The results suggest that the level of acetylisoniazid in natural 
fingerprint samples are not comparable due to the large variability (in ratio A/IS) observed 
between participants in Figure 5.8 and Figure 5.9 for the same concentration due to sample 
matrix effects.  
 
Figure 5.8: Average peak area ratio analyte (A) to internal standard (IS) (± standard 
deviation, n = 5 measurements) for isoniazid and acetylisoniazid in natural 
fingerprint samples extracted and spiked with (C2) 20 ng/ml and (D2) 80 
ng/ml of standard solution containing 50 ng/ml isoniazid-d4 as internal 
standard. 
 
Figure 5.9: Average peak area ratio analyte (A) to internal standard (IS) (± standard 
deviation, n = 5 measurements) for isoniazid and acetylisoniazid in 
fingerprint samples collected after handwashing extracted and spiked with 
(C3) 20 ng/ml and (D3) 80 ng/ml of standard solution containing 50 ng/ml 
isoniazid-d4 as internal standard. 
The matrix effects observed for acetylisoniazid are not corrected to the same degree as 
isoniazid, as the chromatographic peak for the internal standard does not coincide with 
acetylisoniazid resulting in a difference in the observed degree of ionisation suppression. 
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However, the sample matrix effects for acetylisoniazid are corrected best using isoniazid-d4 
as the internal standard. 
5.2.3 Method recovery 
The recovery of isoniazid and acetylisoniazid using the developed extraction method was 
assessed at 1, 5 and 10 ng of analyte residue on surface in the presence of fingerprints (n = 
5 participants). The percentage recovery for isoniazid and acetylisoniazid at each level was 
calculated based on the original spiked concentration (see Table 5.4). The results indicate 
that similar percentage recoveries (58 – 61%) were obtained for isoniazid at 1 and 5 ng in 
fingerprint samples (natural and after handwashing). In contrast, a slightly higher value (64 
– 70%) is observed at 10 ng (natural and after handwashing). This can be a result of the 
sample matrix effects observed due to ionisation suppression which can be concentration 
dependent and therefore relates to the sample matrix-to-analyte ratio. For acetylisoniazid, 
the presence of a fingerprint (natural and after handwashing) resulted in very high recoveries 
(139 – 186%). This was a result of sample matrix effects (in the form of ionisation 
suppression) which were not corrected for acetylisoniazid using isoniazid-d4 as the internal 
standard due to a difference in the degree of ionisation suppression.  
There are a number of limitations, including the fingerprint variability (volume and size), 
matrix effects (ionisation suppression) and lower percentage recoveries, which will 
influence the fingerprint results obtained in this study. The difference in the levels of 
isoniazid and acetylisoniazid in the presence of a fingerprint sample compared to a standard 
of the same concentration highlights it is not possible to accurately determine the percentage 
recoveries of the analytes of interest in fingerprint samples or carry out quantitation using 
the current method.  
Table 5.4: Percentage recovery range for isoniazid and acetylisoniazid for (n = 5 
measurements) spiked fingerprints (natural and after washing hands with 
soap). 
Concentration 
Percentage recovery (%) 
Fingerprints (natural) Fingerprints (soap) 
Isoniazid Acetylisoniazid Isoniazid Acetylisoniazid 
10 ng/ml 58 147 61 142 
50 ng/ml 56 148 59 139 
100 ng/ml 64 186 70 181 
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5.2.4 Method performance 
A validation study was carried out for qualitative confirmation/identification measurements 
according to the Scientific Working Group for Forensic Toxicology guidelines to evaluate 
the analytical performance of the developed method. A set of experiments were performed 
to determine the reliability of the method for its intended use and evaluate the limitations of 
the method, including the working range, sensitivity (limit of detection) and sample stability. 
Definitions of terms used are detailed in Chapter 2, section 2.3.7.1. 
5.2.4.1 Working range 
A linear calibration curve for isoniazid and acetylisoniazid in standard solution was prepared 
with a concentration range of 50 – 1000 ng/ml in methanol. Each calibration standard was 
prepared from a stock solution (at 5000 ng/ml in methanol). The stock solution was prepared 
using isoniazid and acetylisoniazid. Calibration standards were prepared at 50, 100, 200, 
400, 600, 800 and 1000 ng/ml in methanol by appropriate dilution of the stock solution. Ten 
microlitres of the calibration standard was added to the paper substrate (Whatman 1-Chr 
grade paper, 2 x 2 cm) to produce 0.5, 1, 2, 4, 6, 8, and 10 ng of analyte residue on surface. 
The samples were subsequently extracted using the method described in section 5.2.1. Each 
calibration standard was measured five times over five consecutive days. A blank mobile 
phase injection was performed after each calibration standard in triplicate to evaluate the 
potential for carryover at each concentration level. No carryover was observed at any 
calibration level for isoniazid, acetylisoniazid or the internal standard (isoniazid-d4). An 
overview of the calibration curve data for isoniazid and acetylisoniazid over five separate 
runs is shown in Appendix D.1. The results suggest that the analytes of interest are not stable 
in the standard solution (50:50 (v/v) ACN in H2O + 0.1% formic acid) as the linearity (R2) 
over the concentration range is decreased over five consecutive days, particularly for 
acetylisoniazid.  This was confirmed by the analysis of freshly extracted calibration 
standards where linear calibration curves were obtained over n = 5 days (Appendix D.2). 
Additionally, the precision of the method for the retention time and peak area ratio A/IS, the 
relative standard deviation (%RSD) was calculated for the repeated measurements for each 
standard of the calibration curve. The method provided good RSD values of 0 – 3% for the 
repeated measurements (peak area ratio A/IS) in a single run (n = 5), demonstrating that the 
method has a satisfactory level of repeatability. In contrast, poor peak area ratio A/IS 
reproducibility was observed due to the stability of isoniazid and acetylisoniazid in 50:50 
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(v/v) ACN in H2O + 0.1% formic acid. The reproducibility of freshly prepared calibration 
curves over n = 5 days produced RSD values of 1 – 9% for isoniazid and acetylisoniazid, 
with an exception for isoniazid for 5 ng/ml at 19%. The correlation coefficients (R2) were 
calculated with R2 > 0.998. Standards were therefore prepared daily for each run. 
5.2.4.2 Limit of detection 
The sensitivity of isoniazid and acetylisoniazid was determined using the method outlined 
in section 2.3.7.3. Six standards were prepared to produce 10, 20, 40, 60, 80 and 100 pg of 
analyte residue on surface, including a blank sample substrate and blank solvent (methanol). 
The limit of detection was determined to be the concentration at which reproducible and 
reliable measurements were obtained for the lowest analyte concentration (Armbruster et 
al., 1994). The acceptance criteria were based on the retention time within ±2% (for n = 5 
measurements) and repeatability of the measurement ≤20% (Armbruster et al., 1994). Figure 
5.10 shows the trend of the standards extracted from paper used to evaluate the limit of 
detection. For isoniazid and acetylisoniazid, the minimal detectable limit was 10 pg of 
extracted analyte on paper (ratio A/IS 0.003 for both isoniazid and acetylisoniazid). 
 
Figure 5.10: Evaluation of the limit of detection for isoniazid and acetylisoniazid by 
analysing progressively more dilute standards using extracted analyte 
standards in methanol. Data represented as the average peak area ratio analyte 
(A) to internal standard (IS) (± standard deviation, n = 5 measurements) with 
error bars indicating the standard deviation. 
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5.2.4.3 Sample stability – processed sample  
The stability of the analytes in standard solution was evaluated over n = 5 days. Analyte 
standards (containing isoniazid and acetylisoniazid) in methanol were prepared at 50, 100, 
200, 400, 600, 800 and 1000 ng/ml. Ten microlitres of analyte standard (in methanol) was 
spiked onto paper (2 x 2 cm) to produce 0.5, 1, 2, 4, 6, 8, and 10 ng of analyte residue on 
surface. The samples were extracted using the method described in section 5.2.1. The sample 
stability of isoniazid and acetylisoniazid in standard solution (50% (v/v) ACN in H2O with 
0.1% formic acid) was evaluated. Each standard was measured n = 5 times to provide an 
average peak area ratio A/IS. The samples at each concentration level were analysed after 
sample preparation to establish the time zero response (run 1). Each subsequent analysis of 
the standards was performed in 24 hours increments; run 1 = 0 h, run 2 = 24 h, run 3 = 48 h; 
run 4 = 72 h and run 5 = 96 h. Figure 5.11 shows the level of stability for isoniazid and 
acetylisoniazid at each concentration level. The results show an increase in the ratio A/IS 
over the five consecutive days. This is because the average peak area (n = 5 replicate 
measurements) for all analytes decreased, but more rapidly for isoniazid-d4, resulting in a 
higher ratio A/IS over time. Therefore, analytes were only considered to be stable during the 
first run (10 h). Samples were prepared daily to prevent degradation.  
 
Figure 5.11: Evaluation of sample stability (processed sample) for isoniazid and 
acetylisoniazid in standard solution (50:50 (v/v) acetonitrile in water with 
0.1% formic acid and 50 ng/ml internal standard isoniazid-d4). Data 
represented as average peak area ratio analyte (A) to internal standard (IS) (± 
standard deviation, n = 5 measurements). 
5.2.5 Patients on treatment 
A total of 27 participants (10 female and 17 male) were recruited who were prescribed 
isoniazid as part of their treatment for tuberculosis. The dose prescribed is dependent on the 
weight of the patient (5 mg/kg). However, the maximum dose of isoniazid prescribed is 300 
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mg. The medication is to be taken daily on an empty stomach before breakfast. All 
participants admitted having taken their tablets on the day of fingerprint sample collection. 
Information about each participant including age, gender and dose of medication are detailed 
in Table 5.5. 
Table 5.5: Participant information, including gender (F = female, M = male), age (years) 
and dose of medication, for each patient on treatment. 
Participant number Gender Age Dose of isoniazid (mg) 
TB-2017-FP006 M 23 300  
TB-2017-FP011 F 23 300  
TB-2017-FP013 M 58 300 
TB-2017-FP014 F 37 300 
TB-2017-FP015 M 24 300 
TB-2017-FP016 F 77 300 
TB-2017-FP017 M 27 300 
TB-2017-FP018 F 49 300 
TB-2017-FP019 F 50 300 
TB-2017-FP030 M 49 300 
TB-2017-FP031 M 36 300 
TB-2017-FP032 M 38 300 
TB-2017-FP033 M 50 900 
TB-2017-FP034 F 21 300 
TB-2017-FP035 M 39 300 
TB-2017-FP036 M 61 300 
TB-2017-FP037 M 37 300 
TB-2017-FP038 M 29 300 
TB-2017-FP039 M 87 250 
TB-2017-FP040 F 25 250 
TB-2017-FP042 F 33 300 
TB-2017-FP043 M 40 300 
TB-2017-FP044 M 41 300 
TB-2017-FP045 F 43 250 
TB-2017-FP046 M 50 250 
TB-2017-FP047 M 56 300 
TB-2017-FP048 F 45 300 
 
Figure 5.12 shows the fingerprint results obtained for all participants on treatment. From 
135 natural fingerprint samples collected, isoniazid and acetylisoniazid were detected in 102 
(76%) and 125 (93%) samples, respectively. The majority of fingerprint samples analysed 
were positive for isoniazid and acetylisoniazid. However, in some cases only one of the 
analytes of interests was detected. Nineteen percent (26 samples) of fingerprint samples 
collected was positive for the metabolite acetylisoniazid only. In contrast, two samples (1%) 
were positive for isoniazid only. Additionally, 6% (eight samples) was negative for isoniazid 
and acetylisoniazid.  
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Figure 5.12: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for isoniazid and 
acetylisoniazid in natural fingerprints from (n = 27) participants on treatment 
for tuberculosis. Solid line represents limit of detection (LOD). 
The lack of detection for either isoniazid or acetylisoniazid in fingerprint samples was only 
observed for three participants, namely TB-2017-FP030 and TB-2017-FP-037 and TB-
2017-FP045. For participant TB-2017-FP030, none of the analytes of interest were detected 
in the right thumb, ring and little finger in samples collected as natural fingerprints. The 
remaining fingerprint samples (index and middle finger) were positive for acetylisoniazid 
only. Additionally, all fingerprint samples collected from participant TB-2017-FP037 were 
negative for isoniazid and acetylisoniazid, with the exception of the right index finger which 
was positive for isoniazid only. For participant TB-2017-FP045, isoniazid and 
acetylisoniazid were not detected in the right thumb. However, the right index and middle 
finger were positive for acetylisoniazid and the remaining fingerprint samples were positive 
for both analytes. The discrepancies observed between the fingerprint samples from the 
same participant highlights the difficulty associated with the use of fingerprints to monitor 
compliance. It is possible that the levels of isoniazid and acetylisoniazid were below the 
limit of detection and therefore a negative fingerprint result was obtained. This could be 
either due to a low concentration of analytes or a poor fingerprint deposition. However, to 
monitor whether a patient is compliant with their treatment, the presence of either the 
antibiotic (isoniazid) or the metabolite acetylisoniazid would be significant. Overall, based 
on this principle 94% (127 samples) of all fingerprints was positive (see Table 5.6). The 
findings show that fingerprint samples could potentially be used to monitor compliance with 
tuberculosis treatment. However, in order to understand the discrepancy in results obtained, 
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a corresponding blood sample would be required. Additionally, it is important to understand 
the discrepancy in fingerprint samples from the same participant. 
Table 5.6: Detection rate (percentage) for isoniazid and acetylisoniazid in natural 
fingerprint samples from tuberculosis patients on treatment. 
Fingerprint sample 
Detection rate (%) 
Isoniazid Acetylisoniazid Isoniazid or acetylisoniazid 
Right thumb (n = 27) 74 89 89 
Right index finger (n = 27) 74 96 100 
Right middle finger (n = 27) 74 96 96 
Right ring finger (n = 27) 81 93 93 
Right little finger (n = 27) 74 89 93 
Based on all fingerprints (n = 135) 76 93 94 
 
5.2.6 Patients who completed treatment 
A total of 6 participants (3 female and 3 male) were recruited who completed their 
tuberculosis treatment. The participants were recruited between 2 – 8 months after 
completion of their treatment. Information about each participant, including age, gender, 
dose of medication, treatment completion date and sample collection date are detailed in 
Table 5.7. 
Table 5.7: Participant information, including gender (F = female, M = male), age (years) 
and dose of medication for each patient on tuberculosis treatment. 
Participant 
number Gender Age 
Dose of 
isoniazid (mg) 
Treatment 
completion date  
(2017) 
Sample collection 
date 
(2017) 
TB-2017-FP001 F 32 300  1 February 26 April 
TB-2017-FP004 M 49 300  1 Jan 26 April 
TB-2017-FP005 M 41 300 1 March 26 April 
TB-2017-FP009 F 59 300 1 February 1 May 
TB-2017-FP012 F 31 300 1 May 1 June 
TB-2017-FP041 M 21 300 1 March 1 November 
The fingerprint results obtained for these participants is shown in Figure 5.13. The results 
show that isoniazid is not detected in the fingerprint samples for participants who have 
completed treatment. Similarly, for acetylisoniazid, no fingerprint sample showed 
acetylisoniazid levels above the limit of detection, with the exception of participant TB-
2017-FP009, which showed detectable levels of acetylisoniazid in all fingerprint samples. 
However, the leves of acetylisoniazid observed for this participant are lower compared to 
those observed for participants on treatment. Additionally, the levels observed for this 
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participant have a greater uncertainty (standard deviation) as the values are just above the 
limit of detection (ratio A/IS 0.003) for acetylisoniazid (see section 2.3.7.3). 
 
Figure 5.13: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for isoniazid and 
acetylisoniazid in natural fingerprint samples collected from (n = 6) 
participants who have completed treatment for tuberculosis. Solid line 
represents limit of detection (LOD). 
5.2.7 Negative control group 
Ten participants (5 male and 5 female) were recruited as a negative control group to evaluate 
whether the analytes of interest or interfering compounds could be detected in natural 
fingerprint samples. Information about participants in the negative control group (including 
age and gender) are detailed in Table 5.8. 
Table 5.8: Participant information, including gender (F = female, M = male) and age 
(years) for the negative control group. 
Participant number Gender Age 
TB-2017-N001 F 25 
TB-2017-N002 F 24 
TB-2017-N003 M 23 
TB-2017-N004 M 30 
TB-2017-N005 M 24 
TB-2017-N006 F 24 
TB-2017-N007 M 21 
TB-2017-N008 M 26 
TB-2017-N009 F 23 
TB-2017-N010 F 26 
Isoniazid was detected in one fingerprint sample (TB-2017-N001, right thumb), resulting in 
a 2% detection rate (see Figure 5.14). In contrast, the metabolite acetylisoniazid was not 
detected in any fingerprint sample from the negative control group. The results demonstrate 
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that (i) these analytes of interests are not detected in fingerprint samples from individuals 
who have not received any tuberculosis medication and (ii) “no interfering compounds” 
were detected at the same retention time with the same mass as the analytes of interest. 
Although a limited sample size was evaluated in this research, the results suggest that the 
detection of the isoniazid and acetylisoniazid in fingerprints is significant and arises from 
administration of the prescribed medication. 
 
Figure 5.14: Fingerprint results average peak area ratio analyte (A) to internal standard 
(IS) (± standard deviation n = 5 measurements) for isoniazid and 
acetylisoniazid in natural fingerprint samples collected from (n = 10) 
participants from the negative control group. Solid line represents limit of 
detection (LOD). 
5.2.8 Effect of washing hands 
The sampling strategy for the analysis of isoniazid and acetylisoniazid in fingerprints was 
evaluated by washing hands with soap and water. This was to explore whether the analytes 
of interest could still be detected after an individual has washed their hands prior to sample 
collection.  
5.2.8.1 Patients on treatment 
Twenty-seven participants (10 female and 17 male) were recruited who were prescribed 
isoniazid as part of their treatment for tuberculosis. Two sets of fingerprint samples were 
collected for these participants (i) without preparation of the hands and (ii) after washing 
hands with soap and water. Information about each participant including age, gender and the 
dose of medication are detailed in Table 5.5.  
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Figure 5.15 shows the fingerprint results obtained for isoniazid and acetylisoniazid for each 
participant. After washing hands with soap and water, isoniazid was detected in 83 samples 
(61%). Additionally, the metabolite acetylisoniazid was detected in 117 samples (87%). 
Compared to the results obtained in section 5.2.5, the detection rate for both analytes has 
decreased (from 76 to 61% for isoniazid and from 93 to 87% for acetylisoniazid) by using a 
handwashing procedure prior to sample collection.  
 
Figure 5.15: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for isoniazid and 
acetylisoniazid in samples collected after washing hands with soap and water 
for (n = 27) participants on treatment for tuberculosis. 
A discrepancy was observed for the presence of the analytes of interest in fingerprint 
samples for 5 participants (TB-2017-FP019, TB-2017-FP035, TB-2017-FP037, TB-2017-
FP042 and TB-2017-FP043). For participant TB-2017-FP019, all fingerprint samples were 
positive for acetylisoniazid only, with the exception of the right middle finger which was 
negative for both isoniazid and acetylisoniazid. Fingerprint samples for participant TB-
2017-FP035 showed that acetylisoniazid was detected in the right middle, ring and little 
finger, whereas the right thumb and index finger were negative for both isoniazid and 
acetylisoniazid. For participant TB-2017-FP037, all fingerprint samples were negative for 
isoniazid and acetylisoniazid, which is surprising. However, natural fingerprint samples 
collected for this participant showed that only one fingerprint sample (right index finger) 
was only positive for isoniazid. The remaining fingerprint samples were negative for both 
analytes of interest. This questions whether this participant is compliant with their treatment, 
or if the method is not sensitive enough to detect these low levels of isoniazid and 
acetylisoniazid. Results obtained for participant TB-2017-FP042 showed that the right index 
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and little finger were positive for isoniazid only, whereas the right thumb and ring finger 
were positive for both isoniazid and acetylisoniazid. However, both isoniazid and 
acetylisoniazid were not detected in the right middle finger collected for this participant. 
Additionally, for participant TB-2017-FP043 all fingerprint samples were positive for 
acetylisoniazid only, except for the right middle finger.  
The results show that although the majority of fingerprint samples are positive for 
tuberculosis medication, a discrepancy is observed between fingerprint samples for a 
number of participants. Collection of multiple fingerprint samples would be advantageous 
to confirm the presence of the analytes of interest. Additionally, based on the detection of 
either isoniazid or acetylisoniazid, 120 samples (89%) were positive for the presence of 
tuberculosis medication after handwashing (right thumb 89%; right index finger 89%; right 
middle finger 81%; right ring finger 93%; right little finger 93%).   
5.2.8.2 Patients who completed treatment 
Six participants were recruited within 2 – 8 months of completing their treatment for 
tuberculosis. Information about the participants, including age, gender, dose of medication, 
treatment completion date and sample collection date are outlined in Table 5.7. The 
fingerprint results obtained for these participants showed that isoniazid was not detected in 
any fingerprint sample for the 6 participants. In contrast, acetylisoniazid was present in 17% 
(5 samples) (see Figure 5.16).  
 
Figure 5.16: Fingerprint results (average peak area ratio analyte (A) to internal standard 
(IS), ± standard deviation n = 5 measurements) for isoniazid and 
acetylisoniazid in fingerprint samples collected after washing hands with 
soap and water for (n = 6) participants who have completed treatment for 
tuberculosis. Solid line represents limit of detection (LOD). 
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This is a result of participant TB-2017-FP009, as all fingerprint samples were positive for 
acetylisoniazid, consistent with the results obtained for natural fingerprints. However, the 
lack of detection of isoniazid and acetylisoniazid in fingerprint samples for participants who 
have completed treatment at different time periods shows that the compounds are not present 
in the system long after completion of treatment. This is important as a long detection 
window would not be beneficial in monitoring compliance with tuberculosis treatment if an 
individual has not taken their medication for a couple of days or weeks.  
5.2.8.3 Negative control group 
A total of 10 participants (5 male and 5 female) were recruited as negative control subjects 
to evaluate whether the analytes of interest or interfering compounds could be detected in 
fingerprint samples collected after handwashing. Information about participants in the 
negative control group, including age and gender, are detailed in Table 5.8. The results show 
that both isoniazid and acetylisoniazid are not detected in fingerprint samples collected from 
participants who have never received tuberculosis medication. Additionally, no interfering 
compounds were present at the same mass and retention times of the analytes of interest. 
This shows that the detection of isoniazid and acetylisoniazid is significant as these analytes 
are not commonly observed in fingerprint samples. Although a 2% false positive rate was 
observed for natural fingerprints as 1 sample was positive for isoniazid (TB-2017-N001, 
right thumb), this signal was not observed after washing hands with soap and water. 
5.2.9 Elimination profile 
One participant was recruited who was completing their tuberculosis treatment to evaluate 
the drug elimination of isoniazid and acetylisoniazid in fingerprint samples. It is important 
to illustrate that if an individual is not compliant with their medication, the fingerprint 
sample is able to confirm this. However, in order to confirm non-compliance, the drug 
elimination of the analytes of interest in fingerprints must be short (e.g. 1 day). Otherwise 
the sample is not able to determine when an individual is not complying with their treatment 
based on a qualitative fingerprint test.  
Fingerprint samples were collected from participant TB-2017-E001 on three occasions: (i) 
on the last day of their treatment (T = 0), (ii) two days after completing treatment (T = 2) 
and (iii) four days after completing treatment (T = 4). Fingerprint samples (n = 5) were 
collected natural and after washing hands with soap and water. The results showed that on 
the last day of treatment (T = 0) both isoniazid and acetylisoniazid were detected in all 
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natural fingerprint samples and after handwashing (Figure 5.17). However, isoniazid and 
acetylisoniazid were not present in any natural fingerprint samples and after handwashing 
on T = 2 and T = 4 days. The drug elimination profile for isoniazid and acetylisoniazid in 
fingerprint samples for TB-2017-E001 is shown in Figure 5.17. 
As isoniazid and acetylisoniazid were not detected in fingerprint samples collected 2 and 4 
days after completing treatment, the results indicate that the elimination of the antibiotic is 
short (<2 days). This demonstrates that when an individual is not complying with their 
treatment, the fingerprint results can confirm no analytes are present two days afterwards. 
However, a limitation of this experiment is that only participant was recruited. A larger 
group of individuals would have to be evaluated to determine the drug elimination profile 
of isoniazid and acetylisoniazid in fingerprint samples to confirm these preliminary findings, 
including various time periods to capture when the analytes of interest cannot be detected 
anymore. 
 
Figure 5.17: Drug elimination profile of isoniazid and acetylisoniazid in natural 
fingerprints and after washing hands with soap and water for participant TB-
2017-E001. Solid line represents the limit of detection (LOD). 
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5.3 Summary 
The extraction of isoniazid and acetylisoniazid from paper was performed using 10% 
dicholoromethane in methanol (section 5.1.5). Matrix effects were observed in the form of 
ionisation suppression for isoniazid and acetylisoniazid. However, the degree of variability 
in ionisation suppression was minimised with the use of an internal standard (isoniazid-d4) 
(section 5.2.2). The recovery values based on spiked fingerprints (natural and after washing 
hands) were 58 –70% for isoniazid and 139 – 186% for acetylisoniazid (section 5.2.3). A 
linear response was obtained for isoniazid and acetylisoniazid (0.5 – 10 ng of analyte residue 
on surface) with correlation coefficients (R2) > 0.998 (section 5.2.4.1). Peak are ratio A/IS 
demonstrated good reproducibility 1 – 9% for isoniazid and acetylisoniazid, with an 
exception for isoniazid at 5 ng/ml (19%) (section 5.2.4.1). The limit of detection for 
isoniazid and acetylisonoazid was at 10 pg of analyte residue on surface (section 5.2.4.2). 
Additionally, the analytes of interest were stable in solution over 10 hours (section 5.2.4.3). 
Isoniazid (76%) and acetylisoniazid (93%) can be detected in natural fingerprints from 
patients receiving tuberculosis treatment, even after a handwashing procedure (section 
5.2.5). However, a lower detection rate was observed after washing hands (61% for isoniazid 
and 81% for acetylisoniazid) (section 5.2.8.1). These analytes are not detected in fingerprints 
from a negative control group, if samples are collected after washing hands (one sample was 
positive in natural fingerprints) (section 5.2.8.3). Additionally, isoniazid was not present in 
samples collected from patients who completed their treatment (2 – 8 months prior to 
recruitment). In contrast, acetylisoniazid was detected in 17% (five samples, all arising from 
the same participant) even after washing hands (section 5.2.8.2). However, the observed 
acetylisoniazid levels were lower compared to patients currently on treatment. This has 
shown that fingerprints could potentially be used to monitor compliance with tuberculosis 
treatment based on the presence of isoniazid and acetylisoniazid in fingerprint samples. 
In addition, samples collected from a patient coming off treatment showed that isoniazid and 
acetylisoniazid were not detected in fingerprint samples collected two and four days after 
completing treatment. This suggests that there is a potentially short detection window for 
the analytes of interest, which is advantageous for monitoring compliance with tuberculosis 
treatment. However, further work is required to establish the detection window of the 
analytes of interest in fingerprints. 
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Chapter 6 Detection of Cocaine and Benzoylecgonine in Bodily 
Fluids using a Portable Mass Spectrometer 
6.0 Introduction 
One of the aims of this research was to evaluate the use of a portable screening method for 
the analysis of drugs of abuse in biological matrices, with an initial aim of developing a 
portable method for detecting cocaine in fingerprints. It was quickly established that a 
fingerprint sample proved too challenging for this novel detection set up. Additionally, the 
results in Chapter 3 (drug administration) and Chapter 4 (drug contact) highlighted the 
challenges associated with the use of fingerprints for drug testing. The unknown sample 
volume of fingerprints impacts the potential for quantification and the limited sample 
volume requires high sensitivity instrumentation. This pilot research study was therefore 
conducted to evaluate a portable screening system for drug testing using more conventional 
and established sample matrices, urine and oral fluid (saliva). The main advantage of a 
portable mass spectrometer system is the ability to analyse samples on-site (point-of-care). 
This in combination with a surface analysis technique that requires little to no sample 
preparation will allow rapid high throughput screening of samples. In addition, the rapid 
assessment of samples on-site will allow for subsequent samples to be collected and sent off 
to a laboratory for confirmation (e.g. workplace drug testing).  
The potential use of portable mass spectrometers for on-site analysis of drugs has been 
investigated previously (O'Leary et al., 2015; Li et al., 2014). However, these methods rely 
on the use of ambient ionisation methods. The main disadvantage for ambient ionisation 
methods is selectivity. This is due to the need for a high resolution mass spectrometer to 
confidently assign peaks in a mass spectrum. Additionally, the lack of chromatographic 
separation of compounds prior to mass analysis makes it more vulnerable to ion suppression 
making quantitative profiling difficult. Ion suppression can be problematic in experiments 
where the ionisation of the analyte of interest is affected by the presence of other compounds, 
thereby limiting the sensitivity (Annesley, 2003).  
This chapter explores the possibility of decoupling extraction from ionisation in a portable 
system, to reduce ion suppression effects and thereby improve sensitivity and selectivity. 
This enables the advantages of using a portable system for on-site analysis. 
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For the analysis of drugs of abuse in biological matrices (e.g. urine and oral fluid), a key 
application is the use of cut-off levels to determine a screening result as either positive or 
negative. There are two types of cut-off levels, screening and confirmation cut-off levels 
(Substance Abuse and Mental Health Services Administration, 2015; Substance Abuse and 
Mental Health Services Administration, 2008). A screening cut-off level is used to provide 
an initial presumptive result which qualitatively assesses the presence of a drug. A negative 
screening result does not always indicate that the sample does not contain any drugs, as it 
might contain drug levels below the cut-off used. Screening tests are usually based on 
immunoassay screening using antibodies as these are rapid and inexpensive to conduct. 
However, the main disadvantage of the use of antibodies is that they can bind to other 
substances and therefore cause false positive results. A screening result is therefore followed 
up with a confirmation test which is based on mass spectrometry. Confirmation tests are 
more selective and sensitive as they only monitor a few compounds compared to the initial 
screening of multiple drugs and drug metabolites using immunoassays.  
For the purpose of this pilot research study, only a small sample size (n = 2 participants) was 
used to assess the potential suitability of the method for drug screening as the 
instrumentation was available for a limited time period. As a result, the possibility for 
method optimisation and development was therefore further restricted. Urine and oral fluid 
samples were collected from individuals attending an NHS drug and alcohol service for drug 
dependency. Informed consent was taken from participants prior to sample collection. 
Analysis of cocaine and benzoylecgonine in urine and oral fluid was carried out by a Plate 
Express™ system coupled to an expression Compact Mass Spectrometer (CMS) (see section 
6.1.4). The following section will outline the sample collection and preparation methods for 
the study populations investigated (see section 6.1). All urine and oral fluid samples 
collected were stored (at 4 ºC) at the University of Surrey until required for analysis. All 
instrumentation and methodology used for the analysis of urine and oral fluid samples are 
detailed in section 6.1.5. The analysis of cocaine and benzoylecgonine in urine and oral fluid 
for both study populations (negative controls and drug dependent participants) are outlined 
in sections 6.2.1 and 6.2.2.  
This chapter investigates the possibility of using a portable mass spectrometer set up (in 
combination with chromatography) for the purpose of drug testing from oral fluid and urine, 
in accordance with recognised workplace drug testing guidelines. For this study, the portable 
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system was evaluated in one location to demonstrate the potential to detect cocaine use. 
However, in order to demonstrate a point-of-care system, multiple locations would need to 
be tested. The system evaluated in this research can be placed in the back of the van for 
portability and on-site analysis. 
6.1 Experimental 
6.1.1 Chemicals and reagents 
Quantisal™ collection devices were used for oral fluid samples (Alere Toxicology, UK). 
Sterilin™ polystyrene containers were used for the collection of urine samples (Scientific 
Laboratory Supplies, Nottingham, UK). Certified reference materials (CRM) of cocaine and 
benzoylecgonine were used to prepare drug standards (Sigma Aldrich, Dorset, UK). CRM 
of cocaine-d3 was used as an internal standard (Sigma Aldrich, Dorset, UK). Optima grade 
LC-MS solvents of acetonitrile and water were used to prepare solutions and solvent 
mixtures (Fisher Scientific, Leicestershire, UK). Formic acid was added to the mobile phase 
solvents at 0.1% (v/v) (Fischer Scientific, Leicestershire, UK). Scintillation vials for sample 
preparation were purchased from Fisher Scientific, Loughborough, UK. 
6.1.2 Study populations 
Study participants from two populations (drug users and non-drug users as negative control 
group) volunteered to provide samples for the purpose of this pilot research project in 2015. 
Negative control samples were collected from non-drug users (n = 10) at the University of 
Surrey. Samples from cocaine users (n = 2 participants) were collected at an NHS drug and 
alcohol service, to demonstrate the application of the method. Informed consent was 
obtained from participants prior to sample collection. The samples collected for the purpose 
of this research project included oral fluid and urine.  
6.1.3 Sample collection and sample preparation 
6.1.3.1 Oral fluid 
Oral fluid samples were collected from non-drug users (n = 5 females and n = 5 males) at 
the University of Surrey. Oral fluid samples (1 ml per participant) were collected using a 
syringe. The samples were used to prepare blank (negative control) and spiked standards for 
cocaine and benzoylecgonine. Oral fluid samples from drug users were collected using 
Quantisal™ oral fluid collection devices at an NHS drug and alcohol service (as described 
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the SOP in Appendix B. 1). The oral fluid samples were given a unique identifier (e.g. 
04831605) to enable storage (at 4 °C) of samples in anonymised form at the University of 
Surrey.  Both participants 04831605 and 04857599 admitted having taken cocaine in the 
past 24 h. 
Oral fluid samples collected from the negative control group (n = 5 males and 5 females) 
were pooled and used to prepare blank and spiked drug standards of cocaine and 
benzoylecgonine to provide a calibration concentration range (see section 6.1.7). Oral fluid 
samples were prepared in two steps prior to analysis, which involved the preparation of 
spiked oral fluid drug standards and absorption of the spiked oral fluid standards using 
Quantisal™ oral fluid collection devices. A 1 µg/ml stock solution of cocaine and 
benzoylecgonine was prepared by dilution of the certified reference materials (CRM) of 
cocaine and benzoylecgonine (at 1 mg/ml in acetonitrile and methanol, respectively) in 
water. The pooled oral fluid sample was used to prepare spiked drug standards over the range 
0 – 600 ng/ml by appropriate dilution of the stock solution. The spiked oral fluid samples 
were then placed in separate scintillation vials for absorption using Quantisal™ oral fluid 
collection devices. Once the volume indicator (1 ml ± 10%) on the Quantisal™ oral fluid 
collection device turned blue, the collection wand was placed in the transfer tube. The 
Quantisal™ oral fluid collection devices contain a stabilising buffer to stabilise drugs during 
transport and storage. This method was used to demonstrate the analytical performance of 
the detection of cocaine and benzoylecgonine in oral fluid using commercially available 
collection devices. 
6.1.3.2 Urine 
Urine samples were collected from non-drug users (n = 3 males) at the University of Surrey. 
Samples (60 ml) were collected in Sterilin™ polystyrene containers. Urine samples (60 ml) 
from participants (n = 2 males) at an NHS drug and alcohol service were also collected using 
Sterilin™ polystyrene containers. The urine samples were given the same unique identifier 
(e.g. 04831605) as the corresponding oral fluid sample to enable corroboration of samples. 
Samples were stored at 4 °C at the University of Surrey until required for analysis using the 
portable mass spectrometer set up. 
Urine samples collected from non-drug users (n = 3 males) were pooled and used to prepare 
a blank negative control and spiked urine drug standards (see section 6.1.7). A 1 µg/ml stock 
solution of cocaine and benzoylecgonine was prepared in pooled urine by dilution of CRM 
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standards of cocaine (1 mg/ml) and benzoylecgonine (1 mg/ml). Spiked drug standards were 
prepared in urine by appropriate dilution of the stock solution over the range 0 – 600 ng/ml. 
For the analysis of oral fluid and urine samples collected from individuals at NHS drug and 
alcohol services, samples were analysed without sample preparation. Urine samples were 
collected in Sterilin™ polystyrene containers and no additive was added to stabilise the 
drugs up to the point of analysis to maintain the integrity of the sample. 
6.1.4 Plate Express™ - Compact Mass Spectrometer (CMS) 
The purpose of using chromatography in combination with a portable single quadrupole 
mass spectrometer is to enhance the selectivity of the portable system by separating the 
analytes prior to mass analysis in the detector. This is necessary as portable mass 
spectrometers lack the resolving power and sensitivity compared to laboratory-based 
instruments. Qualitative analysis was conducted by the use of a Plate Express™ system 
coupled to an expression compact mass spectrometer (CMS) by a chromatography column.  
The CMS is a portable single quadrupole mass analyser that was introduced in 2012, 
followed by the later release of the Plate Express™ system in 2015 (Advion Inc. Ithaca, 
USA). The instrument was designed to provide rapid information and increase the workflow 
of chemists by the identification of compounds and monitoring the progress of a reaction. 
However, for the purposes of this research, the system has been evaluated for the 
identification of drugs of abuse (cocaine and its metabolite benzoylecgonine) in bodily 
fluids, including oral fluid and urine. 
The following sections outline the principal components present in the portable mass 
spectrometer system used, including the surface extraction using the Plate Express™ for 
sample introduction, chromatography method for the separation of analytes and mass 
analysis using a single quadrupole mass spectrometer. 
6.1.4.1 Sample introduction 
The Plate Express™ is designed for the extraction of analytes from a variety of different 
surfaces (such as glass, paper, aluminium foil and TLC plates). Sample introduction with 
the Plate Express™ system is facilitated by the use of an oval shaped elution head (4 x 2 
mm, with a depth of 250 µm) under which the sample is placed. The Plate Express™ system 
is also equipped with a laser device to help target the correct sampling area for analysis. The 
system also features an automated head cleaning procedure with high pressure nitrogen gas, 
which is applied in between sample analysis to limit contamination and carryover. For 
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analysis the sample is loaded onto the sample substrate (e.g. Whatman 1-Chr paper) and 
placed under the elution head of the Plate Express™ system. Automated software is used to 
initiate sample extraction by driving the elution head down to make contact with the sample 
substrate. After contact with the sample substrate, a force is applied to seal the spot for 
extraction by compression of the spring inside the elution head. The elution head features 
an oval shaped knife edge which is used to seal against the sample substrate. The solvent 
from the binary pump is used to flush across the surface of the sample substrate to extract 
compounds. The knife edge is equipped with a frit to filter the extracted sample before 
introduction to the chromatography column for separation and subsequent mass analysis 
with the compact mass spectrometer. 
6.1.4.2 Chromatography 
An ultra-biphenyl column (50 x 2.1 mm, 5 µm) (Restek, Buckinghamshire, UK) was used 
for the separation of cocaine and benzoylecgonine in oral fluid and urine samples. A binary 
gradient method was applied to reduce run time and improve separation power. A binary 
pump was used to deliver gradient elution with 0.1% formic acid in water (solvent A) and 
0.1% formic acid in acetonitrile (solvent B) (see section 6.1.5). After the extracted sample 
is introduced in the chromatography column, the analytes of interests are separated based on 
their affinity to the stationary phase. Ionisation and mass analysis of the separated 
compounds can then be accomplished allowing greater sensitivity using the compact mass 
spectrometer. 
6.1.4.3 Plate Express™ - CMS Interface 
An electrospray ionisation source was used as the interface between the chromatography 
column and the mass spectrometer. The mass spectrometer operates at high vacuum (10-6 
mbar) to prevent collisions with air molecules, which can lead to fragmentation. Liquid 
chromatography is a high pressure technique, which operates at flow rates that would 
overwhelm the mass spectrometer (Harris, 2007). The main function of the interface is to 
remove most of the volatile solvent between the column and the mass spectrometer and to 
ionise the compounds of interest (McMaster, 2005). Further information on the principles 
of electrospray ionisation can be found in section 2.1.2. 
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6.1.4.4 Quadrupole mass spectrometer 
A quadrupole mass spectrometer is a mass analyser consisting of four cylindrical or 
hyperbolic rods. The mass analyser is positioned between the ion optics and the detector and 
acts as a mass filter. A combination of a direct current (DC) and radio frequency (RF) voltage 
is applied to the rods to allow for the transmission of ions of a specific mass to the detector 
(Dunn, 2011). By varying the voltage applied with time, ions with a specific mass-to-charge 
(m/z) ratio will have a stable path to the detector. This makes it possible to scan across an 
entire mass range allowing multi-component analysis. Ion detection on the compact mass 
spectrometer is achieved by a dynode electron multiplier scanning every 2 µs. The stable 
ions that pass through the quadrupole mass analyser collide with the dynode and cause a 
cascade of secondary electrons to be released on contact. The amplified signal of the ion 
will finally reach the anode cup at the end of the detector where the current is measured 
(Harris, 2007).  
6.1.5 Instrumentation and conditions 
Analysis of all samples was carried out on a Plate Express™ system coupled to an expression 
compact mass spectrometer (Advion Inc., Ithaca, USA) at the University of Surrey 
(Guildford, Surrey, UK). Figure 6.1 shows a schematic diagram of the Plate Express™ 
system coupled to the compact mass spectrometer. Details of the specification of the 
compact mass spectrometer are shown in Table 6.1.  
 
Figure 6.1: Schematic diagram of Plate Express™ system coupled with compact mass 
spectrometer (schematic provided by Advion Inc.). 
The Plate Express™ system was connected to a binary pump to allow gradient elution for 
the separation of cocaine and benzoylecgonine. Chromatographic separation was achieved 
by the adaptation of a previously developed method for the analysis of cocaine and 
benzoylecgonine on a Waters 2695 separation module and Micromass Quattro Ultima mass 
Chapter 6: Detection of Cocaine and Benzoylecgonine in Bodily Fluids using a Portable Mass Spectrometer 
174 
 
spectrometer. The method was modified for the use on the Plate Express™ system as a lower 
flow rate was required to extract the sample beyond the Rheodyne valve (6 port injection 
valve), as this would otherwise lead to seal leakage.  
Table 6.1: Specifications of compact mass spectrometer (CMS) used in this study. 
Type Specification 
Mass range 10 – 2000 amu 
Mass resolution m/z 0.5 – 0.7 (at full width half maximum) at 1000 units sec-1 
Weight 
Expression CMS detector 32 kg 
Rotary pump 30 kg 
Dimensions 
Expression CMS detector 66 x 28 x 56 cm 
Rotary pump 26 x 23 x 46 cm 
Power consumption 
Expression CMS detector 300 VA maximum 
Rotary pump 550 VA maximum 
Table 6.2 shows the gradient used for the analysis of cocaine and benzoylecgonine on the 
Plate Express™ system using 0.1% formic acid in water (solvent A) and 0.1% formic acid 
in acetonitrile (solvent B). The sample extraction is initiated by the initial mobile phase 
composition used by passing the solution over the sample surface. After the sample 
extraction (120 s), the head disengages and the gradient elution is applied. Instrument 
optimisation was achieved by using a 1 µg/ml solution of cocaine and benzoylecgonine in 
5% (v/v) acetonitrile in water. 
Table 6.2: Binary gradient used for the separation of cocaine and benzoylecgonine on 
an Ultra biphenyl column (50 x 2.1 mm, 5 µm) on the Plate Express – CMS 
system. 
Time 
(min) 
Flow (ml/min) Solvent A (%) Solvent B (%) Gradient type 
0.10 0.100 95.0 5.0 Step 
2.00 0.100 95.0 5.0 Step  
1.00 0.500 95.0 5.0 Linear 
2.00 0.500 80.0 20.0 Linear 
1.00 0.500 0.0 100.0 Step 
1.00 0.500 95.0 5.0 Step  
Table 6.3 details the optimised operating conditions used for mass spectral analysis of 
cocaine and benzoylecgonine on the Plate Express™ – CMS system. The source voltage and 
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source voltage dynamic were optimised to add selectivity and confirmation of the 
identification of compounds by producing mild in-source fragmentation of cocaine, 
benzoylecgonine and cocaine-d3. Ten µl of standard solution (1 µg/ml in 5% (v/v) 
acetonitrile in water + 0.1% formic acid) was loaded onto the sample substrate (2 x 2 cm, 
Whatman 1-Chr paper) to check instrument response and mass fragmentation before each 
analysis run. Mass analysis of samples on the compact mass spectrometer was carried out in 
selected ion monitoring (SIM) mode. Using SIM mode increases the sensitivity of the mass 
spectrometer as more time is spent scanning for the compounds of interest. The mass 
spectrometer was set to only monitor a few m/z values for cocaine (m/z 304 and 182), 
benzoylecgonine (m/z 290 and m/z 168) and cocaine-d3 (m/z 307 and m/z 171). Both the 
molecular ion and fragment ion were used to qualitatively confirm the presence of cocaine 
and benzoylecgonine. 
Table 6.3: Operating conditions of Plate Express™ – CMS for the analysis of cocaine 
and benzoylecgonine in urine and oral fluid. 
Parameter Operating condition 
Sample introduction 
Extraction time 120 s 
Force  250 N 
Source parameters 
Capillary temperature 250 ºC 
Capillary voltage 150 V 
Source voltage 25 V 
Source voltage 
dynamic 
30 V 
Gas temperature 200 ºC 
Electrospray voltage 3.5 kV 
Detector settings 
Scan mode Selected ion monitoring (SIM) 
Dwell time 50 ms 
Span m/z 0.3 
Figure 6.2 shows an example of an extracted ion chromatogram of a spiked drug standard 
(at 200 ng/ml) in urine analysed with the Plate Express™ - CMS system. The respective 
retention times of cocaine and benzoylecgonine were 4.13 and 4.01 min. The 
chromatograms show the presence of the molecular ion as well as the fragment ion for 
cocaine (m/z 304 and 182) and benzoylecgonine (m/z 290 and 168) formed by the mild in-
source fragmentation to confirm the presence of the analytes of interest. 
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Figure 6.2: Extracted ion chromatograms of (a) cocaine and (b) benzoylecgonine in a 
spiked urine standard (at 200 ng/ml containing 100 ng/ml internal standard 
cocaine-d3) analysed using Plate Express™ - compact mass spectrometer 
(CMS) system. 
6.1.6 Internal standard 
A 1 µg/ml internal standard (IS) solution of cocaine-d3 was used to plot the ratio of analyte 
(A) to internal standard (IS) against the concentration of spiked drug standard in urine and 
oral fluid. The IS solution was prepared by dilution of certified reference material of 
cocaine-d3 (1 mg/ml in acetonitrile). For oral fluid standards, the IS solution was prepared 
in water (Fisher Scientific, LC-MS grade). The IS solution was spiked into the oral fluid 
drug standards to produce a final concentration of 150 ng/ml. The IS solution prepared in a 
pooled urine sample at 1 µg/ml was spiked into the urine drug standards to produce a final 
concentration of 100 ng/ml. 
6.1.7 Method performance 
The performance of the portable mass spectrometer was evaluated for qualitative 
confirmation/identification measurements according to the Scientific Working Group for 
Forensic Toxicology guidelines. A set of experiments were performed to determine the 
reliability of the method for its intended use and evaluate the limitations of the method, 
including the working range and sensitivity (limit of detection). 
6.1.7.1 Linear working range 
A concentration range of 0 – 600 ng/ml was selected to determine the linear working range 
of the method. All calibration curves were plotted as the concentration of the analyte, against 
the average ratio of the analyte (A) signal to the internal standard (IS) signal (n = 3). 
Calibration curves for both cocaine and benzoylecgonine were linear over the range 0 – 600 
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ng/ml in both urine and oral fluid, and had R2 values of at least 0.998 (see Figure 6.3 and 
Figure 6.4).   
 
Figure 6.3: Calibration curve of (a) cocaine (m/z 182.1) and (b) benzoylecgonine (m/z 
168.1) in pooled urine containing 100 ng/ml internal standard (cocaine-d3) 
analysed using Plate Express™ - compact mass spectrometer (CMS) system. 
The precision of the method was evaluated by calculating the relative standard deviation 
(RSD) % of the repeated measurements (n = 3). The repeatability of the measurements was 
below 15%, except for benzoylecgonine in pooled urine at 50 ng/ml which provided an RSD 
value of 23%. 
 
Figure 6.4: Calibration curve of cocaine (m/z 304.1) and benzoylecgonine (m/z 290.1) in 
pooled oral fluid containing 150 ng/ml internal standard (cocaine-d3) 
analysed using Plate Express™ - compact mass spectrometer (CMS) system. 
6.1.7.2 Limit of detection and quantitation 
The limit of detection is the concentration at which the instrument signal is significantly 
different from the blank or background signal (Miller & Miller, 2005). The limit of detection 
and quantitation of cocaine and benzoylecgonine were calculated based on Equations 6.1 
0 100 200 300 400 500 600
0
2
4
6
8
0 100 200 300 400 500 600
0
1
2
3
4
5
B
R2 0.9998 
A
ve
ra
ge
 p
ea
k 
ar
ea
 ra
tio
 A
/IS
 (n
 =
 3
)
Cocaine concentration (ng/ml)
A
R2 0.9987 
A
ve
ra
ge
 p
ea
k 
ar
ea
 ra
tio
 A
/IS
 (n
 =
 3
)
Benzoylecgonine concentration (ng/ml)
0 100 200 300 400 500 600
0
2
4
6
8
10
12
14
16
0 100 200 300 400 500 600
0
1
2
3
4
5
6
R2 0.9981 
A
ve
ra
ge
 p
ea
k 
ar
ea
 ra
tio
 A
/IS
 (n
 =
 3
)
Cocaine concentration (ng/ml)
A B
R2 0.9981 
A
ve
ra
ge
 p
ea
k 
ar
ea
 ra
tio
 A
/IS
 (n
 =
 3
)
Benzoylecgonine concentration (ng/ml)
Chapter 6: Detection of Cocaine and Benzoylecgonine in Bodily Fluids using a Portable Mass Spectrometer 
178 
 
and 6.2 for n = 3 replicate measurements of blank urine or oral fluid. Table 6.4 details the 
calculated LODs and LOQs for both analytes in urine and oral fluid. 
LOD = yB + 3SB      Eq. 6.1 
[LOD = limit of detection; yB = mean blank signal; sB = standard deviation of the blank signals] 
LOQ = yB + 10SB      Eq. 6.2 
[LOD = limit of detection; yB = mean blank signal; sB = standard deviation of the blank signals] 
Table 6.4: Limit of detection and quantitation of cocaine and benzoylecgonine in oral 
fluid and urine. 
Sample matrix Limit of detection (ng/ml) Limit of quantitation (ng/ml) Cocaine Benzoylecgonine Cocaine Benzoylecgonine 
Oral fluid 31 17 44 27 
Urine 10 21 19 42 
Table 6.4 shows the United States Substance Abuse and Mental Health Services 
Administration (SAMHSA) and European Union’s research project on Driving Under the 
Influence of Drugs, Alcohol and Medicines (DRUID) proposed cut-off levels for screening 
and confirmation tests for cocaine in urine and oral fluid (Substance Abuse and Mental 
Health Services Administration, 2015; Verstraete et al., 2011; Substance Abuse and Mental 
Health Services Administration, 2008). Compared to the SAMHSA guidelines for urine, the 
sensitivity of the developed method was below the recommended confirmatory cut-off 
concentration for cocaine, demonstrating its potential applicability. However, the SAMHSA 
and DRUID recommended cut-off levels for cocaine/benzoylecgonine in oral fluid are 
below the sensitivity of the developed method.  
Table 6.5: United States Substance Abuse and Mental Health Services Administration 
(SAMHSA) and European Union’s research project on Driving Under the 
Influence of Drugs, Alcohol and Medicines (DRUID) recommended 
confirmation cut-off levels in urine and oral fluid. 
Sample 
matrix Analyte 
Concentration (ng/ml)   
SAMHSA 
 screening 
SAMHSA 
confirmation 
DRUID 
confirmation 
LGC 
screening 
LGC 
confirmation 
Oral 
fluid 
Cocaine/ 
benzoylecgonine 15 8 10 30 8 
Urine Benzoylecgonine 100 100 - 150 150 
In comparison to commercial cut-off levels, the limit of quantitation calculated for urine 
using the portable mass spectrometer demonstrates that the level is below the screening cut-
off level used for laboratory-based instruments. This shows the potential applicability of the 
portable system for drug detection in accordance with commercial cut-off levels, but not 
against recognised SAMHSA and DRUID guidelines. Additionally, quantitation limits 
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observed for oral fluid are slightly higher than those currently used by UK forensic providers 
Private Communication with LGC (20 January 2014).  
A limitation of the oral fluid screening method used with the portable system is that there 
was no sample clean up or preparation step applied. As a result, the oral fluid is diluted by 
the 3 ml of buffer used in the transfer tube and 0.5 ml of spiked IS solution. For analysis 
using the Plate Express™ system only 10 µl of the resulting buffer solution was analysed 
for screening purposes. It can be anticipated therefore that detection limits would be 
improved using a modified collection device containing a small quantity of buffer as a 
sample clean up method would not be feasible on-site. 
6.2 Results and Discussion 
6.2.1 Detection of cocaine and benzoylecgonine in oral fluid 
A total of n = 2 oral fluid samples were analysed using the Plate Express™ from drug users 
to evaluate the analytical method for the detection of cocaine and benzoylecgonine. To 
demonstrate the significance of the detection of cocaine and benzoylecgonine in those 
samples, a pooled oral fluid sample was also analysed from a negative control group (n = 5 
males and n = 5 females). The collection of oral fluid samples from these participants is 
described in section 6.1.3. The limit of detection for cocaine and benzoylecgonine in oral 
fluid using the portable set-up is provided in Table 6.4. The qualitative analysis of cocaine 
and benzoylecgonine in oral fluid samples from both groups; negative control and drug users 
is outlined in the following section.  
Analysis of cocaine and benzoylecgonine in spiked oral fluid (at 200 ng/ml) showed that 
both analytes could be detected with the current set-up of the portable system. The spiked 
oral fluid standard provided a reference chromatogram for both cocaine and 
benzoylecgonine, which was used to identify the presence of the analytes in blank oral fluid 
and oral fluid samples collected from participants admitted having taken cocaine. A problem 
that could arise from the use of a portable mass spectrometer that has lower resolving power 
than laboratory-based instruments is the presence of interferences. Interferences could be 
present in the sample from compounds that have the same mass-to-charge ratio as the 
analytes of interest. However, the addition of chromatographic separation should improve 
the selectivity of the instrument as previously described. Figure 6.5 shows chromatograms 
for cocaine and benzoylecgonine in blank and spiked oral fluid samples. Cocaine and 
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benzoylecgonine are present in the spiked oral fluid samples with retention times of 4.13 
min and 4.01 min, respectively. In addition, the mild in-source fragmentation that is 
produced in the source confirms the presence of the corresponding fragment ions for cocaine 
(m/z 182) and benzoylecgonine (m/z 168). In contrast, both the molecular ion and fragment 
ion for cocaine and benzoylecgonine are not present in the pooled blank oral fluid sample. 
This suggests that no interferences were present for both analytes. 
 
Figure 6.5: Extracted ion chromatograms for (a) cocaine and (b) benzoylecgonine in 
blank oral fluid and (c) cocaine and (d) benzoylecgonine in spiked oral fluid 
standard (at 200 ng/ml). 
Oral fluid samples collected from n = 2 participants who admitted having taken cocaine, 
were positive for both the presence of cocaine and its major metabolite benzoylecgonine. 
Figure 6.6 shows the chromatograms for cocaine and benzoylecgonine for both participants. 
Comparison of the spiked oral fluid standard against the participant’s oral fluid samples 
shows the levels of benzoylecgonine detected are in the same range as to those of the spiked 
oral fluid standard.  
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Figure 6.6: Extracted ion chromatograms for (a) cocaine and (b) benzoylecgonine in oral 
fluid for participant 04831605. 
6.2.2 Detection of cocaine and benzoylecgonine in urine 
A urine samples was collected from n = 1 participant to assess the detection of cocaine and 
benzoylecgonine from an individual admitted having taken cocaine. The detection window 
for drugs of abuse in urine after a single dose is 1.5 to 4 days, dependent of the drug. In 
contrast, oral fluid is used to determine recent drug use with a detection time of 5 – 48 hours 
(Verstraete, 2004). For chronic drug users, the detection time of drugs in urine can be longer 
(up to a week). The different matrices can therefore provide different information about the 
administration of drugs. 
Urine samples were collected from n = 3 non-drug users as a negative control group at the 
University of Surrey. The urine samples were pooled and used to determine the presence of 
any interference that could be present in the sample matrix. The limit of detection of cocaine 
and benzoylecgonine in urine are detailed in Table 6.4. Figure 6.7 shows chromatograms for 
cocaine and benzoylecgonine in blank urine and spiked urine drug standard. In contrast to 
the blank oral fluid samples, there is a small peak observed at the same retention time for 
cocaine (4.13 min) in the blank urine sample. It is possible that this peak is from interference 
in the sample matrix as the corresponding fragment ion of cocaine (m/z 182) is not present 
in the blank urine sample or that the concentration was too low to provide the fragment peak. 
The results indicate the importance of mass spectrometry and the ability for induced 
fragmentation to confirm the presence of compounds. The chromatogram for 
benzoylecgonine showed that no peaks were present for the retention time of both its 
molecular ion and fragment ion, indicating there are no interferences detected in the sample 
matrix.  
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The qualitative analysis of cocaine and benzoylecgonine in the urine sample from the 
participant admitted having taken cocaine showed the presence of benzoylecgonine, but not 
the parent drug cocaine. As urine is the last excretion path for the elimination of drugs from 
the human body, it is to be expected that drug metabolites levels are higher than those for 
the parent drug. However, instability of drugs in urine can influence the interpretation of 
drug testing results (Dixon et al., 2015; Cone et al., 2003). This work has been published in 
Analytical Methods (Ismail et al., 2017). 
 
Figure 6.7: Extracted ion chromatograms for (a) cocaine and (b) benzoylecgonine in 
blank urine and (c) cocaine and (d) benzoylecgonine in a spiked urine 
standard (at 200 ng/ml). 
6.3 Summary 
The use of a portable mass spectrometer for the analysis of cocaine and benzoylecgonine in 
urine and oral fluid was evaluated. The portable set up was equipped with a chromatography 
column to improve selectivity of the single quadrupole mass spectrometer. Analysis was 
performed on urine and oral fluid samples collected from non-drug users as well as cocaine 
users. No interferences were detected in the blank urine (see Figure 6.5) and oral fluid (see 
Figure 6.5) analysed. A limit of detection was achieved at 31 ng/ml and 17 ng/ml in oral 
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fluid for cocaine and benzoylecgonine, respectively. For urine, the limit of detection was 10 
ng/ml for cocaine and 21 ng/ml for benzoylecgonine (Table 6.4). In addition, the presence 
of cocaine and benzoylecgonine was confirmed in the oral fluid samples (n = 2) by mild-in 
source fragmentation (Figure 6.6). The limit of quantitation obtained in urine and oral fluid 
for both cocaine and benzoylecgonine were higher than recognised SAMHSA and DRUID 
guidelines. As the focus of this research was the use of the Quantisal™ oral fluid collection 
devices (which contains a 3 ml buffer solution), there is a possibility that dissimilar results 
would have arisen if other collection devices had been investigated or a sample clean-up 
was performed. This pilot research study showed the proof of concept for using a small 
(single quadrupole) mass spectrometer for drug analysis is bodily fluids with minimal 
sample preparation. 
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Chapter 7 Conclusions and Future Work 
7.0 Introduction 
A fingerprint is a challenging sample matrix for drug detection as the amount of analyte 
present in the sample is small. Significant challenges are attributed to fingerprint analysis 
due to the nature of the sample matrix. Not only does the sample size vary within and 
between individuals, but the limited sample volume offers minimal sample preparation. This 
inevitably affected the analytical performance and results. A fingerprint sample collection 
procedure was implemented to help control these variabilities (section 3.1.2). A simple 
sample preparation method was developed, which included a pre-concentration step 
(reconstitution in a small volume) to allow for the detection of the analytes of interest in 
fingerprints (section 2.3.4). 
A primary aim of this research was to investigate the significance of the detection of drugs 
from fingerprints and to evaluate the suitability of a fingerprint sample to determine cocaine 
and heroin use. This was evaluated by detecting cocaine and heroin in fingerprint samples 
from individuals receiving treatment for drug dependency at NHS Drug and Alcohol 
Services (Surrey and Borders Partnership NHS Foundation Trust). To evaluate the presence 
of cocaine and heroin in fingerprints from drug administration, the detection of both the 
parent drug (cocaine and heroin) and respective major metabolites benzoylecgonine and 6-
acetylmorphine was investigated. The presence of the major metabolites is toxicologically 
important as it is indicative of the administration of the drug rather than contamination 
picked up from a surface or handling the parent drug (Jacob et al., 2008). The possibility to 
use fingerprints for drug testing has become the subject of recent studies (Ismail et al., 2018; 
Costa et al., 2017; Zhang et al., 2015; Goucher et al., 2009). However, the reliability of a 
fingerprint sample matrix for the detection of drugs has not yet been investigated. 
Fingerprint samples were also collected from non-drug users after contact with the parent 
drug, to evaluate the presence of cocaine, heroin and respective metabolites in various 
scenarios (e.g. hand cleaning procedures and secondary transfer) (Chapter 4, section 4.2). A 
summary of the suitability for the use of fingerprints to detect cocaine and heroin use is 
outlined in section 7.1.
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A secondary aim of this research was to evaluate the use of fingerprints to detect the 
medication used to treat tuberculosis (in particular isoniazid and its respective metabolite 
acetylisoniazid) and the possibility to use fingerprints to monitor compliance. Fingerprint 
samples were collected from individuals receiving treatment for tuberculosis at King 
Edward VII Hospital in collaboration with Frimley Health NHS Foundation Trust (Chapter 
5). The use of fingerprints for a clinical application to monitor compliance with tuberculosis 
medication is summarised in section 7.2. 
Finally, a pilot research study was carried out to evaluate the use of a portable mass 
spectrometer for drug testing purposes using more conventional matrices, such as urine and 
oral fluid from individuals receiving treatment for drug dependency (Chapter 6). Section 7.3 
summarises the findings of this study.  
7.1 Detection of Cocaine and Heroin use in Fingerprints 
A liquid chromatography mass spectrometry (LC-MS) method was developed for the 
analysis of cocaine, heroin and their respective metabolites benzoylecgonine and 6-
acetylmorphine in fingerprint samples from two study populations, including (i) a 
background population of non-drug users and (ii) individuals seeking treatment for drug 
dependency at NHS Drug and Alcohol Services (Chapter 2, section 2.2.2). All fingerprint 
samples were analysed by LC-MS at the University of Surrey, whilst oral fluid samples were 
sent to a commercial provider for analysis (Claritest, Norwich, UK). Comparison with oral 
fluid samples showed that discrepancies were obtained between the two matrices for a 
number of participants (Chapter 3, section 3.2.2). However, as the detection window of 
cocaine in fingerprints is unknown, the influence of this is difficult to determine. Therefore, 
results were based on participant testimony, which has limitations as these may not 
necessarily be accurate. The significance of the detection of the analytes of interest in 
samples was evaluated by comparing natural fingerprints (without any preparation of the 
hands) from the two study populations (Chapter 3, section 3.2.1). The analysis of fingerprint 
samples from the background population demonstrated that a threshold level needs to be 
proposed for natural fingerprints due to traces of cocaine and benzoylecgonine detected as 
a result of environmental exposure (Chapter 3, section 3.2.4). In contrast, heroin and 6-
acetylmorphine were not prevalent (£1%) in natural fingerprints collected from the 
background population (Chapter 3, section 3.2.3.2). Compared to cocaine, heroin is not as 
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prevalent on banknotes and is more likely to degrade (Carter et al., 2003; Jenkins, 2001). 
Therefore, environmental exposure to heroin is less likely to occur. Based on the results 
obtained, there was no requirement to propose threshold levels as the presence of the 
analytes of interest was significant to differentiate drug users from non-drug users. This 
demonstrates that it is possible to differentiate drug users from non-drug users based on the 
detection of the analytes of interest in fingerprints.  
This is the first study to evaluate the significance of the detection of drugs in fingerprints by 
comparison to a background population and evaluating different sampling strategies, 
including (i) washing hands with soap and water, and (ii) wiping hands with alcohol free 
wipes (Chapter 3, sections 3.2.5 and 3.2.6). In order for fingerprints to be suitable for drug 
testing, it is important to evaluate the influence of the sampling strategy on the detection rate 
and to demonstrate that the test cannot be easily falsified by simply using a hand cleaning 
procedure prior to the test. The prevalence of the analytes of interest in fingerprint samples 
from non-drug users was reduced using a handwashing procedure (Chapter 3, section 3.2.7). 
If a handwashing procedure is used prior to a fingerprint test, there is no requirement to 
propose a threshold level in order to differentiate drug users from non-drug users. The use 
of a handwashing procedure is advantageous as it will reduce the possibility of 
contamination present on the hands that could lead to false positive results.  However, it has 
been demonstrated that both the parent drug and metabolite (as contamination in street 
drugs) can be present in fingerprint samples after handling 2 mg of the parent drug (see 
section 4.2.1) even after the use of hand cleaning procedures (see sections 4.2.3 and 4.2.4). 
In light of this, no differentiation was possible between the presence of the parent drug and 
metabolite in fingerprint samples due to administration or handling of the drug. 
A possible concern for drug testing from fingerprints is the secondary transfer of drugs 
between individuals. Cocaine and heroin can easily be transferred by individuals who have 
admitted having taken the parent drug in the past 24 h (section 3.2.9) and those who have 
handled a large amount (2 mg) of the parent drug, by shaking hands (section  4.2.5). The 
removal of secondary transfer of cocaine present in fingerprint samples from participants 
after shaking hands with an individual who had handled 2 mg of cocaine was not possible. 
In contrast, the use of a handwashing procedure removed all traces of secondary transfer of 
heroin present on the hands.  
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Based on the results obtained in this study, the relationship between the presence of the 
parent drug and metabolite did not provide additional information between participants who 
had positive or negative oral fluid results, or those who had handled or taken the drug. 
Overall, it is possible to discriminate individuals from the background population from those 
who have taken cocaine or heroin recently based on the presence of the parent drug and 
metabolite in fingerprint samples (Chapter 3, sections 3.2.3 and 3.2.7). However, the 
detection of cocaine and heroin in fingerprints does not necessarily indicate administration 
of the drug, but rather that the individual has either handled or administered the drug. 
Depending on the application of the test, both of these results could be incriminating.  
7.2 Detection of Tuberculosis Medication in Fingerprints 
Fingerprints can be used to determine the presence of drugs of abuse, however in this study 
the detection of prescribed medication to treat tuberculosis was the main focus (Chapter 5). 
Tuberculosis is one of the top 10 cause of deaths and the formation of drug resistant 
tuberculosis is a great concern (World Health Organisation, 2017). The World Health 
Organisation (WHO) recommends the use of directly observed treatment (DOTS) to monitor 
adherence to treatment. However, this is not often used by clinicians. Current methods rely 
on clinical improvement, tablet counts and engagement with tuberculosis nursing teams to 
help assess adherence (Nackers et al., 2012; Osterberg & Blaschke, 2005). An alternative 
method to monitor compliance with medication would be advantageous to ensure patients 
are adhering to their treatment and help prevent the formation of drug resistant tuberculosis. 
The complex nature of fingerprint analysis effected the analytical methodology for the 
analysis of tuberculosis medication in fingerprints in terms of matrix effects. The matrix 
effects in the form of ionisation suppression were observed for isoniazid and acetylisoniazid 
in the presence of fingerprints (section 5.2.2). However, with the use of an internal standard 
(isoniazid-d4) these effects were minimised for isoniazid but not to the same degree for 
acetylisoniazid. The ionisation suppression effects could be overcome by changing the 
chromatographic conditions to separate the compounds and with the use of an appropriate 
internal standard for acetylisoniazid.   
Isoniazid (76%) and acetylisoniazid (93%) were detected in natural fingerprint samples (n 
= 135) collected from individuals who all admitted having taken their medication on the day 
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of sample collection (section 5.2.5). In contrast, the analytes of interest were not prevalent 
in fingerprints collected from the negative control group or participants who had completed 
their treatment (2 – 8 months prior to recruitment) (sections 5.2.6 and 5.2.7). The use of a 
handwashing procedure reduced the detection rate for isoniazid (61%) and acetylisoniazid 
(81%). The lower detection rate could be possible due to a lack of sensitivity of the method 
or not enough sweat was secreted from the fingertips after handwashing (section 5.2.8). 
However, the analytes of interest were not prevalent in the negative control group or 
participants who had completed treatment after the handwashing procedure (sections 5.2.8.2 
and 5.2.8.3). In order to maximise the detection rate for isoniazid and acetylisoniazid to 
monitor adherence, collection of natural fingerprint samples would be advantageous.  
Evaluation of the elimination profile of isoniazid and acetylisoniazid in fingerprint samples 
demonstrated that when a participant stopped their medication, neither analytes could be 
detected two and four days after completing tuberculosis treatment (section 5.2.9). The 
present findings show that it is possible to detect prescribed medication in fingerprints and 
that it is not possible to detect the isoniazid or acetylisoniazid two days after completing 
treatment. In light of this, fingerprints could be a potential sampling matrix to monitor 
compliance with tuberculosis medication, but further work is required to establish the 
detection window of isoniazid and acetylisoniazid in fingerprints. 
7.3 Detection of Cocaine use in Urine and Oral Fluid using a Portable Mass 
Spectrometer 
Evaluation of the use of a portable mass spectrometer to allow for the detection of cocaine 
use in urine and oral fluid was explored (Chapter 6). In this pilot research study, a 
chromatography column was used to help increase the selectivity of a portable single 
quadrupole mass spectrometer. Urine and oral fluid samples were collected from non-drug 
users as well as drug users receiving treatment for drug dependency at NHS Drug and 
Alcohol Services (section 6.1.3). No interfering compounds were detected in urine and oral 
fluid samples collected from non-drug users. For the oral fluid samples collected using 
Quantisal™ oral fluid collection devices, the subsequent buffer solution was used for 
analysis. The method was able to detect both cocaine and benzoylecgonine in the biological 
matrices collected from the drug users, without any sample preparation, with adequate 
sensitivity (<30 ng/ml). 
Chapter 7: Conclusions and Future Work 
189 
 
7.4 Future Work 
This research has highlighted challenges associated with the use of fingerprints as a 
sampling matrix for drug testing. The variable sample matrix and the absence of a fingerprint 
standard made it impossible to produce matrix matched calibration curves and the possibility 
for quantitative analysis. In order to minimise the variability of a fingerprint sample, the 
sample size and volume should be controlled. The influence of this would be an interesting 
next step to help compare results between individuals. 
Although cocaine, heroin and their respective metabolites (benzoylecgonine and 6-
acetylmorphine) can be detected in fingerprints collected from individuals who admitted 
having taken the drug in the past 24 h (Chapter 3, section 3.2.2), the source of the detection 
of these analytes cannot solely be attributed to administration of the drug, as these analytes 
can also be present after handling the parent drug (Chapter 4, section 4.2.1). In order to use 
fingerprints to detect cocaine or heroin use, more research would be required to explore 
strategies to differentiate individuals who have administered cocaine or heroin from those 
who have handled the parent drug. A hand cleaning procedure that is possible to remove all 
contact residue after handing the parent drug would be advantageous to support this. 
Additionally, the detection of other markers in fingerprints that are indicative of 
administration of cocaine or heroin would also be a step forward to overcome the challenges 
associated with the use of fingerprints to detect cocaine and heroin use. Alternatively, the 
use of imaging mass spectrometry could be used to explore differences in analyte 
distribution in fingerprints to help differentiate between drug administration and contact.  
The application of fingerprint testing for clinical purposes was evaluated by exploring the 
detection of tuberculosis medication in fingerprints. Although all participants admitted 
having taken their medication, this was not confirmed for all participants in all the 
fingerprint samples collected (Chapter 5, section 5.2.5). In order to understand the 
discrepancy between the fingerprint samples collected from the same participant as well as 
between participants, corresponding blood samples should be taken to help corroborate 
results.  Additionally, the fingerprint analysis method developed required further work. The 
most important limitation on the developed method was the observed matrix effects 
(ionisation suppression) and the absence of a suitable internal standard for acetylisoniazid 
to correct for the effects observed (Chapter 5, section 5.2.2). Additional work is required to 
improve the matrix effects observed, including improvement of the chromatographic 
Chapter 7: Conclusions and Future Work 
190 
 
separation between the analytes of interest and evaluation of the use of washing the paper 
substrate prior to fingerprint deposition. This could help enhance the sensitivity of the 
method, which could improve the detection of isoniazid and acetylisoniazid in fingerprint 
samples. 
The use of a portable drug testing system was able to detect cocaine use in urine and oral 
fluid samples from individuals admitted having taken cocaine in the past 24 h, without 
sample preparation. However, as this was a preliminary study, only a few participants were 
included in the study and optimisation of the method was limited. To improve sensitivity 
further, in particular with the use of oral fluid collection devices further work is required. 
The Quantisal™ collection device used consists of a 3 ml buffer solution, which will dilute 
the oral fluid sample and therefore affect the sensitivity of the method. A sample clean-up 
method or use of a smaller buffer solution could be investigated to improve sensitivity. 
Additionally, a more robust method evaluation is required to validate the use of the portable 
system. The use of a mobile drug testing device could have a wide range of applications 
(e.g. workplace drug testing, GP practices and hospitals) and this would be an interesting 
area of research.
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Appendix A 
A. 1 Chromatographic separation on a Waters Acquity UHPLC combined with a Q-ToF 
Premier using solvent A1 (20 mM ammonium acetate in 5% (v/v) acetonitrile in 
water) and solvent B1 (acetonitrile + 0.1% formic acid) starting at 80% aqueous and 
20% organic solvent using gradient elution, see Table 2.1 for the LC-MS operating 
conditions. 
 
A. 2 Chromatographic separation on a Waters Acquity UHPLC combined with a Q-ToF 
Premier using solvent A2 (water + 0.1% formic acid) and solvent B1 (acetonitrile + 
0.1% formic acid) starting at 80% aqueous and 20% organic solvent using gradient 
elution, see Table 2.1 for the LC-MS operating conditions. 
 
Appendix A 
209 
 
A. 3 Chromatographic separation on a Waters Acquity UHPLC combined with a Q-ToF 
Premier using solvent A2 (water + 0.1% formic acid) and solvent B2 (MeOH + 0.1% 
formic acid) starting at 80% aqueous and 20% organic solvent, see Table 2.1 for the 
LC-MS operating conditions. 
 
A. 4 Chromatographic separation on a Waters Acquity UHPLC combined with a Q-ToF 
Premier using solvent A1 (20 mM ammonium acetate in 5% (v/v) acetonitrile in 
water) and solvent B1 (acetonitrile + 0.1% formic acid) starting at 95% aqueous and 
5% organic solvent using gradient elution, see Table 2.1 for the LC-MS operating 
conditions. 
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A. 5 Chromatographic separation on a Waters Acquity UHPLC combined with a Q-ToF 
Premier using solvent A2 (water + 0.1% formic acid) and solvent B1 (acetonitrile + 
0.1% formic acid) starting at 95% aqueous and 5% organic solvent using gradient 
elution, see Table 2.1 for the LC-MS operating conditions. 
 
A. 6 Chromatographic separation on a Waters Acquity UHPLC combined with a Q-ToF 
Premier using solvent A2 (water + 0.1% formic acid) and solvent B2 (MeOH + 0.1% 
formic acid) starting at 95% aqueous and 5% organic solvent, see Table 2.1 for the 
LC-MS operating conditions. 
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A. 7 Calibration curve (run 1) of cocaine, benzoylecgonine, heroin and 6-acetymorphine 
ranging from 0 – 100 ng/ml in 5% ACN in H2O + 0.1% formic acid, see Table 2.1 
for the LC-MS operating conditions.   
 
A. 8 Calibration curve (run 2) of cocaine, benzoylecgonine, heroin and 6-acetylmorphine 
ranging from 0 – 100 ng/ml in 5% ACN in H2O + 0.1% formic acid, see Table 2.1 
for the LC-MS operating conditions. 
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A. 9 Calibration curve (run 3) of cocaine, benzoylecgonine, heroin and 6-
acetylmorphineranging from 0 – 100 ng/ml in 5% ACN in H2O + 0.1% formic acid, 
see Table 2.1 for the LC-MS operating conditions. 
  
A. 10 Calibration curve (run 4) of cocaine, benzoylecgonine, heroin and 6-acetylmorphine 
ranging from 0 – 100 ng/ml in 5% ACN in H2O + 0.1% formic acid, see Table 2.1 
for the LC-MS operating conditions.  
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A. 11 Calibration curve (run 5) of cocaine, benzoylecgonine, heroin and 6-acetylmorphine 
ranging from 0 – 100 ng/ml in 5% ACN in H2O + 0.1% formic acid, see Table 2.1 
for the LC-MS operating conditions. 
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Appendix B 
B. 1 Standard operating procedure for oral fluid sample collection. 
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B. 1 continued …  
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B. 1 continued …  
 
  
Appendix B 
217 
 
B. 1 continued…  
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B. 2 Standard operating procedure for fingerprint sample collection. 
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B. 2 continued…  
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B. 2 continued…  
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B. 2 continued…  
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Appendix C 
C. 1 Forensic Science Ireland: Gas chromatography – mass spectrometry (GC-MS) 
analysis of cocaine.  
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C. 2 Forensic Science Ireland: Gas chromatography – mass spectrometry (GC-MS) 
analysis of heroin. 
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C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
 
  
Appendix C 
233 
 
C. 2 continued…  
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C. 2 continued…  
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C. 2 continued…  
 
  
Appendix C 
236 
 
C. 2 continued…  
Appendix D 
237 
 
Appendix D 
D. 1 Calibration curve (run 1) of isoniazid and acetylisoniazid ranging from 0 – 100 ng/ml 
in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the LC-MS operating 
conditions.   
 
D. 2 Calibration curve (run 2) of isoniazid and acetylisoniazid ranging from 0 – 100 ng/ml 
in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the LC-MS operating 
conditions.     
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D. 3 Calibration curve (run 3) of isoniazid and acetylisoniazid ranging from 0 – 100 ng/ml 
in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the LC-MS operating 
conditions.     
 
D. 4 Calibration curve (run 4) of isoniazid and acetylisoniazid ranging from 0 – 100 ng/ml 
in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the LC-MS operating 
conditions.       
 
D. 5 Calibration curve (run 4) of isoniazid and acetylisoniazid ranging from 0 – 100 ng/ml 
in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the LC-MS operating 
conditions.       
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D. 6 Calibration curve (run 1 – prepared daily) of isoniazid and acetylisoniazid ranging 
from 0 – 100 ng/ml in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the 
LC-MS operating conditions.       
 
D. 7 Calibration curve (run 2 – prepared daily) of isoniazid and acetylisoniazid ranging 
from 0 – 100 ng/ml in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the 
LC-MS operating conditions.     
 
D. 8 Calibration curve (run 3 – prepared daily) of isoniazid and acetylisoniazid ranging 
from 0 – 100 ng/ml in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the 
LC-MS operating conditions.      
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D. 9 Calibration curve (run 4 – prepared daily) of isoniazid and acetylisoniazid ranging 
from 0 – 100 ng/ml in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the 
LC-MS operating conditions.    
 
D. 10 Calibration curve (run 5 – prepared daily) of isoniazid and acetylisoniazid ranging 
from 0 – 100 ng/ml in 50% ACN in H2O + 0.1% formic acid, see Table 5.1 for the 
LC-MS operating conditions.      
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Appendix E 
E. 1 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine levels in fingerprints collected from 
cocaine/heroin users and a background population of non-drug users using different 
sample collection procedures (natural, soap and wipe). 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine 
Non-DU v DU N 13 65 0 5.67 Non-DU < DU p < 0.001 
DU N v S 65 40 819 3.17 S < N p = 0.002 
DU N v W 65 25 603 1.89 No difference p = 0.059 
BZE 
Non-DU v DU N 5 61 27 3.04 Non-DU < DU p = 0.001 
DU N v S 61 34 461 4.47 S < N p < 0.001 
DU N v W 61 25 609 1.46 No difference p = 0.144 
Heroin 
DU N v S 59 34 502 4.00 S < N  p < 0.001 
DU N v W 59 20 104 5.48 W < N p < 0.001 
6-AM 
DU N v S 60 35 807 1.88 No difference p = 0.061 
DU N v W 60 20 557 0.48 No difference p = 0.633 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; Non-DU: non-drug users (background 
population; DU: drug users; N: natural fingerprints; S: fingerprints collected after washing 
hands with soap and water; W: fingerprints collected after wiping hands with alcohol free 
wipes. The significance level (p) is 0.05. 
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E. 2 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine levels in natural fingerprints 
collected cocaine/heroin users and after wiping hands with alcohol free wipes (same 
participants). 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine DU N v W 25 25 231 1.58 No difference p = 0.114 
BZE DU N v W 25 25 258 1.06 No difference p = 0.290 
Heroin DU N v W 20 20 43 4.25 W < N p < 0.001 
6-AM DU N v W 20 20 250 1.35 No difference p = 0.183 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; N: natural fingerprints; 
W: fingerprints collected after wiping hands with alcohol free wipes. The significance level 
(p) is 0.05. 
E. 3 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine-to-
benzoylecgonine ratio and heroin-to-6-acetylmorphine ratio in natural fingerprints 
collected from cocaine/heroin users and wiping hands with alcohol free wipes (same 
participants). 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine-
to-BZE DU N v W 25 25 295 0.34 
No difference 
p = 0.734 
Heroin-
to-6-AM DU N v W 20 20 40 4.33 
W < N 
p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; N: natural fingerprints; 
W: fingerprints collected after wiping hands with alcohol free wipes. The significance level 
(p) is 0.05. 
E. 4 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine levels in natural fingerprints 
collected from cocaine/heroin users and after washing hands with soap and water 
(same participants). 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine DU N v S 40 40 516 2.73 S < N p = 0.006 
BZE DU N v S 36 34 260 4.14 S < N p < 0.001 
Heroin DU N v S 39 34 290 4.13 S < N p < 0.001 
6-AM DU N v S 40 35 450 2.66 S < N p = 0.008 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; N: natural fingerprints; 
S: fingerprints collected after washing hands with soap and water. The significance level (p) 
is 0.05. 
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E. 5 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine-to-
benzoylecgonine ratio and heroin-to-6-acetylmorphine ratio in natural fingerprints 
collected from cocaine/heroin users in and wiping hands with alcohol free wipes 
(same participants). 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine-
to-BZE DU N v S 36 34 588 0.28 
No difference 
p = 0.778 
Heroin-
to-6-AM DU N v S 39 33 353 3.28 
S < N 
p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; N: natural fingerprints; 
S: fingerprints collected after washing hands with soap and water. The significance level (p) 
is 0.05. 
E. 6 Kruskal Wallis test (two-tailed) for the comparison of the cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine levels in natural fingerprints collected from 
cocaine/heroin users and fingerprints collected from non-drug users before and after 
shaking hands (secondary transfer). 
Analyte Study population 
Sample 
type n1 n2 n3 c
2calc d.f 
Significant difference? 
(at p = 0.05) 
Cocaine Non-DU v DU N v ST 7 25 75 46.29 2 Yes, p < 0.001 
BZE Non-DU v DU N v ST 2 5 66 12.95 2 Yes, p = 0.002 
Heroin Non-DU v DU N v ST 0 7 65 17.57 1 Yes, p < 0.001 
6-AM Non-DU v DU N v ST 0 6 67 11.12 1 Yes, p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; ST: secondary transfer; N: natural fingerprints; d.f: degrees of freedom. The 
significance level (p) is 0.05. 
E. 7 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine levels in fingerprints collected from 
non-drug users before and after shaking hands with drug users. 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine Non-DU N v ST 7 25 147 2.71 ST > N p = 0.005 
BZE Non-DU N v ST 2 5 6 0.39 No difference p = 1 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; Non-DU: non-drug users; N: natural 
fingerprints; ST: secondary transfer. The significance level (p) is 0.05. 
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E. 8 Kruskal Wallis test (two-tailed) for the comparison of the cocaine-to-
benzoylecgonine ratio and heroin-to-6-acetylmorphine ratio in natural fingerprints 
collected from cocaine/heroin users and fingerprints collected from non-drug users 
before and after shaking hands (secondary transfer). 
Analyte Study population 
Sample 
type n1 n2 n3 c
2calc d.f 
Significant difference? 
(at p = 0.05) 
Cocaine-
to-BZE 
Non-DU v 
DU N v ST 2 5 61 8.45 2 Yes, p = 0.015 
Heroin-
to-6AM 
Non-DU v 
DU N v ST 0 4 59 6.01 1 Yes, p = 0.014 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; ST: secondary transfer; N: natural fingerprints; d.f: degrees of freedom. The 
significance level (p) is 0.05. 
E. 9 Kruskal Wallis test (two-tailed) for the comparison of the cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine in fingerprints collected from non-drug users after 
dermal contact with the parent drug (scenario 1), after wiping hands with alcohol 
free wipes (scenario 2) and after washing hands with soap and water (scenario 3). 
Analyte Scenario n1 n2 n3 c2calc d.f 
Significant 
difference? 
(at p = 0.05) 
Cocaine 1 v 2 v 3 12 12 12 25.61 2 Yes, p < 0.001 
BZE 1 v 2 v 3 12 12 11 26.67 2 Yes, p < 0.001 
Heroin 1 v 2 v 3 12 12 12 28.76 2 Yes, p < 0.001 
6-AM 1 v 2 v 3 12 12 12 30.71 2 Yes, p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; d.f: degrees of freedom. The significance 
level (p) is 0.05. 
E. 10 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine and 
benzoylecgonine levels in fingerprints collected from non-drug users after shaking 
hands with a participant with dermal contact of cocaine and after washing hands 
(scenario 4). 
Analyte Scenario Sample type n1 n2 Ucalc |z|calc Significant difference? (at p = 0.05) 
Cocaine 4 ASH v AWH 8 8 1 3.26 Yes, p < 0.001 
BZE 4 ASH v AWH 8 8 0 3.36 Yes, p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; ASH: after shaking hands; AWH: after 
washing hands. The significance level (p) is 0.05. 
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E. 11 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine levels in natural fingerprints 
collected from cocaine/heroin users and fingerprints collected from non-drug users 
after dermal contact with 2 mg of the parent drug. 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine DU v Non-DU N 65 12 777 5.44 Non-DU > DU p < 0.001 
BZE DU v Non-DU N 61 12 732 5.45 Non-DU > DU p < 0.001 
Heroin DU v Non-DU N 59 12 707 5.42 Non-DU > DU p < 0.001 
6-AM DU v Non-DU N 60 12 242 1.79 No difference p = 0.073 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; N: natural fingerprints. The significance level (p) is 0.05. 
E. 12 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine-to-
benzoylecgonine ratio and heroin-to-6-acetylmorphine ratio in natural fingerprints 
collected from cocaine/heroin users and fingerprints collected from non-drug users 
after dermal contact with 2 mg of the parent drug. 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine-
to-BZE 
DU v Non-
DU N 61 12 143 3.32 
DU > Non-DU 
p = 0.001 
Heroin-
to-6-AM 
DU v Non-
DU N 59 12 543 2.90 
Non-DU > DU 
p = 0.004 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; N: natural fingerprints. The significance level (p) is 0.05. 
E. 13 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine levels in fingerprint samples 
collected after wiping hands with alcohol free wipes from cocaine/heroin users and 
non-drug users after dermal contact with 2 mg of the parent drug. 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine DU v Non-DU W 25 12 269 3.86 Non-DU > DU p < 0.001 
BZE DU v Non-DU W 25 12 292 4.61 Non-DU > DU p < 0.001 
Heroin DU v Non-DU W 20 12 88 1.25 No difference p = 0.224 
6-AM DU v Non-DU W 20 12 212 3.58 Non-DU > DU p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; W: fingerprints collected after wiping hands with alcohol free wipes. The significance 
level (p) is 0.05. 
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E. 14 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine-to-
benzoylecgonine ratio and heroin-to-6-acetylmorphine ratio in fingerprint samples 
collected after wiping hands with alcohol free wipes from drug users and non-drug 
users after dermal contact with 2 mg of the parent drug. 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine-
to-BZE 
DU v Non-
DU W 25 12 99 1.66 
No difference 
p = 0.102 
Heroin-
to-6-AM 
DU v Non-
DU W 25 12 222 3.97 
Non-DU > DU 
p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; W: fingerprints collected after wiping hands with alcohol free wipes. The significance 
level (p) is 0.05. 
E. 15 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine, 
benzoylecgonine, heroin and 6-acetylmorphine levels in fingerprint samples 
collected after washing hands with soap and water from cocaine/heroin users and 
non-drug users after dermal contact with 2 mg of the parent drug. 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine DU v Non-DU S 40 12 305 1.41 No difference p = 0.158 
BZE DU v Non-DU S 34 12 393 4.73 Non-DU > DU p < 0.001 
Heroin DU v Non-DU S 34 12 267 1.58 No difference p = 0.115 
6-AM DU v Non-DU S 35 12 155 1.34 No difference p = 0.180 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; S: fingerprints collected after washing hands with soap and water. The significance 
level (p) is 0.05. 
E. 16 Mann-Whitney U-test (two-tailed) for the comparison of the cocaine-to-
benzoylecgonine ratio and heroin-to-6-acetylmorphine ratio in fingerprint samples 
collected after washing hands with soap and water from drug users and non-drug 
users after dermal contact with 2 mg of the parent drug. 
Analyte Study population 
Sample 
type n1 n2 Ucalc |z|calc 
Significant difference? 
(at p = 0.05) 
Cocaine-
to-BZE 
DU v Non-
DU S 34 12 172 0.80 
No difference 
p = 0.438 
Heroin-
to-6-AM 
DU v Non-
DU S 33 12 329 3.36 
Non-DU > DU 
p < 0.001 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; S: fingerprints collected after washing hands with soap and water. The significance 
level (p) is 0.05. 
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E. 17 Kruskal Wallis test (two-tailed) for the comparison of the cocaine, benzoylecgonine, 
heroin and 6-acetylmorphine levels in natural fingerprints collected from 
cocaine/heroin users and fingerprints collected from non-drug users after shaking 
hands (secondary transfer) and after washing hands. 
Analyte Study population 
Sample 
type n1 n2 n3 c
2calc d.f 
Significant 
difference? 
(at p = 0.05) 
Cocaine Non-DU v DU N v ST 8 8 65 21.24 2 Yes, p < 0.001 
BZE Non-DU v DU N v ST 8 8 61 18.87 2 Yes, p < 0.001 
Heroin Non-DU v DU N v ST 7 0 59 8.05 2 Yes, p = 0.018 
6-AM Non-DU v DU N v ST 7 0 60 3.81 2 No, p = 0.148 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; ST: secondary transfer; N: natural fingerprints; d.f: degrees of freedom. The 
significance level (p) is 0.05. 
E. 18 Kruskal Wallis test (two-tailed) for the comparison of the cocaine-to-
benzoylecgonine and heroin-to-6-acetylmorphine levels in natural fingerprints 
collected from cocaine/heroin users and fingerprints collected from non-drug users 
after shaking hands (secondary transfer) and after washing hands. 
Analyte Study population 
Sample 
type n1 n2 n3 c
2calc d.f 
Significant 
difference? 
(at p = 0.05) 
Cocaine-
to-BZE 
Non-DU v 
DU N v ST 8 8 65 29.97 2 Yes, p < 0.001 
Heroin-
to-6-AM 
Non-DU v 
DU N v ST 8 0 60 3.35 2 No, p = 0.188 
BZE: benzoylecgonine; 6-AM: 6-acetylmorphine; DU: drug users; Non-DU: non-drug 
users; ST: secondary transfer; N: natural fingerprints; d.f: degrees of freedom. The 
significance level (p) is 0.05. 
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E. 19 Average peak area ratio analyte (A) to internal standard (IS) (± standard deviation, 
n = 5 measurements) and statistical data for isoniazid in the presence of fingerprint 
samples (natural and after handwashing) and blank solvent (methanol) extracted 
from paper and spiked with 20 ng/ml and 80 ng/ml compared to the reference 
standard at the same concentration. 
Isoniazid 
Sample 
Concentration level 20 ng/ml Concentration level 80 ng/ml 
Mean ± s 
(n = 5) 
(ratio A/IS) 
Ref. std 
(ratio 
A/IS) 
tcalc tcrit 
Mean ± s 
(n = 5) 
(ratio A/IS) 
Ref. std 
(ratio 
A/IS) 
tcalc tcrit 
Fingerprints 
natural 0.311 ± 0.031 
0.314 ± 
0.003 
 
0.49 2.04 1.475 ± 0.101 
1.383 ± 
0.005 
4.51 2.09 
Fingerprints 
soap 0.324 ± 0.004 0.02 2.04 1.419 ± 0.017 9.10 2.01 
Blank 
solvent 
(methanol) 
0.337 ± 0.005 0.05 2.04 1.409 ± 0.024 5.02 2.04 
Note: s = standard deviation. For the two-tailed t-test: tcrit given in table (Miller & Miller, 2005). 
E. 20 Average peak area ratio analyte (A) to internal standard (IS) (± standard 
deviation, n = 5 measurements) and statistical data for acetylisoniazid in the 
presence of fingerprint samples (natural and after handwashing) and blank 
solvent (methanol) extracted from paper and spiked with 20 ng/ml and 80 
ng/ml compared to the reference standard at the same concentration. 
Acetylisoniazid 
Sample 
Concentration level 20 ng/ml Concentration level 80 ng/ml 
Mean ± s 
(n = 5) 
(ratio A/IS) 
Ref. std 
(ratio A/IS) tcalc tcrit 
Mean ± s 
(n = 5) 
(ratio A/IS) 
Ref. std 
(ratio A/IS) tcalc tcrit 
Fingerprints 
natural 
0.554 ± 
0.176  
0.322 ± 
0.004  
6.61 2.09 2.379 ± 0.485 
1.466 ± 
0.033 
9.29 2.04 
Fingerprints 
soap 
0.471 ± 
0.042 17.26 2.04 
2.142 ± 
0.168 18.43 2.04 
Blank 
solvent 
(methanol) 
0.387 ± 
0.004 0.13 2.04 
1.760 ± 
0.030 0.60 2.04 
Note: s = standard deviation. For the two-tailed t-test: tcrit given in table (Miller & Miller, 2005).
Appendix F 
249 
 
Appendix F 
F. 1 Publication: Ismail et al. (2017) 
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F. 2 Publication: Ismail et al. (2018) 
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